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ABSTRACT 
 
Gout is the most prevalent form of inflammatory arthritis in men older than forty years of 
age and has a significant functional and social impact. Tophaceous gout is the most 
progressed phase of gout and is associated with foot pain, impairment and disability in 
joints (first metatarsophalangeal joint) and soft tissue (Achilles tendon). The structural 
characteristics of the Achilles tendon (AT) enables it to withstand the large forces 
imposed during the gait cycle. Any alteration to the internal structure of the AT may affect 
the ability of the gastro-soleus complex to generate force, transfer muscle power and 
absorb energy during the gait cycle. Current research has reported tophus deposition in 
the AT. However, there is limited information on the impact of tophus on the AT structure 
and the impact of gait characteristics in people with gout. Therefore, the aims of this thesis 
were to investigate the prevalence of ultrasound (US) lesions in the AT and the gait 
parameters of walking velocity, ankle power and ankle range of motion in participants 
with tophaceous gout compared to age and sex-matched control participants. Two 
systematic reviews with meta-analysis were also undertaken. 
 
The first systematic review was conducted on US lesions in the AT of people with 
inflammatory arthritis. The results demonstrated that the majority of studies reporting US 
lesions were in spondyloarthropathies, but limited data relating to tophaceous gout. The 
meta-analysis demonstrated the AT was significantly thicker in people with 
spondyloarthropathies, erosions more prevalent in both spondyloarthropathies and 
rheumatoid arthritis, but enthesophyte formation was not significantly more prevalent in 
participants with spondyloarthropathies when compared to control participants. The 
review highlighted inconsistencies in both defining and scoring US lesions indicative of 
inflammation and structural damage in people with inflammatory arthritis.  
 
The second systematic review evaluated gait parameters in inflammatory arthritis. The 
findings from the review identified the most commonly assessed gait parameters used to 
define gait adaptation in inflammatory arthritis, with the majority of studies focusing on 
gait adaptation in rheumatoid arthritis. The meta-analysis demonstrated significant 
differences in walking velocity, cadence, stride length, double support time, ankle power 
and forefoot plantar pressure, but no significant differences in ankle range of motion when 
participants with inflammatory arthritis were compared to controls. The review 
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highlighted the wide range of methodologies used to acquire spatiotemporal, kinetic and 
plantar pressure gait parameters. 
 
Using a case-control study experimental design, AT structure was investigated using 
grey-scale and power Doppler US imaging. Gait function was evaluated using three-
dimensional (3D) gait analysis.  Twenty four participants with tophaceous gout with a 
mean (SD) age of 62 (12) years old were matched with 24 age and sex-matched control 
participants, with a mean (SD) age of 62 (12) years old. The majority of the participants 
were middle aged males (92%), predominately of European ethnicity (77%). The control 
participants demonstrated a significantly higher number of Europeans (p ≤ 0.01). 
Participants with gout had higher mean BMI compared to controls (p < 0.01). Participants 
with gout had well established disease of 17 years, with a mean serum urate level of 0.37 
mmol/L. Comorbidities that included hypertension, cardiovascular disease and type 2 
diabetes were found in approximately one-third of participants with tophaceous gout. The 
case participants with gout demonstrated had a higher prevalence of hypertension (p < 
0.01) and cardiovascular disease (p = 0.03) compared to the control participants. The 
majority of participants with gout were prescribed allopurinol (n = 20, 83%).   
 
 In order to investigate specific regions of the AT, the tendon was divided into three zones 
(insertion, pre-insertion and proximal to mid-section). US lesions were scored using a 
semi-qualitative scoring system. The scoring system assessed the tophus characteristics, 
tendon echogenicity, tendon vascularity, tendon morphology, enthesis, bursal 
morphology and bone profile using binary, continuous measurement and semi-qualitative 
scale. As lesions were nested within participants, a general estimating equation approach 
was used to analyse data. The results demonstrated participants with tophaceous gout 
showed a significantly higher prevalence of tophus deposition (p < 0.01), intratendinous 
hyperechoic spots (p < 0.01) and intratendinous inflammation (p < 0.01) throughout all 
zones of the AT. There was minimal data reporting hypoechoic areas with loss of fibrillar 
echotexture in the AT of both the case and control participants. These findings suggest 
that tophus deposition and associated inflammation in the AT may be a clinically silent 
process, with containment of inflammation.   
 
In the second case-control study, each participant undertook 3D gait analysis with passive 
lightweight markers used to track and model the lower limb in accordance with the 
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Oxford Foot Model. Surface electromyography signals were recorded during gait from 
the medial gastrocnemius, lateral gastrocnemius and tibialis anterior of both limbs. Gait 
measures included walking velocity, double limb support time, first metatarsophalangeal 
joint motion, peak ankle joint force, ankle moment and power. When compared to control 
participants, participants with tophaceous gout demonstrated significantly decreased 
walking velocity (p < 0.01), with a mean difference of -0.20 m/s, and an increased double 
limb support time (p < 0.01), with a mean difference of 0.05s. Peak ankle joint power was 
reduced with a mean difference of -0.31 W/Kg (p = 0.01), but peak ankle joint force, 
difference of 15.6N (p = 0.25), and peak ankle joint moments, with a mean difference of 
0.06 Nm/Kg (p = 0.16), were not significantly different between the two groups. Medial 
gastrocnemius (p = 0.04), with a mean difference of 2.7 %MVIC/s, and lateral 
gastrocnemius (p < 0.01), mean difference of 6.2 %MVIC/s muscle activity was increased 
in participants with tophaceous gout. Reductions in walking velocity in the cases were 
associated with alterations in cadence, step length, double support time and gait cycle 
time. Reductions in walking velocity were also associated with decreased ankle joint 
angular velocity in the people with gout. With the ankle joint moments preserved and not 
significantly different between the two groups, the reductions in ankle joint angular 
velocity explain the reduced ankle joint power output. These findings highlight the 
importance of walking velocity and imply that walking velocity may be the central 
mechanism by which the body modulates gait adaptation.   
 
The findings of the thesis are clinically relevant. When managing AT pathologies in 
people with tophaceous gout both structure and function must be considered. Structural 
integrity of the AT must be determined and the degree of gait adaptation must also be 
quantified to provide the clinician with a good overall perspective of functional ability. 
The findings are also relevant for the design of future clinical trials. The investigation of 
mechanical properties of the AT in people with gout is warranted. With baseline gait 
adaptations quantified, the impact of non-surgical interventions such as footwear, foot 
orthoses and strength training must also be considered for their ability to alter the process 
of gait adaptation in people with gout. 
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CHAPTER 1:  
Introduction 
1.1. Background to the problem 
Gout is the most prevalent form of inflammatory arthritis in men older than forty years of 
age and has significant functional, social and financial impacts (1, 2). Gout has a special 
context within New Zealand society, with South Auckland being described as the ‘Gout 
Capital’ of the world due to the high prevalence within the male Māori and Pacific Island 
population (3). The high and increasing hospital admission rates, combined with the burden 
of co-morbidities is a significant current and future issue for the New Zealand health care 
system (4).  
 
Gout is a disorder of purine metabolism, the biological precursor being elevated serum 
urate levels (hyperuricaemia). Hyperuricaemia is defined as a serum urate concentration 
greater than 0.42 mmol/L and can lead to the deposition of monosodium urate (MSU) 
crystals within articular and periarticular structures (5-7). During the course of the disease 
the presence of MSU crystals can clinically manifest as acute inflammatory arthritis, tophus 
formation, joint damage and altered tendon and ligament structure and function (8). 
 
Clinically apparent gout is characterised by three overlapping phases, (i) acute arthritis 
with (ii) asymptomatic intervals (inter-critical gout) and (iii) chronic gouty arthritis or 
tophaceous gout (9) that may emerge over a period of 1 to 4 decades (10). Tophaceous gout 
is the most progressed phase of gout and is associated with pain, inflammation, joint 
deformity and/or joint destruction, and tophus deposition in joints and subcutaneous tissues 
(11). Tophus formation has been identified as a risk factor for development of 
musculoskeletal disability, implicated in the pathogenesis of joint damage, the mechanical 
obstruction of joint movement and is linked to a reduction in quality of life (12-14). Tophi 
are defined as granulomatous lesions surrounding a core of MSU crystals, encased by dense 
connective tissue and represent a complex and organised chronic inflammatory response 
to MSU crystals (15). Tophi have a tendency to deposit in the enthesis and body of extensor 
tendons such as the Achilles tendon (AT) (16). A recent study has highlighted the 
significance of the AT as a site for tophus deposition in a cohort of 92 participants with 
tophaceous gout, with urate deposition recorded in 39% of all ATs (17). 
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Tophaceous gout is associated with the development of musculoskeletal foot pain, 
impairment and disability and has been associated with reduced walking velocity (18). 
However, overall gait strategy has not been defined in tophaceous gout, with only one study 
assessing spatiotemporal (time and distance) and plantar pressure parameters, but not 
kinematic or kinetic gait parameters (18). Rome (18) speculated that alterations in gait 
strategy may result from a pain avoidance strategy and ultimately lead to weakness in the 
ankle plantar flexors.  
 
The AT is the strongest tendon in the human body and is subjected to large stresses (up to 
12.5 times bodyweight) during strenuous activities such as running and jumping (19). The 
AT is a conjoined tendon of the two heads of the gastrocnemius and with the soleus muscle; 
this is often referred to as the ‘gastro-soleus complex’ (20). The primary role of the gastro-
soleus complex is plantarflexion of the foot and ankle during gait (21).  Prime activity 
occurs from approximately 10-50% of the cycle with peak activity at approximately 40% 
(22, 23).   
 
Ultrasound (US) imaging provides a non-invasive technique to aid diagnosis, monitor 
disease progression and provide insights into pathological changes in musculoskeletal 
disease (24). US imaging is able to detect various specific and non-specific US lesions in 
gout. Non-specific features include those findings that may be common amongst other 
forms of inflammatory arthritis such as: joint effusion, synovitis, hypervascularisation, 
bony erosion and proliferative new bone formation (25). To date there is limited data 
relating to the structural properties of the AT in people with gout. 
 
The presence of tophaceous deposits within the AT may have significant effects on the 
internal structure leading to: impaired tendon healing, reduced tensile strength and 
ultimately reduced functional ability. Impaired healing of the AT results in the breakdown 
of two key functions: the ability to absorb load and the ability to transmit load (26). 
Alteration to AT function may modify coordinated movements of the hip, knee and ankle 
joints during gait, leading to functional adaptation such as reduced ankle power and 
reduced ankle range of motion (27). However, no research to date has investigated the gait 
parameters of ankle power and ankle range of motion in people with tophaceous gout. 
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1.2. Significance of the study 
Tophaceous gout places a significant economic burden on the health care system and has 
a direct effect on ability to work, work productivity and a reduced quality of life (28-31).  
Impaired quality of life in patients with tophaceous gout is largely associated with clinical 
and musculoskeletal co-morbidity rather than the presence of gout itself (31). A high 
percentage of patients with tophaceous gout develops severe musculoskeletal deformities 
that may lead to functional disability (13, 32, 33).  
 
The mechanical structure of the AT enables it to withstand the large forces imposed during 
the gait cycle. Any alteration to the internal structure of the tendon may affect the ability 
of the gastro-soleus complex to generate force, transfer muscle power and absorb energy 
during the gait cycle (34). The mechanical efficacy and structure of the AT may be 
significantly affected by the clinical manifestations of tophaceous gout (35). The presence 
of tophi within the tendon may alter the collagen structure and prolong inflammatory 
responses, leading to the development of a mechanically weakened AT. Consequently, 
adaptations to gait strategy such as reduced walking velocity, reduced ankle range of 
motion and reduced ankle power may occur. 
 
There is a limited body of research investigating specific biomechanical function in the 
lower limb and foot in tophaceous gout (13, 18). Based on the current data it is unclear 
what adaptations occur to gait strategy in people with tophaceous gout. This necessitates 
research to investigate clinical disease activity in the AT, assessment of the structural 
alterations in the AT and examination of gait strategy in people with tophaceous gout. The 
current research will aid in the understanding of potential pathways leading from 
underlying disease process to localised impairment and enable the development of disease-
stage targeted treatment.  
 
 
  
29 
 
1.3. Objectives of the thesis 
1. Systematically review the literature and where appropriate conduct meta-analysis 
pertaining to: 
 (a) Lesions of the AT assessed by US imaging.  
 (b) Gait characteristics associated with AT in inflammatory arthritis.  
 
2. To assess US lesions of the AT using US imaging between participants with 
tophaceous gout and age and sex matched control participants.  
 
3. To investigate the differences in the kinematic, kinetic and spatiotemporal gait 
parameters between participants with tophaceous gout and age and sex matched 
control participants. 
 
4.  To evaluate the relationship between 3D gait parameters and the US lesions of the 
AT. 
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1.4. Hypotheses 
1. Participants with tophaceous gout have a higher prevalence of US lesions in the AT 
compared to control participants. 
 
2. There are significant differences US lesions in the AT in participants with tophaceous 
gout compared to control participants. 
 
3. Walking velocity is significantly reduced in participants with tophaceous gout 
compared to control participants. 
 
4. Ankle power is significantly reduced in participants with tophaceous gout compared 
to control participants. 
 
5. There is a significant difference in ankle range of motion in participants with 
tophaceous gout compared to control participants. 
 
6. There is a relationship between ankle power, ankle range of motion, walking 
velocity and ultrasound lesions in the AT in participants with tophaceous gout. 
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1.5. Gout: A New Zealand context 
The most recent prevalence estimates indicate that gout is more common among Māori and 
Pacific Islanders, males, people with advancing age and people living in socio-
economically deprived areas (36). The prevalence of gout in New Zealand was first 
measured in 1956 in Māori, 1958 in Europeans and 1980 in Pacific Islanders (37-39). 
Prevalence rates for males and females have been reported to range from 4.5%-13.9 % and 
0-2% in Māori’s, 0.7-5.8% and 0-0.9% in Europeans and 5.3-14.9% and 0.6%- 4.1% in 
Pacific Islanders (36). Gout prevalence rates from previous New Zealand studies are 
displayed in Table 1.1. Winnard (36) investigated prevalence estimates in the New Zealand 
population using national level health data sets (Table 1.2).  
 
Winnard (36) described the epidemiology of hospital admissions associated with gout in 
New Zealand. Using hospital admissions data from a ten year period (1999 to 2009) the 
co-morbidities associated with gout were analysed. Data were analysed from two groups. 
In group one there were 10,241 admissions for gout and in group two 34,318 admissions 
due to complications caused by gout. Results demonstrated gout patients admitted to 
hospital were more likely to be Māori or Pacific Islander and have had 3-7 co-morbidities 
such as: hypertension, cardiovascular disease, diabetes mellitus and chronic renal disease.   
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Table 1.1: Gout Prevalence from Previous New Zealand Studies 
Ethnicity Year Study population 
Prevalence (%) 
Male Female 
European 1958 Rotorua, European (random 
population sample) 
0.7% 0.0% 
1966 Carterton, European (cluster 
sampling) 
1.9% 0% 
1992 Rotorua, European (random 
population sample) 
5.8% 0.6% 
2006 South Auckland, general practice 
database 
4.1% 0.1% 
2009 National health database 3.7% 0.9% 
Māori 1956 Whanau-a-Apanui, Māori (census) 8.2% 1.6% 
 1958 Rotorua, Māori (random population 
sample) 
6.0% 0.0% 
 1963 Ruatahuna, Māori (census) 4.5% 2.0% 
 1963 Māori 8.8% 0.8% 
 1966 Ruatahuna, Tikitiki, Rotorua, Māori 
(census) 
10.4% 1.8% 
 1984 Māori (working age adults from a 
motor assembly plant) 
8.0% NA 
 1992 Rotorua and Ruatahuna, Māori 
(census) 
13.9% 1.9% 
 2006 South Auckland, general practice 
database 
9.3% 2.6% 
 2009 National health database 11.7% 4.0% 
Pacific 1980/1 Migrants from Tokelau (census) 13.9% 1.9% 
 2006 South Auckland, general practice 
database 
9.3% 2.6% 
 2009 National health database 11.7% 4.0% 
Note. From National prevalence of gout derived from administrative health data in Aotearoa New Zealand, 
Winnard (36). Reprinted with permission. 
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Table 1.2: Gout Prevalence in New Zealand from National Level Health Data Sets 
Population Prevalence (%) 
Overall 2.7 
People ≥ 20 3.8 
European males 3.7 
European females 0.9 
Māori males 11.7 
Māori females 4.0 
Pacific males 13.5 
Pacific females 4.1 
Note. From National prevalence of gout derived from administrative health data in Aotearoa New Zealand, 
Winnard (36). Reprinted with permission. 
 
1.6. Gout: Pathophysiology 
Gout is a disorder of purine metabolism and results from urate crystal deposition in and 
around joints (8). Hyperuricaemia occurs when serum urate levels exceed urate solubility, 
which occurs at 0.41 mmol/L (40, 41). Hyperuricaemia is a risk factor in the development 
of gout but does not inevitably cause gout (42, 43). Langford (44) followed a patient cohort 
over a 14 year period and reported that in those with a serum urate level between 0.39-0.44 
mmol/L only 12% developed gout. Urate is the final metabolite of endogenous and dietary 
purine metabolism (45, 46). Purines are organic substances found in many proteins derived 
from animals and plants and are one of the classes of substances from which the nucleic 
acids are constructed (40). The serum urate level in a given individual is determined by the 
amount of purines synthesised and ingested, the amount of urate produced by purines, and 
the amount of uric acid excreted by the kidneys and the gastrointestinal tract (47). Renal 
mechanisms are responsible for hyperuricaemia in approximately 90% of individuals, with 
patients who overproduce uric acid representing only 10-15% of hyperuricaemia cases and 
patients who under-excrete representing approximately 80-90% of hyperuricaemia cases 
(47). 
 
Apart from the concentration of urate the solubility of MSU crystals is modulated by 
several factors. These include: trauma or irritation, tissue pH, tissue temperature, intra 
34 
 
articular hydration state, concentration of cations, and the presence of extracellular proteins 
such as proteoglycans, collagens and chondroitin sulphate (9, 47). Release of MSU crystals 
into the joint space may initiate a dramatic acute inflammatory reaction. Urate crystals are 
directly able to initiate, amplify or sustain an intense inflammatory attack because of their 
ability to stimulate the synthesis and release of humoral and cellular inflammatory 
mediators (47). Resident tissue cells such as macrophages and monocytes react to crystal 
deposition by the uptake of crystals through phagocytosis within the synovial lining (48). 
The stage of differentiation of the monocyte and macrophage has been identified as the 
factor that determines the host response (48). The subsequent recruitment of inflammatory 
leukocytes to the site of MSU crystal deposition accounts for the release of inflammatory 
mediators and the inflammatory manifestations found in acute gout (48).  
 
1.7. Gout: Classification  
In 1977 the American Rheumatism Association (ARA) published preliminary criteria for 
the classification of gout for population-based epidemiological research (49). The 
preliminary criteria for the classification of gout are presented in Table 1.3. A combination 
of microscopic identification of MSU crystals in synovial fluid or tophus or 6 more of these 
features is highly suggestive of gout.  A new classification criteria for gout has recently 
been developed by an international collaborative working group (50).  The new 
classification criteria for gout represent an advance over previous criteria, with improved 
performance characteristics and incorporation of newer imaging modalities. 
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Table 1.3: ARA preliminary criteria for the classification of gout 
MSU crystals in joint fluid during attack 
More than one acute attack of acute arthritis 
Maximum inflammation developed within one day 
Monoarthritis attack 
Redness observed over joints 
First metatarsophalangeal joint painful or swollen 
Unilateral metatarsophalangeal joint attack 
Unilateral tarsal joint attack 
Hyperuricaemia 
Asymptomatic swelling within a joint on x-ray 
Subcortical cysts without erosions on x-ray 
Joint fluid culture negative for organisms during attacks 
Note. From Preliminary criteria for the classification of the acute arthritis of primary gout. Wallace (49). 
Reprinted with permission. 
 
Traditionally, hyperuricaemia and gout has been classified into four disease stages: (1) 
asymptomatic hyperuricaemia (high serum urate but no clinical symptoms); (2) acute gouty 
arthritis (sustained hyperuricaemia with MSU crystal deposition); (3) inter-critical gout 
(the period between acute attacks) and (4) chronic tophaceous gout (longstanding gout 
associated with tophus deposition and bone/joint damage) (51).  
 
Acute gouty arthritis presents with a rapid onset of severe monoarticular arthritis, severe 
pain, erythema and swelling, with maximal intensity of pain over a 8-12 hour period to the 
affected joint (9). The majority of attacks affect the 1st metatarsophalangeal (1MTP) joint 
of the foot, but there may also be involvement of the midfoot, ankle, heel, knee, wrist or 
fingers (10, 52). Episodes of untreated gout flares can span 3 to 10 days (53, 54). Brixner 
and Ho (55) reported that 60% of individuals with an initial gout flare experience a second 
flare within 1 year and 78% within 2 years. 
 
Inter-critical gout is the asymptomatic phase between acute attacks (2). Despite the absence 
of symptoms, MSU crystals remain within the joint and continue to accumulate. Further 
disease progression results in shorter inter-critical periods, with more frequent, more 
protracted and increasingly debilitating flares. The inter-critical period between attacks 
36 
 
may range from months to years, with a reported likelihood of a patient experiencing a 
second attack within a year ranging between 54 and 60% (56).  
 
Tophaceous gout is the most progressed phase of the disease and results from the 
longstanding effects of hyperuricaemia combined with delayed or ineffective treatment 
(11). Tophaceous gout is characterised by destructive polyarticular involvement with low 
grade joint inflammation, joint deformity, bone erosion and tophus formation (8). The time 
course duration from asymptomatic hyperuricaemia to tophaceous gout has been shown to 
vary widely from 3 to 42 years (2, 45, 57). Tophaceous gout develops within 5 years of 
onset of gout in 30% of people, occurs in 12 % of people with gout after 5 years and 55% 
after 20 years of untreated disease (2, 45, 57). 
 
Tophi represent a complex and organised chronic inflammatory response to MSU crystals 
(15). Tophi typically occur within both subcutaneous tissues and within affected joints and 
may cause pain, cosmetic problems, obstruction of joint movement, joint destruction and 
musculoskeletal disability (12, 58). Microscopically, tophi appear as chronic 
granulomatous lesions comprising of mononucleated and multinucleated macrophages 
surrounding a core of MSU crystals and encased by dense connective tissue (15). Previous 
studies suggest that the development of gouty tophus is a dynamic process with a low level 
continuous recruitment, pro-inflammatory activation, maturation and turnover of 
monocyte-macrophages (59). The reason why some individuals are susceptible to 
formation of tophi is unknown, it is postulated that crystals may form at a rate that exceeds 
the handling capacity of tissue macrophages, or the possibility that macrophages fail to 
demonstrate a pro-inflammatory response to crystal uptake (59). Several zones have been 
characterised within tophi. These include the central crystalline zone, the cellular corona 
zone surrounding the central zone and an outer fibrovascular zone (60). Mononcytes and 
macrophages within the tophi have been identified to produce the enzymes gelatinase A 
and gelatinase B. These enzymes are capable of degrading type IV and V-collagen, elastin 
and gelatin (61).  
 
Recently a new clinical staging system for hyperuricaemia and gout has been proposed 
(62). The new proposed staging system (Figure 1.1) provides a clear focus on gout as a 
chronic disease of MSU crystal deposition, as opposed to the traditionally held concept that 
gout is a condition of recurrent flares. 
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Figure 1.1. Proposed staging system for hyperuricaemia and gout. From Hyperuricaemia 
and gout: time for a new staging system? Dalbeth & Stamp (62), Reprinted with 
permission. 
 
1.8. Comorbid conditions associated with gout 
Patients with gout often have multiple comorbid conditions such as hypertension, 
cardiovascular disease (CVD), renal impairment, diabetes, obesity, hyperlipidemia and in 
combination known as the metabolic (63). The relationships between these comorbidities 
and gout are complex. The presence of these comorbidities contributes to the overall 
excessive cardiovascular mortality and morbidity due to myocardial infarction and 
peripheral arterial disease (64-66). 
Complex interactions between comorbidities has been implicated in a cycle whereby 
comorbidities may both cause and affect elevation of serum urate levels (67). The 
fundamental strategy in pharmacological management is long term urate lowering therapy 
to achieve MSU crystal dissolution (68). A recent study reported in participants with gout, 
74% with hypertension, 71% with  ≥ stage 2 chronic kidney disease, 53% with obesity, 
26% with diabetes and 11% with heart failure (69).  
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Gout is associated with increased risk of CVD and death, particularly in those with a high 
cardiovascular risk (64, 70). Hyperuricaemia is an independent risk factor for CVD (71), 
with associations between hyperuricaemia/gout and stroke (72) and peripheral vascular 
disease (73) reported. Relationships between renal function, serum urate and gout are well 
established, with renal impairment associated with hyperuricaemia (74). The relationship 
between blood glucose, serum urate and between diabetes and gout is complex. Research 
suggests that those with moderately increased HbA1c (pre-diabetes) may be at increased 
risk of hyperuricaemia and gout, whereas those with established diabetes or significantly 
increased HbA1c may be at lower risk (74). 
 
1.9. Pharmacological management approaches to gout 
Recent research has provided the first consensus-based pharmacological and non-
pharmacological recommendations for gout (68). The fundamental strategy in effective 
gout management is long term urate lowering therapy to achieve MSU crystal dissolution 
(68). The American College of Rheumatology (ACR) guidelines recommend that for most 
people with gout, the target serum urate concentration is < 0.33 mmol/L, however, a lower 
target serum urate of < 0.27 mmol/L has been proposed for people with tophi. The ACR 
guidelines recommend single-agent xanthine oxidase inhibitors (Allopurinol or 
Febuxostat) to maximum dose as first-line urate-lowering therapy, followed by the addition 
of a uricosuric agent. Probenecid is recommended as an alternative first-line therapy if 
either Allopurinol or Febuxostat are contraindicated or not tolerated. Pegloticase (a form 
of uricase, not available in New Zealand) is recommended as a third-line agent in distinct 
cases for those not achieving target serum urate concentration and continuing disease 
activity (68). In conjunction with intensive urate-lowering therapy, effective anti-
inflammatory medications to both prevent and treat gout flares are required in people with 
tophaceous gout. The 2012 ACR guidelines recommend that low-dose colchicine or Non-
steroidal anti-inflammatory drugs (NSAIDs) are most appropriate for first-line anti-
inflammatory prophylaxis and that in the presence of gouty tophi, a longer duration of anti-
inflammatory prophylaxis is indicated than for those without tophi (68). 
Non-pharmacological recommendations centre on providing patient education surrounding 
the role of uric acid in gout, long term urate treatment targets, dietary and lifestyle factors 
(68). Dietary recommendations include avoidance or high purine containing meats, high 
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fructose beverages or foods and excessive alcohol. People with gout are encouraged to limit 
serving sizes of meats and seafood, table sugar, salt and alcohol. People with gout are 
encouraged to low-fat or non-fat dairy foods and vegetables (68). Recommendations also 
include that all people with gout have a clinical examination to evaluate disease activity 
and burden, with attention to modifiable secondary causes of hyperuricaemia such as 
comorbidities, and medications (68). Recent research suggests that walking shoes with 
good cushioning and motion control may reduce foot pain and disability (75).  
 
1.10. Gout and the foot 
The most commonly affected joints in a gouty attack are the 1MTP joint, the midfoot and 
the ankle (76). The first attack of gout affects the 1MTP joint in 56-78% of patients, with 
90% having an attack in the hallux at some point in their disease course (77-80). Midfoot 
and ankle involvement occurs in 25-50% and 18-60% of patients, respectively (10, 78, 81). 
A community based observational study also found hallux valgus present in 41% of 
participants compared to 25% of controls (82). Recent research has highlighted the 
significance of MSU crystal deposition in the tendons and bones of the foot (17). Dalbeth 
(17) assessed multiple joint in 92 feet of patients with tophaceous gout using dual energy 
computerised tomography. Thirty eight percent of cases showed MSU deposition in the 
1MTP joint, 22% in the 5th metatarsophalangeal (5MTP) joint and 11% in the 2nd 
metatarsophalangeal (2MTP) joints. The study also reported MSU deposition through 
multiple midfoot joints. 
 
1.11. Gout and the Achilles tendon 
Limited research has been conducted describing structural, functional and biomechanical 
changes in the AT resulting from tophaceous gout. Naredo (83) using grey-scale US in 92 
men with gout, reported the AT abnormalities (hyperechoic areas) to be present in 34% of 
AT examined and 7% of control participants. Dalbeth (84) reported in 92 people with 
tophaceous gout, 39% displayed MSU crystal deposition within the AT using dual-energy 
computerised tomography imaging. In the 72 AT that were affected, 38% had only non-
entheseal involvement, 40% had both entheseal and non-entheseal involvement and 22% 
had only entheseal involvement. The authors postulated that the deposition of MSU crystals 
in the AT may be as a result of increased biomechanical strain within the AT. Case reports 
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have associated rupture of the AT with gout (85, 86). Mahoney (85) reported a case of AT 
rupture in a patient with tophaceous gout, postulating rupture was associated with MSU 
crystal deposition, reducing the tensile strength of the tendon. However, no data was 
provided or statistical analysis performed to link MSU crystal deposition and tendon 
rupture. Dodds & Barry (87) investigated the association between serum urate level and 
rupture of the AT. The serum urate levels were compared in 30 patients who presented with 
an AT rupture, and compared to age and sex matched controls with no history of AT 
rupture. Results demonstrated people with an AT rupture had a higher average serum urate 
level when compared to controls. The authors postulated that a raised serum urate level 
may affect tendon nutrition through alteration of proteoglycan metabolism. In a review of 
60 people with crystal related arthropathies using US imaging, Grassi (35) reported the 
normal fibrillar echotexture of tendons can be completely deranged by the presence of 
intratendinous tophus deposits.  
 
1.12. Structure, function and biomechanics of the Achilles 
tendon 
The AT is a confluence of the gastrocnemius and soleus muscles. As the tendon fibres of 
the gastrocnemius and soleus descend in the lower leg they converge and rotate in a 
spiraling fashion (approximately 90º) with full incorporation typically occurring 8 to 10 
cm superior to the calcaneal insertion (88). The rotation is more evident in the lower 5 to 6 
cm of the tendon and is thought to aid its elastic recoil (20).  
 
The tendinous fibres from the gastrocnemius insert into the posterolateral calcaneus, while 
those of the soleus insert into the posteromedial aspect of the calcaneus (89). The zone 
where the AT inserts into the calcaneus has been named the enthesis organ in recognition 
of the functional and dynamic events that occur at this anatomical site (90). The enthesis 
itself, the sesamoid and periosteal fibrocartilages, the retrocalcaneal bursa and its 
associated fat pad (Kager’s fat pad) are the components of the enthesis organ as originally 
defined by Benjamin and McGonagle (90, 91). The AT attaches into the middle third of 
the posterior surface of the calcaneus, allowing the upper third (the superior tuberosity) to 
act as a pulley mechanism for the AT, reducing the stress concentration on the enthesis. 
The retrocalcaneal bursae and fat pad further aid stress dissipation in this zone by 
minimizing frictional forces between the AT and superior tuberosity (92). 
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The AT is the thickest and strongest tendon in the human body (19). The basic structural 
elements of the AT consist of collagen fibres synthesised by tenocytes contained within an 
extracellular matrix. The major fibrillar component of the AT is closely packed Type I 
collagen, which account for 60% dry weight of the tendon and 95% of the total collagen 
fibres (93). Type I collagen is responsible for the tendon’s mechanical strength and its 
ability to withstand tensile stress (94). Type III and V collagen represent approximately 
5% of the tendon composition, the size and orientation of these fibrils, along with the 
overall physiological composition, determine the mechanical properties of the tendon (94). 
The extracellular matrix is composed of water (approximately 55% of the weight of 
tendon), elastin fibres and several glycoproteins that provide functional stability to the 
collagen fibres (94, 95). The collagen fibre structural units are bound into bundles by the 
endotenon to give higher structural units called fascicles, which in turn are bound together 
by epitenon and paratenon to form the tendon (Figure 1.2) (20). The endotenon contains 
the vascular, lymphatic, and neural transmission routes to maintain tendon fibroblasts, and 
the epitenon binds the fascicles together and supplies blood. The paratenon permits tendon 
sliding relative to adjacent structures (20). The AT receives blood supply from the 
musculo-tendinous junction, along the length of the tendon (via the paratenon) and junction 
with the calcaneus (96). The blood supply consists mainly of longitudinal arteries that 
course the length of the tendon, derived from either the peroneal and posterior tibial arteries 
(97). An area of low vascularity approximately 2 to 6 cm superior to the insertion is 
described in literature (95).  
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Figure 1.2. The multi-unit hierarchical structure of the human tendon. From 
Mechanobiology of tendon, Wang (94), Reprinted with permission. 
 
The gastro-soleus complex primarily provide a plantarflexion moment at the talocrural 
joint that accounts for 93% of the plantar flexor torque (98). The range of motion of the 
ankle joint during a normal gait cycle is plantarflexion to about 7 degrees (0 to 12% of gait 
cycle) and dorsiflexion to approximately 10 degrees (between 12% to 48% of gait cycle) 
and plantarflexion to 20 degrees (48% to 62% of the gait cycle) (22). The gastro-soleus 
complex is active in the stance phase, with activity beginning at approximately 10% of the 
gait cycle; maximal activity occurs at 40% and activity ceases at 50% of the gait cycle (22). 
The main function of the gastro-soleus complex is to restrain the forward movement of the 
tibia over the stance foot (22). 
 
 
The arrangement of the AT within this muscle tendon complex supplements passive force 
transmission with energy storage and recycling (99). These mechanisms enhance joint 
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performance and efficient power production (100). The AT, like other tendons, is a 
viscoelastic tissue that displays stress relaxation and creep (101). The mechanical behavior 
of the AT can be depicted by a stress strain curve (Figure 1.3). The tendon then deforms in 
a linear fashion indicative of collagen sliding with fibres becoming more parallel. The 
tendon will behave in an elastic fashion and return to original length when unloaded at 
strains under 4%. Microscopic failure occurs when the strain exceeds 4%, and, beyond 8-
10% strain, macroscopic failure occurs from intrafibril damage by molecular slippage 
(102). 
 
 
Figure 1.3. Stress strain curve demonstrating mechanical behavior of normal tendon. From 
Biology of tendon injury: healing, modelling and remodelling, Sharma and Maffulli (101).  
Reprinted with permission. 
 
The mechanical traits of the AT are primarily responsible for its ability to withstand large 
muscular forces with minimal deformation (100). Stiffness, an important constituent of 
tendon mechanical properties, is the ratio of force applied to the tendon and its elongation 
in response to the force. It has a significant influence on force transmission, muscle power, 
and energy absorption and release during locomotion (103). An optimal level of tendon 
stiffness is critical for effective muscle-tendon interactions and for minimizing the 
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energetic costs of locomotion (100). Tendon stiffness may be influenced by tendon length 
and cross sectional area (CSA). A shorter tendon with larger CSA is expected to have 
greater stiffness (100). Young’s modulus (stiffness normalized to tendon CSA and length) 
provides a measure of tendon material properties irrespective of its geometric 
characteristics. This is especially important in the case of pathological tendons, as 
pathological tendons usually present with greater CSA (100). 
 
Acute tendon injuries heal in a standard triphasic response: inflammation, proliferation and 
maturation and return slowly to a normal tendon structure (101). Tendons affected by 
overuse injury (tendinopathy) do not follow this same healing pathway, the result being 
long term disruption to the internal structure of the tendon (26). Tendon pathology is 
characterised by four main structural changes: a change in cell function, an increase in 
ground substance, a breakdown of collagen bundles and neurovascular proliferation 
(neovascularisation) (104). Previous studies have shown that type III collagen is 
synthesized during the healing process at the repair site by cells that once produced type I 
collagen (102). A disruption to this structure and arrangement, accompanied by an increase 
in mechanically weaker type III collagen fibres may weaken the tendons’ mechanical 
(stiffness) and material properties (Young’ modulus) (34, 100).  
 
1.13. Three-dimensional gait analysis of the foot 
Human movement analysis using stereophotogrammetric measurements and rigid body 
modelling requires the identification of appropriate body segments and axes (105). The 
systems of axes is defined by the positioning skin mounted markers (105). The 
understanding of foot and ankle motion during gait has grown substantially in the past 
decade with the developments in 3D multi-segment foot models. Prior to the development 
of multi-segment foot models the understanding of foot function was based on a single 
segment foot model. These models were unable to demonstrate the complex interactions 
of joint articulations distal to the ankle (106). Over fifteen foot models based on skin 
mounted markers have now been developed to explain joint kinematics in the foot (107). 
All 3D multi-segment foot models vary with regard to marker placement and the number 
of foot segments modelled. The number of segments modelled varying between 3 to 9 foot 
segments (107-109). Foot segments commonly modelled include the hindfoot, forefoot and 
hallux, with recent models separating the midfoot into a medial and lateral component 
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(109). Although there is no consensus regarding the most appropriate number of foot 
segments to model, there is consensus that modelling the foot by multi-segment 
methodologies is more appropriate than viewing the foot as a single segment (107, 110, 
111). 
 
The most commonly applied 3D multi-segment foot models include the Milwaukee Foot 
model (112), the Oxford Foot Model (113) and the Heidelberg Foot Model (114). The most 
commonly applied model in inflammatory arthritis is the Oxford Foot Model. Chapter 3 
provides a detailed review of the spatiotemporal, kinematic, kinetic and plantar pressure 
gait parameters that have been assessed in people with inflammatory arthritis. The chapter 
also details the 3D multi-segment foot models used to acquire kinematic gait data in 
inflammatory arthritis. 
 
1.14. Assessment of gait in gout 
Limited research has been conducted using 3D analysis methodologies to assess kinematic 
or kinetic gait parameters in tophaceous gout. Rome (18) assessed the impact of tophaceous 
gout on foot function, plantar pressure and the spatial and temporal gait parameters in 25 
people with tophaceous gout, compared to age and sex matched controls. The spatial and 
temporal gait parameters investigated included: step and stride length, single and double 
leg support, velocity and cadence. Results indicated that patients with tophaceous gout had 
foot related pain and disability, reduced step length, stride length, velocity and cadence 
when compared to controls. Plantar pressure results demonstrated a reduction in peak 
plantar pressure under the hallux. The authors postulated that people with tophaceous gout 
alter their gait pattern to reduce pressure to the 1MTP joint as a pain-avoidance strategy.  
 
1.15. Ultrasound Imaging 
US waves projected into the tissue are either reflected back or penetrate into the tissue. By 
timing the period elapsed between the US production and echo reception the distance can 
be calculated and an image formed (115). US images produced are described in terms of 
their echogenicity. The common US terminology related to description of the echogenicity 
is presented in Table 1.4. 
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Table 1.4: Ultrasound lesion terminology 
Ultrasound lesion Definition 
Anechoic No internal echoes, appears dark or black 
Isoechoic Similar appearance to surrounding tissue 
Hypoechoic Less echoic or darker than surrounding tissue 
Hyperechoic More echoic or whiter than surrounding tissue 
Note. From Ultrasound Physics and Instrumentation, Case (115). Reprinted with permission. 
 
US imaging is an ideal modality to assess pathological changes to the AT and is considered 
the first choice imaging technique when assessing tendon pathology (116-119). US 
imaging can assess the internal structural organisation of the tendon as well as the 
peritendinous structures (sheath, bursae, enthesis). US imaging has been used extensively 
in the assessment of AT pathology, with the technique assessing both chronic degenerative 
and acute inflammatory tendon pathology (116, 120). Additional US imaging techniques 
such as power Doppler (PD) has allowed for assessment of vascularisation in the AT (121, 
122).  In the last decade, PD, imaging has been used to quantify the degree of inflammatory 
change in numerous forms of inflammatory arthritis (123).  
 
When examined in a longitudinal orientation by US imaging, the AT appears as a 
homogenous ribbon-like structure with a parallel fibrillar pattern of tendon fibres outlined 
by a straight hypoechoic border representing the paratenon (124). Hypoechoic lines within 
the tendon represent acoustic borders between the fibrils and intervening connective tissue. 
In transverse orientation these lines are represented by a honeycomb pattern (124). The 
normal appearance of the AT when examined by US imaging is displayed in Figure 1.4. 
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Figure 1.4. Longitudinal ultrasound image of normal Achilles tendon (A), calcaneus (B), 
fat pad (K), soleus muscle (S). From The role of ultrasound imaging in acute rupture of the 
Achilles tendon, Elias & McKinnon (124). Reprinted with permission. 
 
1.16. Ultrasound imaging and tophaceous gout 
US imaging is being increasingly used to investigate gout due to its low cost, the lack of 
ionising radiation, its multi-planar imaging capability, its high resolution, and the ability to 
perform a dynamic assessment (125). The physics of US imaging make it an ideal tool to 
detect crystalline material in soft tissues. Crystalline material found in gouty joints reflects 
US waves more strongly than surrounding tissues such as unmineralised hyaline cartilage 
or synovial fluid, and can thus be readily distinguished (125).  
 
Although the gold standard for diagnosis of gout remains positive identification of MSU 
crystals via arthrocentesis (joint aspiration), US imaging provides a non-invasive technique 
to aid diagnosis, monitor disease progression and provide insights into pathological 
changes (24). US imaging is able to detect various specific and non-specific US lesions in 
gout. Non-specific features include those findings that may be common among other forms 
of inflammatory arthritis such as: joint effusion, synovitis, hypervascularisation, bony 
erosion and proliferative new bone formation (25).  
 
Detection of MSU crystals by US imaging allows for non-invasive assessment and a 
potential method of monitoring disease progression. Under US imaging MSU crystals may 
appear within synovial fluid as a snowstorm appearance. The snowstorm appearance is 
determined by the presence of multiple foci with different echogenicity or within articular 
cartilage as the double contour sign (35). The double contour sign is US lesion specific to 
gout and refers to a hyperechoic irregular band over the superficial margin of the anechoic 
cartilage and is produced by deposition of MSU crystals on the surface of hyaline cartilage 
48 
 
(126, 127). Thiele & Schlesinger (127) retrospectively compared US images of gout 
patients to images of controls with rheumatic diseases. The results demonstrated the double 
contour was a specific finding occurring in 92% of gouty joints. Wright (126) demonstrated 
that the double contour sign was present in 22% of gout patients when investigating bony 
erosions at the 1MTP joint. Figure 1.5 demonstrates the typical appearance of the double 
contour sign in the 1MTP joint. 
 
 
Figure 1.5. The double contour sign. From Diagnosis of gout by ultrasound, Thiele & 
Schlesinger (127). Reprinted with permission. 
 
US imaging has been used to assess and characterise tophi. Under US imaging tophi present 
as hypoechoic or hyperechoic non-homogenous mass surrounded by an anechoic rim (128). 
de Ávila Fernandes (129), using an observational cross-sectional methodology, described 
the US features of tophi in 138 affected areas in 31 patients with tophaceous gout. Results 
indicated that tophi were largely hyperechoic (brighter than surrounding tissue), displayed 
heterogeneous echotexture (stippled areas of intensity within tophi), and had poorly 
defined borders. Although this study defined the characteristics of tophi, enabling the 
differentiation of tophi from other soft tissue structures, the tophi examined were from 
various locations in the participants including the hand, forearm, knee, leg ankle and foot. 
The authors provided no detail specific to the anatomical locations of the tophi. Puig (130) 
assessed 35 hyperuricaemia patients and found tophi were present in 34% of soft tissue. 
The authors did report tophi to be located in the knees, ankle and patellar tendon, but did 
not define the specific anatomical locations of the tophi.  
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US imaging has also been used to quantify tophus size, with reduction in tophus size 
considered important for studies of patients with tophaceous gout (131, 132). US imaging 
has also a reported ability to detect 90% of tophi detected by magnetic resonance imaging 
(MRI) and the ability of being able to assess subcutaneous and intra-articular tophi (131). 
Figure 1.6 displays the typical US appearance of a hyperechoic tophus (dotted lines 
surrounded by Xs) surrounded by a partial anechoic halo (arrow) in the elbow. The 
posterior aspect of the tophus has an imprecise contour (arrowheads). 
 
 
Figure 1.6. The appearance of a tophi under ultrasound imaging. From Ultrasound features 
of tophi in chronic tophaceous gout, de Ávila Fernandes (129). Reprinted with permission. 
 
 
Tophi are frequently observed by US imaging to be in contact with bone and joint structures 
(129). Wright (126) was the first to demonstrate US imaging was able to detect 
significantly more erosions than x-rays at the 1MTP joint in gout.    
 
The development of new blood vessels within an articular or periarticular structure due to 
active inflammation can be assessed using PD (133). PD assessment of Achilles 
tendinopathy has demonstrated vascularisation, even when vessels are too small to be 
visualised by MRI (133). Normal tendons do not exhibit PD signal but in tendinopathy 
tendon vascularisation has been demonstrated to be present within the small vessels and 
has been associated with pain and poor function (133-135). PD has also been used to 
investigate inflammatory arthropathies, most notably RA (136-138). In RA, PD has been 
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used to grade inflammatory change (synovitis) with semi-quantitative grading systems 
developed to score PD signal (139). In spondyloarthropathy (SpA) PD has been used to 
demonstrate vascularisation in the mid-portion and insertion of the AT (140). The use of 
PD in the study of gout is limited. Puig (130) investigated 35 people with asymptomatic 
hyperuricaemia and found increased vascularity within or around tophi in 23% of patients. 
This study was limited by the lack of comparison to control participants. Though the 
research identified tophi location within periarticular structures, specific anatomical 
locations of the tophi were not provided.  
 
Although the radiographic appearance of gout is well recognised and is included in the 
ACR preliminary clinical classification criteria for gout (49), US imaging is reported to 
have various advantages over conventional radiography (141). US imaging has 
demonstrated increased sensitivity to detect early signs of small bone changes in gout can 
be detected when compared to conventional radiography (141, 142). Howard (143) 
reported high agreement between rheumatologists in reading of ultrasonography images 
obtained by a single operator, for the features of MSU crystal deposition. In this study, 
ultrasonography features of MSU crystal deposition (defined as tophus or the double-
contour sign) were present in 50% of people with gout, 29% of people with asymptomatic 
hyperuricaemia, and 5% of controls. 
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CHAPTER 2  
The assessment of inflammatory and 
structural lesions of the Achilles tendon by 
ultrasound imaging in inflammatory 
arthritis: a systematic review and meta-
analysis 
2.0. Purpose of the systematic review 
The systematic review was undertaken for the following purposes: 
1. To determine what US lesions have been used to quantify structural change in the 
AT of people with inflammatory arthritis. 
2. To guide research design, specifically: 
a. To determine how US lesions have been scored by previous research in 
inflammatory arthritis. 
b. To determine appropriate definitions for US lesions of the AT in the 
context of inflammatory arthritis. 
3. To conduct meta-analysis to demonstrate what AT lesions significantly differ and 
the degree to which these lesions differ across different forms of inflammatory 
arthritis. 
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2.1. Introduction 
US imaging is a highly sensitive, reliable and non-invasive tool which allows for the 
assessment of lesions of tendons and entheseal sites and is considered the gold standard for 
imaging tendons in rheumatology (144-147). US has greater sensitivity than conventional 
radiography in the detection of erosions, synovitis (142, 148) and urate deposition in gout 
(141). Compared to magnetic resonance imaging, US has demonstrated higher sensitivity 
in the detection of enthesitis (149) and higher specificity and sensitivity than clinical 
examination. Subsequently, the use of US imaging to assess lesions in the AT and calcaneal 
enthesis has increased (150).  
 
In clinical practice, the identification of inflammatory and structural lesions in the AT and 
enthesis are important to establish the extent of pathology, to monitor disease activity and 
to determine treatment efficacy in inflammatory arthritis. However, Gandjbakhch (151) 
reported that poor quality exists in defining US lesions. In order to standardise US lesion 
definitions the Outcome Measures in Rheumatology Clinical Trials (OMERACT) US task 
force provided consensus-derived definitions of bone erosion, synovial fluid, synovial 
hypertrophy, tenosynovitis and enthesopathy related to RA (152). With the increased use 
of US imaging the OMERACT US task force further defined B-mode US lesions in SpA, 
providing definitions encompassing entheseal thickening, calcification and Doppler signal 
(153). Furthermore, the OMERACT US task force proposed separation of US lesions into 
those reflective of inflammation and structural damage. US lesions indicative of 
inflammation (acute/active US enthesitis) include hypoechogenicity, tendon thickening 
and Doppler signal. US lesions representative of structural damage (chronic/inactive US 
enthesitis) include erosions, enthesophytes, calcification and cortical irregularities (153). 
However, there was poor consensus agreement for differentiation between acute and 
chronic US lesions (153).  
 
Previous systematic reviews have reported the level of homogeneity in the ultrasound 
definitions for the principal lesions of enthesitis, evaluated the metric properties of 
ultrasound for detecting enthesitis in spondyloarthropathy (SpA) and RA (151, 154). They 
have also examined the prevalence of US abnormalities and assessed the diagnostic 
accuracy and the sensitivity of US evaluation of the enthesis in SpA (151, 154). US lesions 
reflective of calcaneal enthesitis and structural damage are a typical clinical aspect of SpA 
(14), but have not been evaluated in other forms of inflammatory arthritis. The aim of this 
53 
 
systematic review and meta-analysis was to identify differences in US lesions of the AT 
between people with inflammatory arthritis and healthy controls. This is the first systematic 
review to examine the prevalence of US lesions specific to the AT across different forms 
of inflammatory arthritis.  
2.2. Methods 
2.2.1. Identification of studies 
Four electronic databases were searched (Medline, CINAHL, SportDiscus and The 
Cochrane Library). The search was conducted between June and July, 2014 and the search 
strategy combined terms appropriate to: RA, SpA, ankylosing spondylitis (AS), psoriatic 
arthritis (PsA), gout, and calcium pyrophosphate deposition (CPPD); AT pathology and 
US imaging (Table 2.1). The term SpA encompasses a heterogeneous group of conditions, 
characterised by vertebral involvement, peripheral oligoarthritis or polyarthritis, enthesitis, 
AS, PsA and undifferentiated spondyloenthesoarthritis (14, 15). The review included SpA 
but also reported on AS and PsA as separate diseases. 
 
Table 2.1: Search strategies: (a) search terms for rheumatic disease (b) search terms for 
Achilles tendon pathology (c) search terms for ultrasonography, and (d) combination of 
search terms 
a 1 Subject term exp. Rheumatic Disease 
 2 Keywords Rheumatoid or Rheumatic or Rheumatology or Inflammatory rheumat* or 
Rheumatic disease or Rheumatoid arthritis or Gout or Psoriatic arthritis or 
Ankylosing spondylitis or Spondyloarth* or Calcium pyrophosphate deposition or 
CPPD 
b 3 Keywords Achilles tend* or Achilles paratendin* or Achilles paratendon* or Achilles 
enthesis* or Achilles insertion or Achilles Burs* or Calcaneal burs* or Achilles 
thicken* or Bone spur or Entheso* or Calcaneal erosion or Erosion or 
Vascularisation or Neovascularisation or hypoecho* 
 4 Subject term exp. Pathology 
c 5 Subject term exp. Ultrasonography 
 6 Keywords Ultrasonograph* or Sonograph* or Ultrasound or US or MSUS or Doppler or 
Power Doppler or PDUS or Colour Doppler 
d 7 Combine 1 or 2 
 8 Combine 3 or 4 
 9 Combine 5 or 6 
 10 Combine 7 [and] 8 [and] 9 
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2.2.2. Inclusion/exclusion criteria 
The selection of titles, abstracts and articles was undertaken by one reviewer. All titles 
were screened, subsequently selected abstracts retrieved and full-text articles reviewed. 
Studies were included if they: reported people with inflammatory arthritis; assessed adults 
aged >18 years old; reported US lesions of the AT or enthesis; included a healthy 
comparison control participants; were articles published in English. Surgical and 
pharmacological intervention studies were excluded. No limitation was placed on the date 
of publication. 
2.2.3. Assessment of methodological quality and diversity 
The quality of studies was assessed independently by two reviewers, who were blinded to 
author and publication details. Study quality was rated using a modified version of the 
quality index tool originally described by Downs and Black (155). The quality index tool 
consists of 27 items, which allows for assessment of internal and external validity, quality 
of reporting and study power. A total of 14 questions were considered not applicable to the 
study designs included in this review, resulting in the retention of 13 questions (Table 2.2). 
Each question was scored “0” or “1” (0 = no/unable to determine, or 1 = yes). The total 
percentage score for each paper was determined. In the absence of validated cut-off scores 
and following a review of past articles that have applied the Downs and Black criteria, 
studies that scored: ≥11 (85%) were deemed high quality; 8-11 (61%-84%) moderate 
quality; and <8 (61%) poor quality (156, 157). 
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Table 2.2: Questions included from the Quality Index checklist (155) 
1 Is the hypothesis/aim/objective of the study clearly described? 
2 Are the main outcomes to be measured clearly described in the Introduction or Methods section?  
3 Are the characteristics of the patients included in the study clearly described? 
6 Are the main findings of the study clearly described? 
7 Does the study provide estimates of the random variability in the data for the main outcomes? 
10 Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main 
outcomes except where the probability value is less than 0.001? 
11 Were the subjects asked to participate in the study representative of the entire population from 
which they were recruited? 
12 Were those subjects who were prepared to participate representative of the entire population 
from which they were recruited? 
16 If any of the results of the study were based on “data dredging”, was this made clear? 
18 Were the statistical tests used to assess the main outcomes appropriate? 
20 Were the main outcome measures used accurate (valid and reliable)? 
21 Were the patients in the cases and controls (case-control studies) recruited from the same 
population? 
22 Were study subjects in the cases and controls (case-control studies) recruited over the same 
period of time? 
 
2.2.4. Data extraction 
A standardised form was used by one a reviewer to extract publication details (authors and 
year), sample characteristics (sample size) and participant characteristics (age, sex and type 
of inflammatory arthritis). Frequencies and measurements of the US lesions indicative of 
inflammation and structural damage were also extracted. The OMERACT US lesion 
definitions were used to group and define lesions (153). Lesions relating to inflammation 
included hypoechogenicity, tendon thickening and Doppler signal (153). Lesions of 
structural damage included erosions, enthesophyte formation, calcification and cortical 
irregularities (153). The scoring methods for the inflammatory and structural lesions were 
also recorded. 
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2.2.5. Data analysis and synthesis 
The clinical and methodological diversity among the studies was assessed to determine the 
appropriateness of data pooling for meta-analysis. Two reviewers reached consensus 
regarding the appropriateness of conducting meta-analysis. The criteria for pooling 
included: (a) participants exhibited the same type of inflammatory arthritis, (b) US lesions 
were clearly defined in text and/or supported by in-text citations and (c) direct 
measurement of an US lesion occurred, and the same methodology was used to score the 
lesion. Odds ratios (OR) with 95% CI (confidence intervals) were calculated, where data 
pooling was considered appropriate. OR were considered significant if the 95% CI did not 
contain zero. An OR = 1 indicated exposure does not affect the odds of the outcome; OR 
> 1 indicated exposure associated higher odds of the outcome and OR < 1 indicated 
exposure associated with a lower outcome (158). The difference in means and 95% CI was 
calculated for studies that directly measured US lesions.  
 
Meta-analysis was performed using the Comprehensive Meta-analysis, versions 2 (159). 
Heterogeneity was considered low if the I2 value was 25% or less, moderate if the value 
was between 25% and 50%, high if between 50% and 75% and very high if greater than 
75% (160). A fixed-effect model was applied where the I2 statistic was less than 50% and 
the Chi2 test indicated a non-significant degree of heterogeneity (P > 0.1). The random-
effect model was used where the I2 statistic was greater than 50% and the Chi2 test indicated 
statistically significant heterogeneity (P < 0.1) (161).  
2.3. Results 
2.3.1. Selection and inclusion of studies 
All items were reported using the PRISMA statement (162). A total of 469 references were 
initially identified for screening (Figure 2.1). Detailed review of abstracts and full-text 
reviews resulted in 445 records being excluded and thirteen articles being included in the 
final analysis (163-175). 
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Figure 2.1. PRISMA flow diagram  
2.3.2. Methodological quality of studies 
Two reviewers independently scored 169 items and agreed on 162 items (96%), with an 
inter-rater agreement kappa of 0.85 (p < 0.001). The seven disagreements were resolved 
following discussion, whereupon consensus was reached. Twelve studies (163-168, 170-
175) were considered of high quality and one (169) of moderate quality. None of the 
included studies described the time period for the recruitment for both case and control 
populations (QI criteria 22). The numerical (%) quality scores ranged from 10-12 (76-
93%), with a median (%) score of 12 (93%), suggesting the majority of studies were of 
high quality (Table 2.3). 
 
  
[445] Excluded  
No relevance to research question 
[12] Excluded  
[7] Did not meet inclusion criteria  
[1] No specific measurements reported  
[1] Non-inflammatory condition  
[3] Control group not healthy  
 
Records identified by search strategy 
[397]  Medline   
[58]  CINAHL  
[14]  SportDiscus   
[469] Titles and abstracts screened 
[24] Full text obtained  
[12] Manuscripts meeting inclusion criteria  
[0] Manuscripts added following reference review  
[13] Studies evaluated  
[1] Papers added following auto alerts  
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Table 2.3: Quality Index scores for included articles 
Author 1 2 3 6 7 10 11 12 16 18 20 21 22 
QI score 
n, (%) 
Falsetti (163) 1 1 1 1 1 1 1 1 1 1 1 1 0 12/13 (93%) 
Falsetti (164) 1 1 1 1 1 1 1 1 1 1 1 1 0 12/13 (93%) 
Genc (165) 1 1 1 1 1 1 1 1 1 1 1 0 0 11/13 (84%) 
McGonagle (166) 1 1 1 1 1 1 1 1 1 1 1 0 0 11/13 (84%) 
Li (167)  1 1 1 1 1 1 1 1 1 1 1 0 0 11/13 (84%) 
Feydy (168) 1 1 1 1 1 1 1 1 1 1 1 0 0 11/13 (84%) 
Freeston (169) 1 1 1 1 1 0 1 1 1 1 1 0 0 10/13 (76%) 
Bandinelli (170) 1 1 1 1 1 1 1 1 1 1 1 0 0 11/13 (84%) 
Falcao (171) 1 1 1 1 1 1 1 1 1 1 1 1 0 12/13 (93%) 
Turan (172) 1 1 1 1 1 1 1 1 1 1 1 1 0 12/13 (93%) 
Wiell (173) 1 1 1 1 1 1 1 1 1 1 1 1 0 12/13 (93%) 
Woodburn, (174) 1 1 1 1 1 1 1 1 1 1 1 1 0 12/13 (93%) 
Aydin (175) 1 1 1 1 1 1 1 1 1 1 1 0 0 11/13 (84%) 
          Median 12 (93%) 
 
59 
 
2.3.3. Study characteristics 
The characteristics of the 13 studies are displayed in Table 2.4 and include SpA, AS, PsA, 
RA and CPPD. A total of 1287 participants were reported, 928 with inflammatory arthritis 
and 359 controls. Of the 928 cases, 467 were females and 381 males. The 359 control 
participants included 174 females and 152 males. The mean (SD) age of the cases and 
controls was 45.3 (8.9) and 44.8 (9.2) years, respectively.  
 
Table 2.4: Population characteristics of included studies 
  Case demographics Control demographics 
Study Condition N Sex 
(F:M) 
Mean 
Age 
(years) 
 
N Sex 
(F:M) 
Mean 
Age 
(years) 
Falsetti (163) RA 158 111:47 58.9 50 26:24 56.3  
PsA 125 35:30 54.4 
Falsetti (164) CPPD 57 27:30 69.4  50 25:25 66.3  
Genc (165) RA 24 22:2 44.4 20 15:5 42.6 
AS 18 4:14 41.4 
McGonagle 
(166) 
Early SpA 20 8:12 43.0 10 4:6 44.0 
Established SpA 17 8:9 52.8  
Li (167) AS 50 12:38 33.0 15 10:5 34.0  
RA 10 7:3 34.0  
PsA 5 2:3 50.0 
SpA 5 2:3 32.0 
Feydy (168) SpA: no heel 
pain 
25 13:12 45.0  24 12:12 50.0  
SpA: history of 
heel pain 
13 9:4 50.0  
SpA: heel pain 13 10:3 43.0  
Freeston (169) PsA 42 23:19 46.1 10 6:4 43.9  
Bandinelli 
(170) 
PsA 92 54:41 51.6  40 22:18 49.6 
Falcao (171) SpA 66 34:32 32.5  23 NR NR 
RA 23 NR NR 
Turan (172) AS 41 14:27 38.4  32 11:21 33.1  
Wiell (173) SpA 12 9:3 38.5 10 6:4 41.5  
Non-specific 
SpA 
15 5:10 47.0 
Woodburn 
(174) 
PsA 42 25:17 45.0 29 18:11 40.0  
Aydin (175) SpA 55 33:22 40.2 46 19:17 36.4  
RA, rheumatoid arthritis; PsA, psoriatic arthritis; CPPD, calcium pyrophosphate deposition disease; AS, 
ankylosing spondylitis; PsA, psoriatic arthritis; N, number; F, female; M, male; NR, not reported. 
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2.3.4. Definition of US lesions 
US lesions of inflammation and hypoechogenicity were not assessed or defined as a 
separate entity. AT thickening (cross-sectional diameter at the enthesis) was assessed in 
seven studies (165, 168, 170, 172-175) and was most commonly defined by the cut-off 
value of >5.29 mm (9). Eight studies assessed the presence of Doppler signal (164, 167-
169, 171-174). One study (169) provided a definition of positive Doppler signal (Table 
2.5). 
 
The US lesions of bone-spurs, enthesophytosis and enthesophyte were synonymous. Ten 
studies (163-166, 168-170, 172-174) investigated enthesophyte formation, four provided 
definitions referenced to previous literature (163, 164, 166, 170). Eleven studies assessed 
erosions (163-170, 172-174), with five studies (163-166, 170) providing a referenced 
definition proposed by either OMERACT (152) or Balint (150). Four studies investigated 
tendon calcification (164, 168, 169, 173), with Falsetti (164) and Wiell (173) providing 
definitions, but not referenced to previous work. Cortical bone irregularities were 
investigated by one study (167), but no definition of the lesion was provided (Table 2.5). 
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Table 2.5: Definitions of inflammatory and structural ultrasound lesions 
Study Condition US Lesion Definition of US lesion with reference 
Falsetti (163) RA 
PsA 
Posterior erosions Interruption of the cortical bone profile (117, 176, 177) 
Enthesophytosis Hyperechoic bony spur that interrupts the cortical profile, determining the characteristic shadowing (117, 176, 177) 
Falsetti (164) CPPD Vascular signal Presence of flow in orthogonal scans, presence of pulsatility of flow, permanence of flow at increase of pulse repetition 
frequency (no reference) 
Posterior erosions Interruption of the cortical bone profile (163, 178, 179) 
Enthesophytosis Hyperechoic bony spur interrupting 
the cortical profile, determining the characteristic shadowing (163, 178) 
AT calcification Hyperechoic deposits with acoustic shadowing generally not in continuity with the bone profile observed within the fibrillar 
tendon structure (no reference) 
Genc (165) RA 
AS 
Tendon thickened No specific in-text definitions were provided but references were provided to Balint (150) and Lehtinen (180)  
Bone erosion 
Enthesophyte 
McGonagle 
(166) 
SpA Bony spurs Cortical protrusions seen in at least 2 perpendicular planes (152) 
Entheseal erosions Cortical break visible in at least 2 perpendicular planes (152) 
Li (167) AS 
ReA 
PsA 
SpA 
Abnormal Vascularisation No in-text definitions of lesions or reference provided 
Cortical bone erosion 
Achilles enthesitis 
Cortical bone irregularity 
Feydy (168) SpA Tendon thickening No in-text definitions of lesions or reference provided 
Vascularisation 
Bone erosion 
Enthesophyte 
Calcification 
Freeston 
(169) 
PsA Power Doppler signal Presence of PD signal was considered positive if found within the tendon 2 mm proximal to the bony insertion, but not in the 
body of the tendon or any associated bursa (no reference) 
Erosion No in-text definitions of lesions were provided. The OMERACT (152) recommendations were discussed in text but no 
references were stated Bony spur 
Calcification 
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Bandinelli 
(170) 
PsA AT thickness Defined using Balint cut-off values (150) 
Power Doppler signal No definition or reference as to what was considered presence of PD signal 
Erosions A cortical break with a step down defect of bone 
contour (visible in the longitudinal and transversal axis) (150) 
Enthesophytes Irregularity of cortical bone insertion (150) 
Falcao 
(171) 
PsA 
RA 
Power Doppler signal No definition or reference as to what was considered presence of PD signal 
Turan (172) AS Tendon enlargement No definitions of lesions or reference provided 
Erosions 
Enthesophytes 
Wiell (173) SpA 
Non-
specific 
SpA 
Tendon enlargement Subjective estimation of focal or diffuse increased thickness (also considering the thickness of the opposite 
tendon). No reference 
Intratendinous 
vascularisation 
PD signal inside the tendon (no reference) 
Entheseal vascularisation PD signal at the tendon insertion adjacent to the cortical bone (no reference) 
Erosions Bone cortex discontinuation in the insertional area, visualised in two planes (no reference) 
Enthesophytes Bone cortex proliferation in the insertional area (no reference) 
Calcifications Hyperechoic band or structure not adjacent to 
bone with or without acoustic shadow (no reference) 
Woodburn 
(174) 
PsA Tendon thickening No in-text definitions of lesions. Reference was made to GUESS (150) in the definition of US lesions 
Erosion 
Enthesophyte 
Aydin 
(175) 
SpA Tendon thickness Referred to Balint (150) cut off value to define thickness 
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2.3.5. Scoring of US lesions 
The scoring of US lesions is presented in Table 2.6. AT thickening was scored in eight 
studies (165, 166, 168, 170, 172-175). The cut-off value of AT thickness > 5.29mm (150) 
was applied in five studies (165, 168, 170, 174, 175). AT thickness was directly measured 
in five studies (165, 168, 170, 174, 175), with AT thickness measured proximal to the 
enthesis in two studies (172, 175) (Table 7). Of the eight studies that scored Doppler signal 
(164, 167-173), two used a semi-quantitative system (169, 170). Six studies (164, 167, 168, 
171-173) scored the Doppler signal using a binary system (present absent or 
normal/abnormal). Erosions, enthesophytes, calcifications and cortical irregularities were 
scored using a binary (present/absent) system with the exception of McGonagle (166), who 
used a semi-quantitative system to quantify enthesophyte size (Table 2.6). 
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Table 2.6: Ultrasound lesions and scoring of lesions in the Achilles tendon  
 
Author US 
Mode 
US AT Lesion Condition Frequency (%) Scoring of US AT Lesions 
Cases Control  
Falsetti 
(163) 
Grey-
scale 
 
Posterior erosions RA 12 0 Inflammatory alteration graded according to a semiquantitative scale: 
Grade 1 (mild) 
Grade 2 (moderate)  
Grade 3 (considerable) 
 
Other lesions graded as present/absent expressed as a percentage. 
PsA 5 
Posteroinferior 
enthesophytosis 
RA 34 22 
PsA 49 
Falsetti 
(164) 
Grey-
scale 
Power 
Doppler 
Vascular signal in 
AT insertional on 
PDS 
 11 0 All US lesions graded as present/absent expressed as a percentage. 
Posterior erosions  0 0 
Posterior inferior 
enthesophytosis 
 30 12 
AT calcification CPPD 51 0 
Genc (165) Grey-
scale 
Tendon thickened RA 42 5 In the systematic analysis of the tendon insertions, presence or absence of thickening in the tendon insertions 
(tendinitis), intratendinous focal changes (focal tendinitis), bony erosions and enthesophytes were recorded at each site 
 
Cut off values and measurement locations were defined by GUESS (150) 
AS 67 
  Bone erosion RA 6 0 
AS 11 
Enthesophyte RA 10 0 
AS 28  
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McGonagle 
(166) 
Grey-
scale 
Tendon 
thickening 
Early SpA  80 NR The presence or absence of erosions and spurs was recorded in 3 separate regions within the enthesis organ complex: 1) 
the fibrous distal half of the insertion, 2) the fibrocartilaginous proximal half of the insertion, 3) the fibrocartilage-
covered superior tuberosity. 
 
The sizes of the spurs were documented using a 0–3-point scale, where 1 = minimal, 2 = moderate, and 3 = large. 
 Established 
SpA 
NR  
Entheseal erosions Early SpA  55 0 
Established 
SpA 
41 
Non-specific 
SpA  
27 
Bony spurs Early SpA 40 80 
 Established 
SpA 
100  
 
 
 
  
Li (167) Grey-
scale 
Colour 
Doppler 
Abnormal 
vascularisation 
AS 56 0 All US lesions graded as present/absent expressed as a percentage 
ReA 65 
PsA 80 
uSpA 20 
Cortical bone 
erosion 
AS 11 0 
ReA 15 
PsA 30 
uSpA 10 
Cortical bone 
irregularity 
 
AS 46 0 
ReA 45 
PsA 80 
uSpA 40 
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  Feydy 
(168) 
 
Grey-
scale 
Power 
Doppler 
Tendon 
thickening  
(1cm from 
enthesis) 
 
Entheseal 
thickening 
SpA: no heel 
pain 
SpA: history 
of heel pain 
SpA: heel 
pain 
Refer to table 2.7 
 
 
The following lesions were classified as signs of early injury: tendon and aponeurosis echostructure abnormalities, 
retrocalcaneal bursitis, thickening of the tendon at enthesis insertion and at 1 cm from enthesis, power Doppler signal in 
retrocalcaneal bursa, tendon or aponeurosis. 
 
The following lesions were classified as signs of chronic injury: calcifications, erosions and enthesophytes. 
Tendon thickness graded using Balint cut-off (150). 
 
Doppler signal assess by binary system (% present). 
Vascularisation 
Tendon 
SpA: no heel 
pain 
0 0  
SpA: history 
of heel pain 
2 
SpA: heel 
pain 
2 
Vascularisation 
Bone enthesis 
junction 
SpA: no heel 
pain 
2 0 
SpA: history 
of heel pain 
1 
SpA: heel 
pain 
3 
Bone erosion SpA: no heel 
pain 
2 0 
SpA: history 
of heel pain 
1 
SpA: heel 
pain 
3 
Enthesophyte SpA: no heel 
pain 
8 10 
SpA: history 
of heel pain 
2 
SpA: heel 
pain 
2 
Calcification SpA: no heel 
pain 
3 1 
SpA: history 
of heel pain 
0 
SpA: heel 
pain 
0 
Cortical Bone SpA: no heel 
pain 
0 0 
SpA: history 
of heel pain 
0 
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Falcao 
(171) 
Grey-scale 
Colour 
Doppler 
Doppler signal SpA: heel 
pain 
1 0 The maximal diameter obtained on longitudinal and transversal scan was collected. 
 
The presence or absence of Doppler signal in the cortical bone profile was also recorded 
 
The average of three consecutive measurements of the maximal thickness obtained in longitudinal and transverse axes 
was scored. 
PsA 6 
RA NR 
GUESS, Glasgow Ultrasound Enthesis Scoring System 
Freeston 
(169) 
Grey-
scale 
Power 
Doppler 
Power Doppler  PsA Not 
specific 
to AT 
Not 
specific to 
AT 
US abnormalities were divided into “active inflammation” and “structural 
Change” GS and PD were scored separately on a semiquantitative (SQ) scale (range 0–3) for each enthesis imaged.  
 
The GS score was a composite score of tendon/aponeurosis thickening and hypoechogenicity (loss of fibrillar pattern), 
using the highest score for either parameter as the final GS score.  
 
Presence of PD signal was considered positive if found within the tendon 2 mm proximal to the bony insertion, but not in 
the body of the tendon or any associated bursa.  
 
A score of GS > 1 and/or a PD score > 0 was arbitrarily used to describe US entheseal abnormality, as low-level GS 
changes can be seen in normal subjects (13).  
 
Markers of structural change at the enthesis, such as erosion, bony spur, and intratendinous calcification, were recorded as 
present or absent. Erosions were only scored if identified in 2 planes and located within the area into which the tendon or 
aponeurosis typically inserts. 
Erosion  5 0 
Bony spur @ 
calcaneus 
49 50 
Intratendinous 
calcification @ 
Achilles 
0 0 
    
Bandinelli 
(170) 
Grey-
scale 
AT thickness PsA R 38 0 Enthesis thickness was expressed in millimetres (mm) and was also scored by Balint cut-off (150). 
 
Vascularity, studied at insertion of enthesis at the cortical bone, was scored as a binary item (positive if any signal was 
present and negative if absent) and was also semi-quantitatively graded (no flow (grade 0); only one spot detected (mild 
or grade 1); 2 spots (moderate or grade 2); >3 spots (severe or grade 3), a total PD was calculated by summing semi 
quantitative PD scores of each tendon. L 29 
Power Doppler 
signal 
R 14 0 
L 19 
Erosions R 2 0 
L 1 
Enthesophytes R 52 0 
 L 55 
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Table 2.7: Scoring of Achilles tendon thickness by direct measurement 
Study Condition Cases 
mean thickness, 
mm (SD) 
Controls  
mean thickness, 
mm (SD) 
Genc (165) RA 
 
R - 5.1 (1.0) 4.5 (0.4) 
L - 5.2 (0.8) 
AS R - 4.9 (0.8) 
L - 5.4 (1.2) 
Feydy (168)  SpA no heel pain 
SpA history heel pain 
SpA with heel pain  
4.1 (0.6)a 
4.5 (1.2) 
4.3 (1.2)     
4.4 (0.6) 
Bandinelli 
(170) 
PsA R - 5.0 (1.1)b R - 3.7 (0.4) 
L - 4.9 (1.0) L - 3.8 (0.5) 
Woodburn 
(174)  
PsA with enthesitis 
PsA no enthesitis 
4.6 (1.3) 
3.9 (0.6) 
3.8 (0.7) 
3.6 (0.6) 
Aydin (175) SpA 4.4 (0.8)c 
4.3 (0.6) 
4.0 (0.8) 
4.1 (0.5) 
a  Left and right AT combined in heel pain group. In all other groups, only data from the AT was 
 reported 
b The AT of the most symptomatic limb measured in PsA groups. Not clear in controls if data was 
 unilateral or combined. 
c  Combined data of left and right AT 
2.3.6. Pooled results 
In studies with SpA participants, the lesions of tendon thickness, enthesophyte formation 
and erosion were considered for meta-analysis. Doppler signal was not viewed as 
appropriate for data pooling due to inconsistencies in the definition of what constituted a 
positive Doppler signal. Similarly, the US lesions of tendon calcifications, cortical 
irregularities and hypoechogenicity were not adequately defined so were not considered 
for meta-analysis. Three studies (163, 165, 171) included a RA participants used as a 
comparison group. Only one AT lesion (erosion) was reported in more than one RA study 
and was considered appropriate for meta-analysis. One study involving participants with 
CPPD (164) and that met the inclusion criteria, was not included for data pooling.  
 
2.3.7. Tendon thickening at the Achilles tendon enthesis 
Eight studies assessed AT thickness by direct quantitative measurement or comparison to 
cut-off values, or a combination of both methods (165, 166, 168, 170, 172-175). Five 
studies (165, 168, 170, 174, 175), all of which included participants with SpA, quantified 
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AT thickness in relation to established cut-off values (150) and were considered 
appropriate for meta-analysis. The mean thickness at the enthesis in SpA participants was 
0.54mm thicker than control participants (95% CI = 0.10 to 0.97mm) (Figure 2.2). Three 
studies (166, 172, 173) were excluded from meta-analysis as assessment of the AT 
thickness was not referenced to a cut-off value or directly measured.  
 
  
Figure 2.2. Forest-plot of studies reporting direct measurement of Achilles tendon 
entheseal thickness in SpA 
2.3.8. Enthesophyte formation 
Ten studies reported enthesophyte formation at the posterior calcaneus (163-166, 168-170, 
172-174). Five studies (163, 166, 170, 173, 174) defined enthesophyte and were considered 
appropriate for meta-analysis, Five studies were excluded from the meta-analysis; four 
studies provided no definition of an enthesophyte (165, 168, 169, 172) and one study was 
in participants with CPPD (164). In the meta-analysis, there was no significant increase in 
enthesophytes in the participants with SpA, compared with the control participants (OR = 
2.48, 95%CI = 0.64 to 9.70, P = 0.19, Figure 2.3). 
  
Study name Condition Statistics for each study Sample size Difference in means and 95% CI
Difference Lower Upper Relative Relative 
in means limit limit IA Control weight weight
Genc 2005 AS 0.68 0.21 1.15 18 20 19.26
Feydy 2011 SpA -0.13 -0 .57 0.31 25 24 19.77
Bandinelli 2013 PsA 1.20 0.83 1.57 55 46 21.01
Woodburn 2013 PsA 0.50 -0 .04 1.04 14 20 18.01
Aydin 2014 SpA 0.40 0.09 0.71 55 46 21.95
0.54 0.10 0.97
-4 .00 -2 .00 0.00 2.00 4.00
Control Condition
Test for heterogeneity: χ2 = 22.23, df = 4 (P < 0.001); I2 = 82% 
Test for overall effect: z = 2.40 (P = 0.016) 
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Figure 2.3. Forest-plot of studies reporting enthesophyte formation at the Achilles 
enthesis in SpA 
2.3.9. Erosions 
Ten SpA studies reported evidence of calcaneal erosions (163-170, 172-174). Five studies 
were excluded from meta-analysis as they did not provide definitions of calcaneal erosion 
or data reporting was incomplete (23, 27, 28, 30, 33). The five remaining SpA studies (165, 
166, 170, 173, 174) defined erosions and were considered appropriate for meta-analysis. 
The meta-analysis demonstrated that calcaneal erosions were observed significantly more 
frequently in participants with SpA compared with healthy controls (OR = 7.43, 95%CI = 
1.99 to 27.77, P = 0.003, Figure 2.4).  
 
 
 
 
Figure 2.4. Forest-plot of studies reporting calcaneal erosion in SpA 
Study name Condition Present / Total Odds ratio and 95% CI
Odds Lower Upper Relative Relative 
ratio limit limit IA Control weight weight
Falsetti 2003 PsA 3.60 1.76 7.35 126 / 250 11 / 50 22.60
McGonagle 2008 SpA 0.52 0.10 2.84 25 / 37 8 / 10 17.55
Wiell 2013 SpA 0.35 0.09 1.36 36 / 54 17 / 20 19.48
Woodburn 2013 PsA 2.69 1.00 7.27 23 / 42 9 / 29 21.35
Bandinelli 2013 PsA 45.42 10.84 190.41 99 / 184 2 / 80 19.02
2.48 0.64 9.70
0.01 0.1 1 10 100
Favours A Favours B
Study name Condition Present / Total Odds ratio and 95% CI
Odds Lower Upper Relative Relative 
ratio limit limit IA Control weight weight
Genc 2005 AS 11.22 0.58 216.00 4 / 36 0 / 40 19.87
McGonagle 2008 SpA 19.92 1.09 364.80 18 / 37 0 / 10 20.56
Wiell 2013 SpA 4.56 0.24 86.21 5 / 54 0 / 20 20.10
Woodburn 2013 PsA 6.90 0.36 133.19 4 / 42 0 / 29 19.83
Bandinelli 2013 PsA 3.10 0.16 60.81 3 / 184 0 / 80 19.64
7.43 1.99 27.77
0.01 0.1 1 10 100
Control Condition
Test for heterogeneity: χ2 = 0.96, df = 4 (P = 0.92); I2 = 0% 
Test for overall effect: z = 2.98 (P = 0.003) 
Test for heterogeneity: χ2 = 27.80, df = 4 (P < 0.001); I2 = 86% 
Test for overall effect: z = 1.31 (P = 0.19) 
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Two RA studies also reported calcaneal erosions (163, 165) and were considered 
appropriate for meta-analysis. The meta-analysis demonstrated that calcaneal erosions 
were present significantly more frequently in participants with RA compared with healthy 
control participants (OR = 9.60, 95%CI = 1.23 to 74.94, p = 0.03, Figure 2.5).  
 
  
 
Figure 2.5. Forest-plot of studies reporting calcaneal erosion in RA 
2.4. Discussion 
This review identified evidence for differences in US lesions of the AT that distinguished 
between people with inflammatory arthritis and healthy controls by reviewing case-control 
studies. The studies were of high quality with the majority involving participants with SpA, 
the main focus pertaining to entheseal lesions of the AT. Limited evidence was found 
comparing US lesions of the AT in RA and CPPD. No studies assessed US lesions of the 
AT in gout. In SpA, pooled estimates suggest increased entheseal thickening, and in both 
SpA and RA, increased frequency of calcaneal erosions compared to controls. There was 
no evidence to indicate that enthesophyte formation was more frequent in SpA compared 
to controls.  
 
To define and score tendon thickness in inflammatory arthritis, the scoring system and cut-
off score proposed by Balint (150) was the most frequently applied method. Although AT 
thickness was defined, this review found limited information (two studies) relating to the 
assessment of AT thickness at sites proximal to the AT enthesis (172, 175). Quantifying 
thickness proximal to the enthesis has become significant as the recent OMERACT 
definition of entheseal tendon thickness references the body of the tendon as a point of 
comparison (153).  
Study name Condition Present / Total Odds ratio and 95% CI
Odds Lower Upper Relative Relative 
ratio limit limit IA Control weight weight
Falsetti 2003 RA 14.12 0.84 238.17 19 / 158 0 / 50 52.88
Genc 2005 RA 6.23 0.31 124.31 3 / 48 0 / 40 47.12
9.60 1.23 74.94
0.01 0.1 1 10 100
Favours A Favours B
Test for heterogeneity: χ2 = 0.15, df = 1 (P = 0.70); I2 = 0% 
Test for overall effect: z = 2.16 (P = 0.03) 
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Although the presence of Doppler signal has been used to discriminate between 
inflammatory and mechanical change at the AT enthesis in SpA, Doppler signal may be 
associated with degenerative change at the AT sites proximal to the enthesis. In CPPD, the 
presence of Doppler signal was not associated with inflammation but linked to tendon 
degeneration (164). No similarities were found in the definition of Doppler signal, with 
only one study (164) providing a definition of a positive Doppler signal. However, the 
definition of Doppler signal has only recently been described by OMERACT (153).  
 
The majority of studies used a simple binary method (present/absent) to score Doppler 
signal. The scoring method is unable to demonstrate the degree of inflammatory activity or 
display sensitivity to change. The two studies that used a semi-quantitative approach to 
score Doppler signal differed (169, 170). Freeston (169) scored the Doppler signal as mild, 
moderate or severe, whereas Bandinelli (170) reported on the quantity of Doppler signal 
detected. 
 
Although the pooled analysis did not demonstrate increased frequency of enthesophyte 
formation in SpA, consideration must be given to the size and location of the enthesophyte 
and relationship to the disease type and stage. McGonagle (166), Bandinelli (170) and 
Freeston (169) investigated enthesophyte formation in the early stages of SpA, with 
McGonagle (166) comparing early and established SpA. McGonagle (166) also quantified 
enthesophyte size, reporting large enthesophytes in established SpA, suggesting that 
enthesophyte formation may be controlled by the inflammatory processes in the early 
stages of the disease and proliferate when inflammation diminishes. 
 
Only one study was found describing the location of the enthesophyte formation (26). 
McGonagle (166) reported the enthesophyte formation in the distal enthesis in both early 
and established SpA. Enthesophyte formation was also a feature in CPPD, but, as with the 
majority of SpA studies, the anatomical location of the enthesophyte at the enthesis organ 
and size was not reported. Enthesophytes were quantified by one of three methods; (i) 
binary (present/absent); (ii) non-validated scoring or (iii) as a component of the Glasgow 
Ultrasound Enthesis Scoring System (GUESS), using the pole of the calcaneus AT enthesis 
subscale (150). Of note, the GUESS has no method for the quantification of enthesophyte 
size or location.  
73 
 
 
Erosions were a feature at the AT enthesis in SpA and RA. Presentation of bone erosions 
across studies differed between SpA and RA in size, location and associated bone 
formation. Li (167) reported cortical bone erosions to have shorter disease duration in SpA, 
than in participants without erosion and cortical bone erosions to occur at areas of the 
periosteal and the enthesis fibrocartilage. McGonagle (166) further reported that erosions 
were observed in fibrocartilaginous areas, either the proximal part of the insertion and the 
superior tuberosity but did not occur in the distal part of the AT enthesis in people with 
early SpA. Falcao (171) demonstrated that erosions typically occur in the bursal proximal 
portion of the enthesis in people with SpA, possibly establishing a link between erosions 
and adjacent anatomical structures. 
 
This systematic review has some limitations. The OMERACT US lesion definitions were 
applied (153) in the review: however all studies included in this review were published 
prior to the release of the OMERACT definitions. A number of studies were excluded from 
data pooling due to inconsistencies in data reporting, and these studies may have added 
significant weighting to the pooled data. The review was restricted to case-control studies 
and did not consider findings from other study designs. 
 
Further work should distinguish between US lesions that are reflective of inflammatory 
and structural damage in the AT and calcaneal enthesis. This may enable the differentiation 
of US lesions of the AT and enthesis in other forms of inflammatory arthritis, for example, 
RA, gout or differentiating between early and established SpA. Investigation into the size, 
specific zones, calcaneal erosions and associated enthesophyte formation will give further 
insights into the differentiation between mechanical and disease-driven enthesophyte 
formation. Future studies should consider the revised OMERACT definition (153) of AT 
thickness in describing lesions at the AT.  
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2.5. Conclusion 
The systematic review identified that the majority of studies reported US lesions in SpA, 
but limited evidence relating to other forms of inflammatory arthritis. Analysis revealed 
significant differences in the presentation of tendon thickness and erosions in participants 
with SpA. US lesions were not consistently defined with regard to OMERACT definitions 
and numerous scoring systems were used across the majority of studies. Consistent 
application of the OMERACT US definitions and the scoring of US lesions is required in 
future studies of AT disease in inflammatory arthritis. Further work should distinguish 
between US lesions reflective of inflammation and structural damage in the AT and 
calcaneal enthesis. 
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CHAPTER 3:  
Gait characteristics associated with the foot 
and ankle in inflammatory arthritis: a 
systematic review and meta-analysis 
3.0. Purpose of systematic review 
The systematic review was undertaken for the following reasons: 
1. To highlight the limited data that exists describing gait adaptations in people with 
tophaceous gout. 
2. To compare and contrast if the gait strategy in people with gout to other forms of 
inflammatory arthritis.  As gout has a different pathological process to other forms 
of inflammatory arthritis it was important to articulate that gait adaptation in gout 
should not be considered a similar process to other forms of inflammatory arthritis.   
3. To establish what gait parameters are frequently assessed in inflammatory arthritis 
to explain adaptations in gait strategy. 
4. To inform research design.  Specifically, information surrounding what gait 
parameters were frequently assessed in inflammatory arthritis guided the gait 
parameters assessed in the thesis.  
5. To evaluate the differing methodologies used to quantify gait strategy in 
inflammatory arthritis.  This was important and guided the decision to use the multi-
segmented foot model detailed in chapter 4. 
6. Where appropriate, to conduct meta-analysis to determine the extent to which gait 
parameters differed between people with inflammatory arthritis and healthy 
controls.  
7. No previous reviews have systematically assessed gait parameters across different forms 
of inflammatory arthritis.   
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3.1. Introduction 
The term inflammatory arthritis has been used to describe a number of inflammatory joint 
diseases including: RA, AS, PsA, gout (181). Inflammatory arthritis can cause lower limb 
and foot pain and impairment, functional disability, reduced mobility, joint deformity and 
altered gait strategies (110, 182-185).  
 
Foot pain is considered an important factor in the development of antalgic gait in 
inflammatory arthritis, specifically in RA and gout (18, 182, 186). In RA, foot pain is 
derived from structural and functional alterations associated with inflammatory and 
structural change (182, 187). With the development of an antalgic gait, adaptations occur 
based upon a pain avoidance strategy. Previous studies have reported gait adaptations in 
RA which include: a decrease in walking velocity and subsequent alterations to velocity-
related spatiotemporal parameters including, reduced cadence, increased double limb 
support time and decreased step length (188-192). Changes to kinematic parameters 
including reduced sagittal plane ankle ROM and increased peak rearfoot eversion have also 
been reported (183, 188, 191, 192). Furthermore, previous studies have reported alteration 
to kinetic parameters including reduced peak ankle plantarflexor power associated with 
reduced walking velocity, reduced ankle joint ROM, reduced ankle joint angular velocity, 
reduced ankle plantarflexor moments and decreased strength of the ankle plantarflexor 
muscles (190, 191, 193). An increase in peak forefoot plantar pressure parameters has also 
been reported in RA (190).  
 
Gait analysis provides information about spatial-temporal parameters, kinetics, kinematics 
and muscle activity to further delineate the relationship between joint disease, joint 
impairments and compensatory gait strategies adopted to overcome painful and disabling 
deformities (189, 194). Gait analysis has been reported as a useful clinical tool to quantify 
foot function in both early and established RA (110, 183, 188, 189). RA commonly affects 
the lower limb and foot in relation to pain, activity limitation and disability, thereby 
affecting people’s quality of life (188, 195). However, less commonly described 
inflammatory arthritic conditions from a lower limb biomechanical perspective, such as 
AS, PsA, gout, polymyalgia rheumatica (PMR), SS and systemic lupus erythematous 
(SLE), also have various consequences for the lower limb such as changes in foot function, 
and extra articular complications involving the skin and vascular integrity (18, 174, 184, 
185, 196-198).  
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In a recent systematic review of studies investigating walking abnormalities associated 
with RA, Baan (199) demonstrated changes in gait such as a slower walking, longer double 
support time, and avoidance of extreme positions. These changes were in relation to the 
frequently found foot deformities in RA, for instance, hallux valgus, pes planovalgus and 
forefoot abnormalities. However, Baan (199) reported only gait parameters in RA and did 
not consider other inflammatory arthritic conditions. Recently there has been an interest in 
evaluating gait patterns in other inflammatory arthritic conditions that includes gout (18), 
PsA (174) and AS (185). No previous systematic review has conducted meta-analysis of 
gait parameters in inflammatory arthritis compared to healthy control population. The aim 
of the systematic review was to evaluate spatiotemporal, foot and ankle kinematic, kinetic, 
peak plantar pressure and muscle activity parameters in people with inflammatory arthritis 
and healthy controls.  
 
3.2. Methods 
3.2.1. Identification of studies 
Four electronic databases were searched (Medline, CINAHL, SportsDiscus and The 
Cochrane Library). The search was completed in March 2015. The search strategy 
combined terms appropriate to the anatomical location; the type of gait analysis and 
inflammatory arthritic condition (Table 3.1). An initial review was undertaken of all titles 
and abstracts. All articles considered appropriate were read in full to establish if they met 
the eligibility criteria. 
  
78 
 
Table 3.1: Search strategy 
Search strategy: Gait characteristics associated with the foot and ankle in inflammatory arthritis. 
(a) Search terms for gait analysis (b) search terms for inflammatory rheumatic disease (c) 
Combination of search terms  
3.2.2. Inclusion and exclusion criteria 
Studies were included if they: reported people with inflammatory arthritis that included 
RA, AS, PsA, gout, PMR, systemic sclerosis (SSc) and SLE; assessed adults aged >18 
years old; reported spatiotemporal, kinematic, kinetic, peak plantar pressure or muscle 
activity data during gait; were articles that included a healthy group as means of 
comparison; and were published in English. Surgical and pharmacological intervention 
studies were excluded. No limitation was placed on the date of the publication.  
3.2.3. Data extraction 
All titles and abstracts identified through database searches were downloaded into Endnote 
X4 (Thomson, Reuters, Carlsbad, CA). Each title and abstract was evaluated for potential 
inclusion by two independent reviewers. If there was insufficient information contained in 
a 1 Subject term exp. Gait analysis 
 2 Keywords Lower extremi* [or] Lower limb* [or] Foot [or] Feet [or] Ankle* [or] Leg* [or] 
Rear foot [or] Hind foot [or] Knee [or] Hip 
 3 Keywords Kinematic* [or] Kinetic* [or] Spatial [or] Temporal [or] Spatio-temporal [or] 
electromy* [or] EMG [or] plantar pressure [or] pressure [or] force [or] pedobarogr* 
 4 Combine 2 [and] 3 
 5 Combine 1 [or] 4 
b 6 Subject term exp. Rheumatic disease 
 7 Subject term exp. Rheumatoid arthritis 
 8 Subject term exp. Gout 
 9 Subject term exp. Systemic sclerosis 
 10 Subject term exp. Polymyalgia rheumatica 
 11 Subject term exp. Psoriatic arthritis 
 12 Subject term exp. Lupus erythematosus 
 13 Subject term exp. Ankylosing spondylitis 
 14 Keywords Rheumat* [or] Spondyl*  
c 15 Combine 6 [or] 7 [or] 8 [or] 9 [or] 10 [or] 11 [or] 12 [or] 13 [or] 14 
 16 Combine 5 [and] 15 
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the title to determine suitability the full text was obtained. Any discrepancies between the 
two reviewers were resolved at a consensus meeting.  
3.2.4. Assessment of methodological quality and diversity 
The quality of studies was evaluated independently by two reviewers, who were blinded to 
author and publication details. Study quality was rated using a modified version of the 
quality index tool originally described by Downs and Black (155). The quality index tool 
consists of 27 items which allow for assessment of internal and external validity, reporting 
and power. The tool was modified to exclude thirteen questions that were not relevant to 
the articles assessed in this review, resulting in the retention of 14 questions (Table 3.2). 
The scoring system grades each of the 14 questions either a (0 = no/unable to determine, 
or 1 = yes) with the exception of question five (0 = no, 1 = partially, 2 = yes). The summed 
score for each study, the maximum achievable being 15, was calculated. No cut off scores 
have been described to categorise study quality for the Downs and Black quality Index 
(157). In the absence of validated cut-off scores and following review of past articles that 
have applied the Downs and Black criteria the following cut-off values were applied: ≥ 12 
high quality, greater than 7, but less than 12 moderate quality, < 6 poor quality (156, 157). 
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Table 3.2: Questions included from the Quality Index checklist to rate study quality 
 
1 Is the hypothesis/aim/objective of the study clearly described? 
2 Are the main outcomes to be measured clearly described in the Introduction or Methods 
section?  
3 Are the characteristics of the patients included in the study clearly described? 
5 Are the distributions of principal confounders in each group of subjects to be compared clearly 
described? 
6 Are the main findings of the study clearly described? 
7 Does the study provide estimates of the random variability in the data for the main outcomes? 
10 Have actual probability values been reported ( e.g. 0.035 rather than <0.05) for the main 
outcomes except where the probability value is less than 0.001? 
11 Were the subjects asked to participate in the study representative of the entire population from 
which they were recruited? 
12 Were those subjects who were prepared to participate representative of the entire population 
from which they were recruited? 
16 If any of the results of the study were based on “data dredging”, was this made clear? 
18 Were the statistical tests used to assess the main outcomes appropriate? 
20 Were the main outcome measures used accurate (valid and reliable)? 
21 Were the patients in the cases and controls (case-control studies) recruited from the same 
population? 
22 Were study subjects in the cases and controls (case-control studies) recruited over the same 
period of time? 
3.2.5. Data analysis and synthesis 
Relevant gait parameters and information regarding overall study design, subject 
characteristics and gait analysis parameters were extracted from each paper by one 
reviewer from those studies meeting the inclusion criteria. Data was tabulated according to 
the specific inflammatory arthritic condition and gait parameters. 
 
The clinical and methodological diversity among the studies was assessed to determine the 
appropriateness of data pooling for meta-analysis. Factors considered important for 
comparison included: mean age, sex distribution, case and comparison group size, data 
acquisition methodology and instrumentation. Two authors reviewed the included studies 
and reached consensus on the appropriateness of conducting meta-analysis. Heterogeneity 
was considered low if the I2 value was 25% or less, moderate if the value was between 25% 
and 50%, high if between 50% and 75% and very high if greater than 75% (160). A fixed-
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effect model was applied where the I2 statistic was less than 50% and the Chi2 test indicated 
a non-significant degree of heterogeneity (P > 0.1). The random-effect model was used 
where the I2 statistic was greater than 50% and the Chi2 test indicated statistically 
significant heterogeneity (P < 0.1) (161).  
 
Where data was available from each paper a standardised mean difference (SMD) 
(Hedges’s g) and 95% CI were calculated (200). This was calculated as the difference 
between cases and control participant means divided by the pooled SD. Interpretation of 
SMDs was based on previous effect size (ES) guidelines: small effect ≥ 0.2, medium effect 
≥ 0.5, large effect ≥ 0.8 (201). Effect sizes were considered statistically significant if the 
95% CI did not contain zero for the SMD. All data were analysed using the Comprehensive 
Meta-analysis, version 2 (159). Studies that met the inclusion criteria but did not report SD, 
or where the SD could not be obtained were excluded from meta-analysis. 
3.3. Results 
3.3.1. Selection and characteristics of studies 
All items were reported using the PRISMA statement (162). 3134 citations were identified 
for screening with 36 articles being included for further analysis (Figure 3.1). Thirty-one 
studies evaluated gait parameters in RA (110, 183, 186-192, 202-223), three in AS (185, 
224, 225) one in PsA (174) and one in gout (18). Twenty-four studies examined 
spatiotemporal gait parameters, with 19 in RA, two in AS, one PsA and gout (Table 3.3). 
Twenty-one studies assessed kinematic parameters, with 17 in RA, three AS and one in 
PsA (Table 3.4). Ten studies examined kinetic parameters with eight in RA, one AS and 
one in PsA (Table 3.5). Sixteen studies evaluated plantar pressure parameters, with 15 in 
RA and one in gout (Table 3.6). Three studies assessed all gait parameters (spatiotemporal, 
kinematic, kinetic and plantar pressures) in the population (186, 188, 189). No studies 
reported gait characteristics in SSc, PMR or SLE. The total number of participants was 
2275; 1321 with inflammatory arthritis and 954 controls. Case participants included 863 
females and 312 males. The mean (SD) age of the cases and controls was 52.6 (9.3) and 
47.8 (9.2) years, respectively (Table 3.7). 
 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. PRISMA flow chart  
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Table 3.3: Spatiotemporal gait parameters measured and methods of data acquisition. 
 
Author & reference IA Data acquisition method Parameters measured 
Dubbeldam  (205) RA 3D gait analysis 
Walking velocity, cadence, stride time, double 
stance percentage, stride length, stride width, step 
length 
Rome  (207) RA Electronic Walkway 
Walking velocity, cadence, gait cycle time, single 
support time, double limb support time, base of 
support 
Eppeland  (208) RA Electronic Walkway 
Walking velocity, cadence, step length, stance 
phase duration, step width 
Turner (188) RA Electronic Walkway Walking velocity, double support time 
Turner (189) RA Electronic Walkway Walking velocity, double support time 
Weiss  (191) RA 3D gait analysis 
Walking velocity, cadence, stride length, step 
length, single support, double support 
Turner  (190) RA Electronic Walkway Walking velocity, double support percentage 
Turner (183)  RA Electronic Walkway 
Walking velocity, cadence, gait cycle time, stride 
length, double support time 
Laroche (211) RA 3D gait analysis Walking velocity, stride length, walking frequency, 
stance phase duration, double stance phase duration 
Khazzam (192)  RA 3D gait analysis Walking velocity, stride length, cadence, stance 
duration 
Semple (213)  RA Electronic Walkway Walking velocity 
Laroche (212)  RA 3D gait analysis 
Walking velocity, walking frequency, stride length, 
stance duration, double support phase 
duration
  
Woodburn (110)  RA 3D gait analysis Walking velocity 
O’Connell (186)  RA Electronic Walkway Walking velocity, cadence, stride length 
Fransen (219)  RA Electronic Walkway Walking velocity, stride length, percentage double 
support time, stance phase percentage 
Zebouni (225)  AS Electronic Walkway Contact time, stride length & stride frequency 
Isacson (226)  RA Electronic Walkway 
Walking velocity, stride length, duration of gait 
cycle 
Minns (221)  RA Force sandals 
Walking velocity, cadence, stride length, stride 
width 
Simkin (222)  RA Force plate 
Walking velocity, stride frequency, stride length, 
stance time, swing time, double support period 
Stauffer (223)  RA Electronic Walkway Walking velocity, cadence, stance phase percentage 
Del Din  (185)  AS 3D gait analysis 
Walking velocity, stride period, stride length, 
stance period 
Mangone  (224) AS 3D gait analysis Walking velocity, cadence, stride length 
Woodburn  (174)  PsA Electronic Walkway Walking velocity 
Rome  (18)  Gout Electronic Walkway 
Walking velocity, cadence, step length, stride 
length, single leg support, double leg support, 
stance phase duration, swing phase duration 
 
IA, inflammatory arthritis 
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Table 3.4: Kinematic gait parameters measured and methods of data acquisition. 
Author IA Parameters measured 
Kinematic 
Assessment 
Method & model 
Biomechanical 
Model 
Barn (203) RA 
Peak rearfoot eversion, peak rearfoot 
plantarflexion, lowest navicular height, peak 
midfoot inversion, peak forefoot abduction, peak 
forefoot dorsiflexion 
3D analysis Hyslop (109) 
Dubbeldam 
(205) 
RA 
Tibio-talar dorsiflexion, medial arch collapse, 
hallux dorsiflexion, subtalar eversion, mid-
/hindfoot supination, fore-/midfoot supination, 
leg/hindfoot external rotation, forefoot/ankle 
abduction metatarsal 1-5 angle, hallux abduction 
3D analysis (Heidelberg) 
Simon (114) 
Turner 
(188) 
RA 
Rearfoot terminal stance plantarflexion, rearfoot 
midstance eversion, forefoot midstance inversion, 
forefoot peak abduction, lowest navicular height, 
peak hallux dorsiflexion 
3D analysis  Carson (113) 
Turner 
(189)  
RA 
Initial foot contact angle, terminal stance heel rise, 
minimum navicular height in stance, maximum 
rearfoot eversion in stance,  
3D analysis Carson (113) 
Turner 
(190) 
RA 
Initial foot contact angle, terminal stance heel rise, 
minimum arch height, peak eversion 
3D analysis  Carson (113) 
Weiss (191) RA 
Trunk tilt range, trunk lateral sway range, hip 
flexion extension range, hip abduction, knee flexion 
extension range, ankle plantarflexion, ankle 
dorsiflexion 
3D analysis Newington (227) 
Khazzam 
(192) 
RA 
Sagittal, coronal and transverse motion of the 
hindfoot, forefoot and hallux at load response, 
midstance, terminal stance, pre-swing, initial 
swing, mid-swing and terminal swing 
3D analysis Milwaukee (228) 
Laroche 
(211) 
RA 
Range of motion of MTP joints, foot angle at toe-
off 
3D analysis Courtine (229) & 
Borghese (230) 
Laroche 
(212) 
RA 
Mean articular amplitudes of MTP joints, mean 
plantar/dorsi flexion ROM of MTP joints 
3D analysis Courtine (229) & 
Borghese (230) 
Woodburn 
(110) 
RA 
Peak dorsiflexion & plantarflexion & ROM, Peak 
inversion & eversion & ROM, peak adduction, 
abduction & ROM for the rearfoot & forefoot, 
minimum & maximum height & displacement of 
the navicular, peak extension, flexion & ROM of 
the hallux 
3D analysis  Carson (113) 
Turner 
(183) 
RA 
 Max ankle joint dorsi/plantarflexion, maximum 
inversion/eversion, maximum internal/external 
rotation, range of ankle joint motion in sagittal, 
frontal and transvers plane, toe off angle, time to 
maximum eversion motion time integral of sagittal, 
frontal and transverse ankle motion 
Electromagnetic 
tracking 
N/A 
Woodburn 
(187) 
RA 
Dorsi/plantarflexion, inversion/eversion & 
internal/external rotation of ankle joint during 
stance phase of gait 
Electromagnetic 
tracking 
N/A 
Woodburn 
(202) 
RA 
Dorsi/plantarflexion, inversion/eversion & 
internal/external rotation of ankle joint during 
stance phase of gait 
Electromagnetic 
tracking 
N/A 
O’Connell 
(221) 
RA 
Ankle motion during stance, mean heel rise during 
stance phase of gait 
3D analysis Siegel (218) 
Siegel (218) RA 
Foot to floor contact angle, degree of heel rise at 
toe off, foot out toe angle, 
plantar/dorsiflexion/inversion/eversion/abduction/a
dduction of the foot 
3D analysis Siegel (218) 
Isacson 
(220) 
RA 
Hip, knee & ankle joint flexion/extension, 
abduction/adduction, rotation   
Electrogoniometry N/A 
Stauffer 
(223) 
RA 
Standing knee flexion, sagittal, coronal & 
transverse knee motion, stance phase knee flexion 
Electrogoniometry N/A 
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Table 3.5: Kinetic gait parameters measured and methods of data acquisition. 
 
Author  Condition Parameters measured 
Barn (203) RA Peak ankle power, peak ankle moment 
Turner (189)  RA 
Peak ankle plantarflexion moment, peak ankle 
power 
Weiss (191) RA Joint moments at ankle joint 
Turner (190) RA 
Ground reaction forces; peak plantarflexion 
moment, peak ankle joint power 
O’Connell (221) RA 
Ground reaction forces, mean ankle plantarflexion 
net muscular moment 
Siegel (218) RA 
Muscular moment at ankle joint, ground reaction 
forces 
Simkin (222) RA 
Peak force on heel, peak force on midfoot, peak 
force on 1, 2 metatarsal heads, peak force on 3, 4, 5 
metatarsal heads, peak force on toes 
Stauffer (223) RA Ground reaction forces 
Del Din (185) AS 
Flexion-extension, abduction-adduction & internal-
external rotation moments at ankle joint 
Woodburn (174) PsA 
Peak ankle joint moment, peak ankle joint power, 
peak AT force 
 
  
Del Din 
(185) 
AS 
Flexion/extension, abduction/adduction and 
internal/external rotation of the trunk, pelvis, hip 
and ankle. Only flexion/extension reported at the 
knee 
3D analysis  Leardini (231) & 
Sawacha (232)  
Mangone 
(224) 
AS 
Pelvis ROM, pelvic tilt, pelvic rotation, shoulder 
rotation, hip flexion 
3D analysis Davis (233) 
Zebouni 
(225) 
AS Hip flexion & extension, knee flexion & extension 
Electrogoniomet
ry 
 
Woodburn 
(174) 
PsA 
Peak ankle/rearfoot dorsiflexion, peak 
ankle/rearfoot eversion, peak ankle/rearfoot internal 
rotation, navicular height 
3D analysis  Hyslop (109) 
IA, inflammatory arthritis; ROM, range of motion; 3D, three-dimensional; N/A, not applicable 
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Table 3.6: Plantar pressure gait parameters measured and methods of data acquisition. 
 
Author  Condition Acquisition system Parameters measured 
Bowen (204) RA 
In-shoe pressure 
system Peak plantar pressure forefoot 
Yavuz (206) RA Custom device 
Peak plantar pressure (1st metatarsal head, hallux, lesser 
digits); Pressure Time Integral (1st metatarsal head, hallux) 
Schmiegel (210) RA Plantar pressure plate 
Peak plantar pressure (hindfoot, midfoot, metatarsal 1, 2, 3-5, 
hallux, 2nd toe, toes 3-5) 
Schmiegel (209) RA Plantar pressure plate Peak plantar pressure (hindfoot, midfoot, metatarsal 1, 2, 3-5, 
hallux, 2nd toe, toes 3-5) 
Turner (188) RA Plantar pressure plate Centre of pressure at 50% of foot length, lesser toe contact 
area, midfoot contact area, forefoot peak pressure 
Turner (189)  RA Plantar pressure plate 
Centre of pressure at 50% of foot length, lesser toe contact 
area, midfoot contact area, forefoot peak pressure 
Semple (213) RA Plantar pressure plate Velocity and duration centre of pressure  
Rosenbaum (214) RA Plantar pressure plate Peak plantar pressure (hindfoot, midfoot, metatarsal 1, 2, 3-5, 
hallux, 2nd toe, toes 3-5) 
Turner (190) RA Plantar pressure plate Centre of pressure at 50% of foot length, lesser toe contact 
area, midfoot contact area, forefoot peak pressure 
Tuna (215) RA Plantar pressure plate Peak plantar pressure (hindfoot, midfoot, forefoot phalanx) 
Otter (216) RA Plantar pressure plate Peak plantar pressure (forefoot), force time integral (forefoot) 
Turner (183) RA Plantar pressure plate Peak plantar pressure and force, PTI & FTI, total contact area 
for hindfoot, midfoot forefoot, hallux & digits 
O’Connell (186) RA Force plate system Centre of pressure at 50% of foot length 
Woodburn (217) RA 
In-shoe pressure 
system 
Peak plantar pressure (metatarsal heads 1-5) 
Minns (221) RA Plantar pressure plate NR 
Rome (18) Gout 
In-shoe pressure 
system 
Peak plantar pressure ( hindfoot, midfoot, 1st , 2nd , 3rd, 4th & 
5th metatarsal heads, hallux, toes 2-5 
 
PTI, pressure time integral; FTI, force time integral; NR, not reported 
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Table 3.7: Characteristics of included studies. 
 
Author, year (ref) 
 Case demographics Control demographics 
IA 
Number 
Gender 
(F:M) 
Age  
mean (SD) 
Number Gender 
(F:M) 
Age  
mean (SD) 
Barn, 2013, (203) RA 10 6:4 50.0 (9.0) 5 3:2 47.0 (6.0) 
Woodburn, 2013, (174) PsA 42 25:17 45.3 (12.7) 29 18:11 40.0 (10.5) 
Bowen, 2011, (204) RA 114 93:21 59.6 (12.0) 49 37:12 33.2* 
Del Din, 2011, (185) AS 12 4:8 49.4 (10.5) 12 4:8 55.75 (3.2) 
Mangone, 2011, (224) AS 17 2:15 47.0 (21.9) 10 1:9 38.7 (14.5) 
Rome, 2011, (18) GT 25 6:19  61.2 (11.7) 25 6:19 57.3 (12.2) 
Dubbeldam, 2011, (205) RA 21 17:4 46.6 (12.8) 14 11:3 41.6 (8.5) 
Yavuz, 2010, (206) RA 9 8:1 53.2 (12.3) 14 9:5 53.6 (18.7) 
Rome, 2009, (207)  RA 19 15:4 56.1 (11.1) 21 12:9 51.0 (8.9) 
Eppeland, 200, (208) RA 17 7:10 51.1 (6.2) 20 8:12 50.4 (5.3) 
Turner, 2008, (188) RA 12 (FF) 
10 (RF) 
6(COMB) 
9:3 
8:2 
4:2 
7.9 (9.3) 
53.8 (13.2) 
64.7 (6.9) 
53 33:20 55.2 (11.7) 
Turner, 2008, (189)  RA 74 58:16 56.4 (12.0)    
Weiss, 2008, (191) RA 50 43:7 55.0 (14.0)    
Schmiegel, 2008, (210) RA 112 NR 55.0 (11.0) 53 33:20 55.2 (11.7) 
Schmiegel, 2008, (209) RA 21 NR 57.1 (10.2) 37 22:15 51.0 (14.0) 
Khazzam, 2007, (192) RA 22 20:2 54.0* 20 NR 53.2 (12.3) 
Laroche, 2007, (211) RA 9 6:3 60.0 (7.0) 16 NR 50.8 (9.4) 
Semple, 2007, (213) RA 74 58:16 54.6 (12.0) 25 12:13 41.0* 
Laroche, 2006, (212) RA 9 6:3 60.6 (6.8) 9 7:2 60.0 (7.0) 
Rosenbaum, 2006,  (214) RA 25 23:2 55.0 (9.9) 53 33:20 55.2 (11.7) 
Turner, 2006, (190) RA 12 12:0 46.0* 7 5:2 58.5 (7.4) 
Tuna, 2005, (215) RA 50 38:12 50.0 (9.0) 21 20:1 50.8 (9.3) 
Otter, 2004, (216) RA 25 21:4 45.3 (12.7) 12 12:0 47.0* 
Woodburn, 2004, (110) RA 11 9:2 59.6 (12.0) 50 39:11 49.8 (7.6) 
Turner, 2003, (183) RA 23 14:9 49.4 (10.5) 25 22:3 48.0 (8.6) 
Woodburn, 2002, (187) RA 50 34:16 54.0 (11.8) 5 NR NR 
Woodburn, 1999, (202) RA 10 NR 52.3* 23 14:9 49.5 (13.6) 
O’Connell, 1988, (221) RA 10 8:2 54.0 45 29:16 51.8 (12.4) 
Woodburn, 1996, (217) RA 102 76:26 63.5* 10 NR 27.9* 
Siegel, 1995, (218) RA 4 3:1 56.5 (7.2) 7 5:2 34.0* 
Fransen, 1994, (219) RA 113 76:37 60.0 (5.5) 42 31:11 61.0* 
Zebouni, 1992, (225) AS 12 4:8 46.5*  2 2:0 28.0 (11.0) 
Isacson, 1988, (220) RA 17 17:0 40.0 (5.0) 102 67:35 58.7 (5.3) 
Minns, 1984, (221) RA 124 104:20 56.6* 11 NR 39.5* 
Simkin, 1981, (222) RA 18 11:7 58.0* 11 11:0 29.0 (7.0) 
Stauffer, 1977, (223) RA 30 18:12 NR 67 32:35 50.2 (10.2) 
IA, inflammatory arthritis; *SD, SD not reported; NR, not reported; FF group, severe forefoot deformity 
group; RF group, severe rearfoot deformity group; COMB group, severe fore- and rearfoot deformity group 
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3.3.2. Methodological quality of studies 
Two reviewers independently scored a total of 504 items and agreed on 480 items (95%) 
with an inter-rater agreement of ƙ = 0.90 (p < 0.001). Six of the 36 articles were of high 
quality (quality score ≥ 12). The median (%) quality score of all articles was 10 (67%), 
ranging between 20-87% (Table 3.8). There was limited reporting of study recruitment in 
the majority of studies, making it difficult to assess the generalisability of study results. 
The majority of studies investigating kinematic and kinetic parameters also reported small 
sample sizes.  
Table 3.8: Results of the quality index scores in alphabetical order 
 
Quality Index criteria 
QI score 
total (%) 
Author, year (ref) 1 2 3 5 6 7 10 11 12 16 18 20 21 22  
Barn, 2013   (203) 1 1 1 2 1 1 1 0 0 1 1 0 0 1 11  (73) 
Bowen, 2011  (204)  1 1 1 2 1 1 1 0 0 1 1 1 0 1 12  (80) 
Del Din, 2011  (185) 1 1 1 2 1 1 1 1 0 1 1 1 1 0 13  (87) 
Dubbeldam, 2011  (205)  1 1 1 1 0 1 1 0 0 1 1 1 0 0 9  (60) 
Eppeland, 2009  (208) 1 1 1 2 1 1 1 1 1 1 1 0 1 0 13  (87) 
Fransen, 1994  (219) 1 1 1 2 1 1 1 0 1 1 1 0 1 0 12  (80) 
Isacson, 1988  (220) 1 0 1 0 1 0 0 0 0 1 1 0 1 0 6  (40) 
Khazzam, 2007  (192) 1 1 0 0 1 1 1 1 0 1 1 1 1 1 11  (73) 
Laroche, 2007 (211)  1 1 1 0 1 0 1 0 0 1 0 0 0 0 6  (40) 
Laroche, 2006  (212)  1 1 0 0 0 0 0 0 0 1 0 0 0 0 3  (20) 
Mangone, 2011  (224) 1 1 1 0 0 1 1 0 0 1 1 0 0 0 7  (47) 
Minns, 1984  (221)  0 0 1 1 1 0 0 0 0 1 0 0 0 0 4  (27) 
O’Connell, 1988  (186) 1 1 0 0 1 0 0 0 0 1 0 0 0 0 4  (27) 
Otter, 2004   (216)  1 0 1 0 1 1 1 0 0 1 1 0 1 0 8  (53) 
Rome, 2009  (207)  1 1 1 1 1 1 1 0 0 1 1 0 0 0 9  (60) 
Rome, 2011   (18)  1 1 1 1 1 1 1 0 0 1 1 1 1 0 11  (73) 
Rosenbaum, 2006  (214)  1 1 1 1 1 1 1 0 0 1 1 1 0 0 10  (67) 
Schmiegel, 2008  (210)  1 1 1 2 1 1 0 1 1 1 1 0 1 0 12  (80) 
Schmiegel, 2008  (209)  1 1 1 2 1 1 0 0 0 1 1 1 0 0 10  (67) 
Semple, 2007  (213)  1 1 1 0 1 1 1 1 1 1 1 1 0 0 11  (73) 
Siegel, 1995  (218) 1 1 0 0 0 0 0 0 0 1 0 0 0 0 3  (20) 
Simkin, 1981  (222)  1 1 0 0 0 0 0 0 0 1 0 0 0 0 3  (20) 
Stauffer, 1977  (223)  1 1 1 1 1 0 0 0 0 1 0 1 0 1 8  (53) 
Tuna, 2005   (215)  1 1 1 1 1 1 0 0 0 1 1 0 0 0 8  (53) 
Turner, 2003  (183)  1 1 1 1 1 1 0 0 0 1 1 0 0 0 8  (53) 
Turner, 2006  (190)  1 1 1 1 1 0 0 1 1 1 0 1 1 0 10  (67) 
Turner, 2008  (188) 1 1 1 2 1 1 0 0 0 1 1 1 0 0 10  (67) 
Turner, 2008  (189)  1 1 1 2 1 1 1 0 0 1 1 1 1 0 12  (80) 
Weiss, 2008   (191) 1 1 0 1 1 1 1 0 0 1 1 1 1 0 10  (67) 
Woodburn, 1996  (217) 1 1 1 2 1 1 1 0 0 1 1 1 0 0 11  (73) 
Woodburn, 1999  (202)  1 1 1 2 1 0 0 1 0 1 1 1 1 0 11  (73) 
Woodburn, 2002  (187)  1 1 1 2 1 1 1 0 0 1 1 1 0 0 11  (73) 
Woodburn, 2004  (110) 1 1 0 0 0 1 0 0 0 1 0 1 0 0 5  (33) 
Woodburn, 2013  (174)  1 1 1 2 1 1 1 0 0 1 1 0 0 0 10  (67) 
Yavuz, 2010  (206) 1 1 0 0 0 1 0 0 0 1 1 0 0 0 5  (33) 
Zebouni, 1992  (225) 1 1 0 0 0 0 0 0 0 1 1 0 0 0 4  (27) 
            Median 10 (67) 
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3.3.3. Spatiotemporal gait parameters 
Fifteen RA (183, 188-192, 205, 207, 208, 212, 213, 219-222), one PsA (174) and one gout 
study (18) reported significant decreases in walking velocity. No significant differences in 
walking velocity were reported for AS (185, 224). Overall, pooled data (SMD, 95% CI) 
(Figure 3.2) for walking velocity, demonstrated a significant decreased large effect size for 
RA (SMD -1.55, -2.27 to -0.83) and a non-significant decrease for AS (SMD -0.19, -0.73 
to 0.36). 
 
Five RA studies (183, 191, 205, 207, 221) and one gout (52) reported significant decreases 
in cadence. Cadence was not significantly decreased in AS (225). Overall, pooled data for 
cadence in RA (Figure 3.3) showed a decreased but significant large effect size (SMD -
0.97, -1.49 to -0.45). Nine RA studies (183, 191, 192, 205, 212, 219-222), one AS (225) 
and one gout (18) reported significant decreases in stride length. Pooled data for stride 
length in RA (SMD -1.66, -1.84 to -1.49) and AS (SMD -0.62, -1.08 to -0.27) were 
significantly decreased with a large effect size (Figure 3.4). Eight RA studies (183, 188-
191, 205, 207, 219) and one gout study (18) reported significant increases in double 
support. Pooled data for double support in RA showed (Figure 3.5) a significantly increased 
large effect size (SMD 1.01, 0.66 to 1.36).  
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AS: Test for heterogeneity: χ2 = 0, df = 1 (P = 0.74); I2 = 0% 
Test for overall effect: z = -0.68 (P = 0.74) 
 
RA: Test for heterogeneity: χ2 = 324.66, df = 14 (P < 0.001); I2 = 96% 
Test for overall effect: z = -4.51 (P < 0.001) 
 
 
Figure 3.2. Forest plot of studies reporting walking velocity. AS, ankylosing spondylitis; 
RA, rheumatoid arthritis; CI, confidence interval 
 
RA: Test for heterogeneity: χ2 = 38.65, df = 6 (P < 0.001); I2 = 85% 
Test for overall effect: z = -3.69 (P < 0.001) 
 
Figure 3.3.  Forest plot of studies reporting cadence. RA, rheumatoid arthritis; CI, 
confidence interval 
 
 
Group by
IA
Study name Condition Statistics for each study Sample size Hedges's g  and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
AS Del Din  [2011] AS -0.28 -1 .06 0.50 12 12 48.78
AS Mangone [2011] AS -0.10 -0 .85 0.66 17 10 51.22
AS -0.19 -0 .73 0.36
RA Turner [2008a] RA -1.87 -2 .40 -1 .33 28 53 6.88
RA Turner [2008b] RA -1.79 -2 .21 -1 .38 74 53 7.00
RA Eppeland [2009] RA -0.41 -1 .05 0.23 17 20 6.76
RA Weiss [2008] RA -1.36 -1 .83 -0 .89 50 37 6.96
RA Khazzam [2007] RA -1.22 -1 .83 -0 .60 22 25 6.79
RA Laroche [2007] RA -0.89 -1 .81 0.04 9 9 6.35
RA Semple [2007] RA -1.58 -1 .98 -1 .18 74 53 7.02
RA Laroche [2006] RA -0.90 -1 .89 0.08 9 7 6.26
RA Turner [2006] RA -1.30 -2 .16 -0 .44 12 12 6.46
RA Turner [2003] RA -2.07 -2 .78 -1 .36 23 23 6.67
RA Fransen  [1994] RA 0.83 0.56 1.10 113 114 7.11
RA Minns [1984] RA -2.52 -2 .91 -2 .13 124 67 7.03
RA Isacson [1988] RA -3.45 -4 .62 -2 .29 17 11 5.94
RA Rome [2009] RA -1.84 -2 .56 -1 .11 19 21 6.65
RA Dubbeldam [2011] RA -3.59 -4 .66 -2 .52 21 14 6.11
RA -1.57 -2 .25 -0 .89
-2 .00 -1 .00 0.00 1.00 2.00
Favours A Favours B
Study name Condition Statistics for each study Sample size Hedges's g  and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Dubbeldam [2011] RA -2.69 -3 .60 -1 .77 21 14 4.52
Eppeland [2009] RA -0.57 -1 .21 0.08 17 20 9.03
Khazzam [2007] RA 0.05 -0 .51 0.61 22 25 11.86
Minns [1984] RA -1.45 -1 .78 -1 .12 124 67 34.62
Rome [2009] RA -0.82 -1 .45 -0 .19 19 21 9.36
Turner [2003] RA -1.00 -1 .60 -0 .39 23 23 10.34
Weiss [2007] RA -0.61 -1 .04 -0 .18 50 37 20.27
-0 .97 -1 .17 -0 .78
-2 .00 -1 .00 0.00 1.00 2.00
Favours A Favours B
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AS: Test for heterogeneity: χ2 = 2.58, df = 2 (P = 0.27); I2 = 22% 
Test for overall effect: z = -2.63 (P = 0.009) 
 
RA: Test for heterogeneity: χ2 = 34.08, df = 8 (P < 0.001); I2 = 77% 
Test for overall effect: z = -8.47 (P < 0.001) 
 
Figure 3.4. Forest plot of studies reporting stride length.  
 
 
RA: Test for heterogeneity: χ2 = 22.81, df = 8 (P = 0.004); I2 = 65% 
Test for overall effect: z = 5.65 (P < 0.001) 
 
Figure 3.5. Forest plot of studies reporting double support time.  
 
3.3.4. Kinematic and kinetic gait parameters  
Five RA studies reported on the total ankle range of motion (110, 183, 186, 187, 220). 
Three studies reported no significant differences (110, 187, 220), with one study reporting 
a significant increase (183) and one study reporting a significant decrease in the total ankle 
Group by
IA
Study name Condition Statistics for each study Sample size Hedges's g  and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
AS Zebouni [1992] AS -1.13 -1 .98 -0 .27 12 11 29.27
AS Del Din  [2011] AS -0.65 -1 .44 0.15 12 12 33.78
AS Mangone [2011] AS -0.19 -0 .95 0.57 17 10 36.95
AS -0.62 -1 .08 -0 .16
RA Dubbeldam [2011] RA -2.51 -3 .39 -1 .62 21 14 3.92
RA Weiss [2007] RA -1.31 -1 .78 -0 .85 50 37 14.21
RA Khazzam [2007] RA -2.23 -2 .95 -1 .51 22 25 5.89
RA Laroche [2007] RA -1.05 -2 .00 -0 .11 9 9 3.43
RA Laroche [2006] RA -1.33 -2 .37 -0 .29 9 7 2.83
RA Turner [2003] RA -1.69 -2 .35 -1 .03 23 23 6.93
RA Fransen  [1994] RA -1.24 -1 .52 -0 .95 113 114 38.20
RA Isacson [1988] RA -2.30 -3 .25 -1 .35 17 11 3.38
RA Minns [1984] RA -2.38 -2 .76 -2 .00 124 67 21.20
RA -1.66 -1 .84 -1 .49
-2 .00 -1 .00 0.00 1.00 2.00
Favours A Favours B
Study name Condition Statistics for each study Sample size Hedges's g  and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Rome [2009] RA 0.29 -0 .32 0.91 19 21 11.74
Weiss [2007] RA 0.93 0.49 1.38 50 37 14.17
Dubbeldam [2011] RA 2.24 1.39 3.08 21 14 8.86
Turner [2008a] RA 1.16 0.78 1.53 74 53 15.12
Laroche [2007] RA 0.50 -0 .39 1.40 9 9 8.32
Laroche [2006] RA 0.15 -0 .79 1.08 9 7 7.92
Turner [2006] RA 0.82 0.02 1.63 12 12 9.27
Turner [2003] RA 1.67 1.01 2.33 23 23 11.05
Turner 2008b] RA 1.12 0.64 1.61 28 53 13.56
1.01 0.66 1.36
-2 .00 -1 .00 0.00 1.00 2.00
Favours A Favours B
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range of motion (186). Results of the meta-analysis (Figure 3.6) demonstrated that the 
overall effect size for total ankle range of motion was non-significant (SMD –0.64, -1.66 
to 0.39). Ankle power was reported in three RA (189, 190, 203) and one PsA study (174). 
All four studies reported significant reductions in ankle power. The overall effect size for 
ankle power in RA (Figure 3.7) was significantly large (SMD -1.36, -1.70 to -1.02). 
 
 
RA: Test for heterogeneity: χ2 = 39.21, df = 4 (P < 0.001); I2 = 90% 
Test for overall effect: z = -1.29 (P = 0.23) 
 
Figure 3.6. Forest plot of studies reporting ankle range of motion.  
Study name Condition Statistics for each study Sample size Hedges's g and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Isacson [1988] RA -0.45 -1.19 0.30 17 11 14.97
O'Connell [1998] RA -3.92 -5.52 -2.31 10 7 3.23
Woodburn [2004] RA -0.61 -1.64 0.41 11 5 7.97
Woodburn [2002] RA -0.32 -0.72 0.08 50 45 51.49
Turner [2003] RA 1.09 0.48 1.70 23 23 22.34
-0.16 -0.45 0.13
-2.00 -1.00 0.00 1.00 2.00
Favours A Favours B
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RA: Test for heterogeneity: χ2 = 2.01, df = 2 (P =0.37); I2 = 35% 
Test for overall effect: z = -7.85 (P < 0.001) 
 
Figure 3.7. Forest plot of studies reporting ankle power.  
3.3.5. Peak plantar pressure gait parameters 
Three RA studies (188, 190, 215, 216) reported significantly higher forefoot peak plantar 
pressures in RA. Results from the meta-analysis (Figure 3.8) showed that the overall effect 
size for peak plantar pressure to the forefoot was significantly large (SMD 1.09, 0.51 to 
1.67). Pooled results in the RA studies demonstrated no significant difference in peak 
plantar pressure for the rearfoot (Figure 3.9), midfoot (Figure 3.10), first metatarsal (Figure 
3.11), 2nd metatarsal (Figure 3.12) and the 3-5th metatarsal heads (Figure 3.13). Hallux peak 
plantar pressure (Figure 3.14) was reported to be significantly lower in gout (18). 
 
RA: Test for heterogeneity: χ2 = 5.19, df = 2 (P =0.075); I2 = 61% 
Test for overall effect: z = 3.68 (P < 0.001) 
 
Figure 3.8. Forest plot of studies reporting forefoot peak plantar pressure.  
 
Condition Statistics for each study Sample size Hedges's g and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Turner [2006] RA -0.87 -1.68 -0.06 12 12 17.46
Turner [2008a] RA -1.43 -1.83 -1.04 74 53 74.48
Barn [2012] RA -1.77 -2.96 -0.58 10 5 8.07
-1.36 -1.70 -1.02
-2.00 -1.00 0.00 1.00 2.00
Favours A Favours B
Condition Statistics for each study Sample size Hedges's g and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Turner [2008a] RA 1.02 0.54 1.50 28 53 39.73
Turner [2008b] RA 0.51 -0.28 1.29 12 12 27.26
Otter [2004] RA 1.65 1.02 2.29 25 25 33.01
1.09 0.51 1.67
-2.00 -1.00 0.00 1.00 2.00
Favours A Favours B
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RA: Test for heterogeneity: χ2 = 1.36, df = 2 (P =0.51); I2 = 0% 
Test for overall effect: z = -1.23 (P = 0.26) 
 
Figure 3.9. Forest plot of studies reporting rearfoot peak plantar pressure.  
 
 
RA: Test for heterogeneity: χ2 = 0.97, df = 2 (P =0.62); I2 = 0% 
Test for overall effect: z = 1.48 (P = 0.14) 
 
 
Figure 3.10. Forest plot of studies reporting midfoot peak plantar pressure.  
Study name Condition Statistics for each study Sample size Hedges's g  and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Rosenbaum [2006] RA -0.46 -1 .03 0.12 25 21 30.18
Schmiegel [2008a] RA -0.01 -0 .49 0.46 112 20 45.02
Schmiegel [2008b] RA -0.16 -0 .79 0.48 21 16 24.80
-0 .18 -0 .50 0.13
-2 .00 -1 .00 0.00 1.00 2.00
Favours A Favours B
Study name Condition Statistics for each study Sample size Hedges's g  and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Schmiegel [2008a] RA 0.30 -0 .18 0.77 112 20 59.54
Rosenbaum [2006] RA 0.38 -0 .20 0.95 25 21 40.46
0.33 -0 .04 0.69
-2 .00 -1 .00 0.00 1.00 2.00
Favours A Favours B
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RA: Test for heterogeneity: χ2 = 1.12, df = 3 (P =0.77); I2 = 0% 
Test for overall effect: z = 1.07 (P = 0.28) 
 
Figure 3.11. Forest plot of studies reporting 1st metatarsophalangeal joint peak plantar 
pressure.  
 
 
RA: Test for heterogeneity: χ2 = 0.87, df = 3 (P =0.83); I2 = 0% 
Test for overall effect: z = 1.11 (P = 0.27) 
 
Figure 3.12. Forest plot of studies reporting 2nd metatarsophalangeal joint peak plantar 
pressure.  
  
Study name Condition Statistics for each study Sample size Hedges's g  and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Yavuz [2010] RA 0.40 -0 .41 1.22 9 14 13.10
Schmiegel [2008b] RA 0.16 -0 .31 0.64 112 20 38.86
Schmiegel [2008a] RA -0.11 -0 .74 0.53 21 16 21.48
Rosenbaum [2006] RA 0.26 -0 .31 0.83 25 21 26.56
0.16 -0 .13 0.46
-2 .00 -1 .00 0.00 1.00 2.00
Favours A Favours B
Study name Condition Statistics for each study Sample size Hedges's g  and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Schmiegel [2008a] RA 0.16 -0 .31 0.64 112 20 44.72
Schmiegel [2008b] RA -0.11 -0 .74 0.53 21 16 24.72
Rosenbaum [2006] RA 0.26 -0 .31 0.83 25 21 30.57
0.13 -0 .19 0.44
-2 .00 -1 .00 0.00 1.00 2.00
Favours A Favours B
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RA: Test for heterogeneity: χ2 = 0.74, df = 2 (P =0.69); I2 = 0% 
Test for overall effect: z = 0.78 (P = 0.44) 
 
Figure 3.13. Forest plot of studies reporting 3rd to 5th metatarsophalangeal joint peak 
plantar pressure.  
 
 
RA: Test for heterogeneity: χ2 = 0.47, df = 3 (P =0.97); I2 = 0% 
Test for overall effect: z = 1.96 (P = 0.05) 
 
Figure 3.14. Forest plot of studies reporting hallux peak plantar pressure.  
3.3.6. Muscle activity 
One RA study investigated muscle activity of the tibialis posterior muscle and reported 
increased muscle activity during the single support phase of gait (203).  
Study name Condition Statistics for each study Sample size Hedges's g  and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Schmiegel [2008a] RA 0.16 -0 .31 0.64 112 20 44.72
Schmiegel [2008b] RA -0.11 -0 .74 0.53 21 16 24.72
Rosenbaum [2006] RA 0.26 -0 .31 0.83 25 21 30.57
0.13 -0 .19 0.44
-2 .00 -1 .00 0.00 1.00 2.00
Favours A Favours B
Study name Condition Statistics for each study Sample size Hedges's g  and 95% CI
Hedges's Lower Upper Relative Relative 
g limit limit Condition Control weight weight
Yavuz [2010] RA 0.50 -0 .32 1.32 9 14 13.00
Schmiegel [2008a] RA 0.34 -0 .14 0.81 112 20 38.78
Schmiegel [2008b] RA 0.23 -0 .41 0.87 21 16 21.44
Rosenbaum [2006] RA 0.18 -0 .39 0.75 25 21 26.78
0.30 -0 .00 0.59
-2 .00 -1 .00 0.00 1.00 2.00
Favours A Favours B
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3.4. Discussion 
The systematic review highlights significant differences in gait variables between people 
with inflammatory arthritis and controls. The review found the majority of studies report 
on RA with a limited number of studies on other inflammatory arthritic conditions. The 
results reinforced the premise of adoption of a pain avoidance strategy reported in previous 
RA studies, specifically that, people with RA adopt an antalgic gait due to a decrease in 
walking velocity, cadence, increased double limb support time, and decreased ankle power 
with increased peak plantar pressures to the forefoot (186, 189, 191, 192). Antalgic gait 
was also found in gout and AS suggesting that adaptation may occur due to the disease or 
a compensatory mechanism to accommodate for localised foot pain and deformity (188). 
Gait adaptation in PsA may relate to entheseal foot pathologies and foot pain (109, 184). 
Woodburn (174) postulated a stress shielding mechanism may be the driver of gait 
adaptation with walking velocities decreased in attempt to lower stress at the AT. An 
altered gait adaptation in gout illustrates a similar mechanism. The review found a 
reduction in peak plantar pressure under the first metatarsal head, suggesting that people 
with gout use a pain-avoidance strategy to reduce the pain associated with the structural 
joint damage of the first metatarsophalangeal joint.  
 
The chief advantage of 3D motion analysis is that dynamic assessments of foot motion 
during functional activities, such as walking, can be performed (234). Recent advances in 
motion capture technology afford improved spatial resolution and allow the definition of 
relatively small segments in the foot (234). In the last decade there has been an exponential 
growth in the use of 3D models to explain gait strategies (107). The development of 
detailed foot models is beginning to quantify the kinematics and kinetics of the foot, 
however there are limitations for use in people with inflammatory arthritis. Issues related 
to soft tissue artefacts and the validity of skin markers to track underlying skeletal segments 
remains problematic. Inaccurate identification of anatomical landmarks due to the presence 
of foot deformity in inflammatory arthritis may affect the estimation, interpretation and 
reconstruction of joint axis and ultimately the calculation of joint kinematics and kinetics 
(235). The development of foot models has also increased the detail and variety of 3D 
motion analysis variables used to explain gait strategy in people with inflammatory arthritic 
conditions. In comparison to spatiotemporal gait parameters and plantar pressure variables, 
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there appears to be no consensus as to the most important gait variables to report and their 
relationship to overall functional status.  
 
This review has some limitations. There was a large variation in the disease activity, disease 
duration and level of deformities across all studies. Many studies used relatively small 
samples that were underpowered and the heterogeneous nature of the inflammatory 
arthritic population makes interpretation of the data difficult. A number of studies were 
included in the review but excluded from data pooling due to a lack of data reporting of 
standard deviations and mean values of gait parameters. Previous studies have described a 
wide range of methodologies to acquire and define gait parameters and this complicates 
the synthesis of data across different studies. The review was restricted to case-control 
studies and did not consider findings from intervention studies. Analysis only included the 
foot and ankle characteristics in inflammatory arthritis, with no consideration given to data 
from the knee, hip and pelvis. 
 
Two key pathways have been postulated to contribute to the development of foot pain and 
deformity in inflammatory arthritis: inflammatory and mechanical (234). However, limited 
objective evidence exists to comprehensively examine inflammatory and mechanical 
markers in the context of foot pain and deformity across inflammatory arthritic conditions. 
Given the limited data across all inflammatory arthritic conditions, future directions should 
include electromyographic variables that may provide information on the forces producing 
the movements and abnormal muscle activation patterns. Future research is required to 
understand the combined effects of spatiotemporal, kinematic, kinetic and plantar pressure 
that affect foot function. This will allow for relationships to be investigated across the 
differing gait parameters and may further define the mechanism of gait adaptation in 
inflammatory arthritic conditions.  
3.5. Conclusion 
The advancement of 3D gait analysis has given a clearer insight into the complex 
interaction between the underlying mechanisms of inflammation and mechanical pathways 
that influence the development of foot problems in people with inflammatory arthritis. The 
review identified 36 gait studies with the majority of studies reporting gait adaptations in 
RA, but limited evidence relating to other inflammatory arthritic conditions. Poor data 
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reporting, small sample sizes and heterogeneity across inflammatory arthritic conditions 
limit the interpretation of the findings. Future studies should consider a standardised 
analytical approach to gait analysis that will enable comparisons across studies and provide 
clinicians and researchers with objective evidence of foot function in people with 
inflammatory arthritis. 
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CHAPTER 4  
Methodology 
4.1. Introduction 
As identified by the systematic reviews presented in Chapters 2 and 3, no studies have 
assessed US lesions in the AT or conducted 3D gait analysis in a population with 
tophaceous gout. Subsequently, two studies were conducted. 
 
Study 1: A study investigating US lesions of the AT with US imaging in participants 
with tophaceous gout compared to control participants.  
Study 2: A study investigating 3D gait analysis in participants with tophaceous gout 
 compared to control participants. 
 
This chapter will outline in detail an explanation of the methods used in Studies 1 and 2; 
specifically, the recruitment procedures, the clinical characteristics and patient-reported 
outcome measures (PROMs) obtained from the participants, and details of the 
methodological procedures surrounding both US imaging and gait analysis. Finally, the 
statistical techniques used to analyse the two studies will be detailed.  
4.2. Participants 
Twenty-four people with tophaceous gout were recruited from rheumatology outpatient 
clinics at the Auckland District Health Board (ADHB) rheumatology clinic. Twenty-four 
age and sex-matched participants were recruited from the AUT University and general 
population as control participants. The inclusion and exclusion criteria are displayed in 
Tables 4.1 and 4.2. 
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Table 4.1: Case inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Patients with a gout according to the 1977 
preliminary ARA criteria (49)  
Previous rupture of the AT 
18 years or older Current musculoskeletal injury to the lower limb 
At least one subcutaneous tophus Current history of peripheral neuropathy 
Able to walk along a 10m walkway without gait 
aids 
 
 
Table 4.2: Control inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
No previous diagnosis of gout Previous rupture of the AT 
No previous diagnosis of IA Current musculoskeletal injury to the lower limb 
18 years or older Current history of peripheral neuropathy 
Able to walk along a 10m walkway without gait 
aids 
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4.3. Case definition of tophaceous gout 
A participant was considered to have tophaceous gout and to be eligible for inclusion if 
one of the following criteria A, B or C were met (Table 4.3): 
 
Table 4.3: Criteria to define tophaceous gout patient (49) 
A)  The presence of characteristic urate crystals in the joint fluid 
B)  Tophus proven to contain urate crystals by chemical means or  polarised light microscopy: 
C) Presence of 6 or more of the following 12 clinical and radiographic phenomena   
 
1. More than one attack of acute arthritis 
2. Maximum inflammation developed within one day 
3. Monoarthritis attack 
4. Redness observed over joint(s) 
5. First metatarsophalangeal joint painful or swollen 
6. Unilateral first metatarsophalangeal joint attack 
7. Unilateral tarsal joint attack 
8. Tophus (proven or suspected) 
9. Hyperuricaemia 
10. Asymmetric swelling within a joint on x-ray 
11. Subcoritcal cysts without erosion on x-ray 
12. Joint fluid culture negative for organisms during attack 
 
 
 
4.4. Recruitment procedure 
4.4.1. Case participant screening 
A list of participants with tophaceous gout was compiled by the Department of 
Rheumatology from those attending the ADHB Greenlane Rheumatology Clinic between 
January 1st 2013 and July 1st 2013.  
4.4.2. Control participant screening 
Participant names were collected from the AUT Podiatry Clinic patient database who had 
attended the AUT podiatry clinic between July 1st 2012 and July 1st 2013. All participants 
who attend the podiatry clinic signed an informed consent form and provided an indication 
via a tick box if they were interested in participating in research. Recruitment posters were 
also placed around the AUT Akoranga campus.   
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4.4.3. Case and control participant enrolment 
Participants identified as eligible were sent a letter informing them of the study. This 
included a patient information sheet inviting them to participate. For those who agreed to 
participate, the eligibility criteria were confirmed and a data collection appointment 
scheduled. All enrolled participants were either transported to AUT University via taxi 
(vouchers issued to cover the travel cost) or private transport (fuel vouchers to cover the 
cost of travel). 
4.5. Sample size determination 
The sample size was calculated to 22 participants per case and a control group relating to 
differences in estimates by a previous study on walking velocity in participants with 
tophaceous gout (18). This presupposes a mean (SD) walking velocity of 0.90 (0.3) m/s for 
participants with gout and 1.10 (0.3) m/s for control participants. Power was set to 90% 
with a significance level of 5%. Sample size was calculated using (PS Power & Sample 
size Calculations (version 3.0, 2009)). In addition to the sample size calculation, previous 
research using tophaceous gout populations (12, 17, 18) and previous gait research in 
inflammatory arthritis was considered.  
4.6. Ethical approval 
Ethical approval for the studies was approved by the Auckland University of Technology 
Ethics Committee, Auckland, New Zealand. The Auckland District Health Board Ethics 
Committee, Auckland New Zealand provided institutional approval for recruitment. The 
following is a list of the study approval numbers for the two studies undertaken in this 
thesis. 
 
1. Auckland University of Technology Ethics Committee: 13/100 (please refer to 
page XVII of the thesis for evidence) 
2. Auckland District Health Board Ethics Committee: A+5891 (please refer to page 
XVIII of the thesis for evidence) 
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4.6.1. Participant information and consent 
All subjects read the Participant Information Sheet (Appendix 1) and signed a Consent 
Form (Appendix 2) prior to commencement of participation in the study.  
 
4.7. Data collection  
All participants demographic, patient reported outcome measures (PROM) and clinical 
characteristics were recorded. Participants initially underwent US analysis followed by 
gait analysis. The stages of data collection are displayed in Figure 4.1. 
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BMI, bodymass index; HAQ-II, health assessment quesionnaire; LFIS, leeds foot imapct scale; LLTQ 
lower limb task questionnaire; VAS, visual analogue scale; EMG, electromyography; SENIAM, surface 
electromyography for the non-invasive assessment of muscles; MVIC, maximum voluntary isometric 
contraction 
Figure 4.1. Participant journey through data collection 
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4.7.1. Participant examination 
The following information was obtained from each participant: demographic information 
including the participant’s age, sex, height, weight, body mass index (BMI), and ethnicity. 
Clinical characteristics included age of first episode, disease duration, the presence of co-
morbidities; hypertension, diabetes, cardiovascular disease and current medications. The 
latest serum urate and serum creatinine levels were obtained from the ADHB Department 
of Rheumatology. Following completion of the patient exam all participants completed the 
PROMs. 
4.7.2. Rationale for use of outcomes measures 
Pain and global function assessed by the VAS and activity limitation assessed by the HAQ-
II were adopted based on the recommendations of OMERACT 10 pertaining to the 
reporting of PROMs in chronic gout studies (236). At the time of study there were no 
validated disease-specific instruments to quantify the impact of gout on the foot or the 
impact of gout related to lower extremity function. Subsequently, the LFIS and LLTQ were 
selected to assess the impact of tophaceous gout on the foot and the impact of tophaceous 
gout related to lower extremity function. While these PROMs are not validated in 
tophaceous gout both the LFIS and LLTQ have been used in previous studies in tophaceous 
and acute gout (18, 52, 237). 
4.7.3. Patient-reported outcome measures 
Pain: visual analogue scale (VAS) (238) 
 
Pain was quantified using a pain VAS (Appendix 3). Pain severity was scored on a 100 
mm horizontal line, the leftmost boundary representing ‘no pain’ and the rightmost 
boundary representing ‘extreme pain’. The participants marked a cross at a point on the 
line which they felt best represented their current pain level. The distance from the cross to 
the leftmost boundary was measured in mm and scored out of 100. 
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Patient global assessment VAS (238) 
 
A patient global VAS was used to determine the participant’s overall well-being (Appendix 
3). Well-being was scored by the patient marking a cross on a 100 mm horizontal line. The 
leftmost boundary represented ‘completely well’ and the rightmost boundary representing 
‘completely unwell’. Participants marked a cross on the line which they felt best 
represented their current status. The distance from the cross to the leftmost boundary was 
measured in mm, and scored out of 100. 
 
Activity limitations: Health Assessment Questionnaire (HAQ-II) (239) 
 
Functional status of the participants was assessed using the HAQ- II (Appendix 4). The 
HAQ-II contains 10 questions, 9 of which measure functional ability, with 1 question 
measuring disability. Each question can be answered by one of four answers, ‘without any 
difficulty’ (score = 0), ‘with some difficulty’ (score = 1), ‘with much difficulty’ (score = 
2) and ‘unable to’ (score = 3). Scores were totalled and divided by the total number of 
questions answered. If less than 8 questions were answered the HAQ-II was not scored. A 
lower value was suggestive of a better functional status.  
 
1. Function in the lower limb: Lower Limb Tasks Questionnaire (LLTQ) (240) 
 
Function in the lower extremity was quantified by the LLTQ (Appendix 5) (240). The 
LLTQ scores the participants’ account of their functional status in the previous 48 hours. 
The questionnaire is divided into two domains: activities of daily living and recreational 
activities, with each domain containing 10 questions. The questions are scored on a 5-point 
Likert scale (0 = unable, 1 = severe difficulty, 2 = moderate difficulty, 3 = mild difficulty, 
4= no difficulty). The scores from the 10 questions were totalled, the maximum possible 
score being 40. Higher overall scores represented greater levels of lower extremity 
function. In addition, participants also scored the importance of each question on a 5-point 
Likert scale; (1 = not important, 2 = mildly important, 3 = moderately important, 4 = very 
important).  
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2. The Leeds Foot Impact Scale (LFIS) (241) 
 
The LFIS consists of 51 questions, divided into two subcategories; impairment/footwear 
(LFISIF) and activity limitation/participation restriction (LFISAP) (Appendix 6). Questions 
1-21 comprise the LFISIF section and questions 22 to 51 the LFISAP section. Each question 
is marked either ‘true’ or ‘false’ with a true response scored as one point and a false 
response as zero. Scores are totalled to provide an overall score for each subsection. The 
maximum overall score achievable is 51, with higher scores indicative of great levels of 
impairment (241). To interpret, the LFIS cut-off values proposed by Turner were applied 
(189). A LFISIF score ≥ 7 points and an LFISAP score ≥ 10 points indicating a high to severe 
level of foot impairment and disability. 
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4.8. Ultrasonography procedures 
4.8.1. Grey-scale and power Doppler imaging equipment 
US imaging was performed by one experienced radiologist at one location (Horizon 
Radiology, AUT University North Shore campus) who was blind to the clinical details of 
participants. US was performed using a Philips iU22 ™ unit equipped with a broadband 
17-5 Megahertz (MHz) linear probe. Grey-scale machine settings were standardised prior 
to the study to optimise visualisation of superficial and deep structures. These settings were 
as follows: a dynamic range of 40-50dB; a grey-scale frequency of 12-14 MHz; and a gain 
of 60dB. PD settings were standardised with a pulse repetition frequency of 500 Hz, and a 
low wall filter of 42 Hz. The colour gain was increased to the highest value not generating 
PD signal and optimised for low flow.  
4.8.2. Patient positioning 
All participants assumed a prone position with the knee fully extended for visualisation of 
the AT (Figure 4.2). For all participants, bilateral systematic longitudinal and transverse 
imaging of the enthesis and body of the AT were conducted in grey-scale and subsequently 
with PD.   
 
 
Figure 4.2. Patient positioning for ultrasound imaging 
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In order to investigate specific regions of the AT, the tendon was divided into 3 zones for 
analysis (Figure 4.3).  
 Zone 1 (insertional zone): calcaneal enthesis to 2 cm proximal: 
 Zone 2 (pre-insertional): 2 to 6 cm proximal to calcaneal enthesis: 
 Zone 3 (proximal to mid-section): 6 cm proximal to enthesis to myotendinous 
junction of gastrocnemius  
The zones for analysis were defined based on previous cross-sectional analysis of the AT 
which indicated a relative zone of hypovascularity within 2 to 6 cm proximal to the 
calcaneal insertion (242, 243).  
 
 
Figure 4.3. Longitudinal image of AT showing the zones in which lesions were scored. 
Zone 1 insertional 
 
Zone 3 proximal Zone 2 pre-insertional 
 
Calcaneus 
AT 
Enthesis 
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4.8.3. Definitions of Achilles tendon lesions 
The definitions used to diagnose the specific US lesions are presented in Table 4.4. 
 
Table 4.4: Definitions of greyscale and power Doppler ultrasound lesions 
US Lesion Definition 
Tophus characteristics The presence of tophus in each zone was attributed a 
binary value (yes/no). The diameter of the longest tophus 
was measured in mm. A tophus was defined as 
hyperechoic heterogeneous or homogeneous lesions with 
poorly defined contours surrounded by an anechoic halo 
(129).  
Tendon echogenicity Focal hypoechoic areas A lack of the homogeneous fibrillar pattern with loss of 
the tightly packed echogenic lines after correcting for 
anisotropy (153). 
 Hyperechoic spots Hyperechoic spots were defined as hyperechoic (bright) 
foci consistent with calcific deposits (relative to the 
tendon fibres), with or without acoustic shadow, seen in 2 
perpendicular planes (153, 244). 
Tendon vascularity Intratendinous power 
Doppler signal 
PD signal in the AT (140).  
Tendon morphology Partial tendon tear Focal discontinuity visualized with the US beam exactly 
perpendicular to the tendon to avoid anisotropy (147). 
 Complete rupture Complete loss of tendon substance visualized with the US 
beam exactly perpendicular to the tendon to avoid 
anisotropy (245). 
 Entheseal tendon 
thickness 
Abnormal AT thickness was defined as ≥ 5.29 mm (150). 
 Tendon length Measured as the longitudinal length between the AT 
insertion into the Achilles notch and the soleus-Achilles 
musculotendinous junction Enthesis (MTJ). The soleus-
Achilles MTJ was defined as the location where the AT 
divides into the soleus aponeurosis and gastrocnemius 
tendon (246). 
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Enthesis Entheseal echogenicity Circumscribed hypoechoic areas with loss of fibrillar 
echotexture (140).  
 Entheseal echogenicity:  
calcifications 
Calcifications appearing as intratendinous hyperechoic 
spots (140).  
 Entheseal vascularity Doppler activity approximately < 2 mm near the bony 
cortex. The Doppler signal must be at the enthesis, 
different from reflecting surface artefact or nutrition vessel 
signal, with or without cortical irregularities, erosions, or 
enthesophytes (153) 
Bursal morphology Retrocalcaneal bursitis Bursa with well-defined compressible, anechoic or hypo 
echoic area inside with maximal diameter larger than 2mm 
as viewed in the longitudinal plane (247).  
 Bursal size score Diameter of the bursa scored (0: < 2 mm; 1: between 2–4 
mm; 2: > 4 mm) (140). 
 Bursal snowstorm 
appearance 
Echogenic aggregates observed with the bursa (35). 
 Tophus present in bursa Aggregates located in bursa that were heterogeneous 
hyperechoic (relative to subdermal fat) aggregates with 
poorly defined margins with or without areas of acoustic 
shadowing (244).  
 Bursal power Doppler 
signal 
PD signal in the bursa (140). 
Bone profile Calcaneal bone cortex 
irregularities 
A loss of the normal regular bone contour without any 
clear sign of enthesophyte and/or erosion (153).  
 Calcaneal enthesophytes:  A step up of bony prominence at the end of the normal 
bone contour, seen in 2 perpendicular planes, with or 
without acoustic shadow (153). 
 Calcaneal bone erosions:  A cortical breakage with a step down contour defect, seen 
in 2 perpendicular planes, at the insertion of the enthesis to 
the bone (152). 
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4.8.4. Scoring of grey-scale and power Doppler lesions 
US lesions were scored using a semi-qualitative scoring system adapted from the work of 
Filippucci (140) conducted on the AT. The scoring system assessed the tophus 
characteristics, tendon echogenicity, tendon vascularity, tendon morphology, enthesis, 
bursal morphology and bone profile using binary, continuous measurement and semi-
qualitative scale. The scoring system is summarised in Table 4.5 with the full scoring sheet 
located in Appendix 7, demonstrating the characteristics of the scoring system. 
 
Table 4.5: Scoring system applied to grey scale and power Doppler ultrasound lesions 
at the Achilles tendon.  
Tophus 
characteristics 
Tophus present (yes/no) 
If tophus present, longest diameter (mm) 
Tendon echogenicity Focal hypoechoic areas with loss of fibrillar echotexture* 
Intratendinous hyperechoic spots* 
Tendon vascularity Intratendinous power Doppler signal* 
Tendon morphology Tendon tear: (0, absent; 1, partial tear; 2, complete rupture) 
Tendon thickness at the insertion of the deeper margin into the calcaneal bone (mm)  
Tendon thickness (mm) 
Tendon length (mm) 
Enthesis Entheseal echogenicity: focal hypoechoic areas* 
Entheseal echogenicity: calcifications* 
Entheseal vascularity* 
Bursal morphology Bursal size (mm) 
 Bursal size score (0, < 2 mm; 1, between 2–4 mm; 2, > 4 mm) 
Bursal snowstorm appearance* 
Bursal power Doppler signal* 
Bone profile Calcaneal bone cortex irregularities* 
Calcaneal enthesophytes* 
Calcaneal bone erosions (0, no bone erosion; 1, between 0.1 and 2 mm; 2, > 2 mm) 
 
*Scoring system ranging from 0 to 2 (0, none/absent; 1, mild–moderate; 2, severe); mm, 
millimetres. 
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4.9. Three-dimensional gait analysis  
4.9.1. Gait analysis system 
A nine-camera motion analysis system (Qualysis AB, Gothenburg, Sweden) was linked to 
a single desktop within the motion analysis laboratory and synchronised with a force plate 
and EMG system allowing simultaneous collection of kinematic, kinetic and EMG data. 
The cameras were positioned to provide the maximum field-of-view of the experimental 
area (Figure 4.4).  Qualysis Track Manager (software) collected all kinematic and kinetic 
and EMG data.  Two Advanced Mechanical Technology Inc., USA (AMTI) force plates 
outputted analogue signals which were amplified and then collected simultaneously with 
motion data.  Force plate and EMG data were sent to a 64 channel analogue digital board, 
connected to the computer via a USB connector. Qualysis Track Manager software 
synchronised and stored the data with the motion data.  Both AMTI force plate consisted 
of 2 piezoelectric transducers with dimensions of 508mm (length) x 463mm (width) x 
82mm (depth). The plate was embedded into the walkway. EMG data were recorded using 
a Noraxon Desktop Direct Transmission System (DTS) enabling wireless surface EMG 
signal to be captured. The Noraxon system was synchronised within the Qualisys 3D 
motion analysis system to enable kinematic, kinetic and EMG data to be captured 
simultaneously.  
 
 
 
Figure 4.4. Camera placement of Qualysis system 
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4.9.2. System calibration 
Prior to collection of kinematic, kinetic and EMG data the motion capture system was 
calibrated. Dynamic calibration was performed using a reference object, an ‘L” shaped bar 
with 4 markers placed inside the force plate margins. The bar has 4 predefined reflective 
markers attached, one at each corner of the bar and one midway along the bar axis. The 
reference object defined the lab global coordinate system (x, y and z axis). The calibration 
procedure was performed by randomly moving a wand (‘T’ shaped wand with 2 reflective 
markers) through a circular motion in the volume to be calibrated (the region of interest). 
The system recorded a calibration file of 30 seconds at 100Hz. The residuals of each camera 
were expressed as the SD in millimetres (mm) of wand length. If the average resolution SD 
was less than 0.5mm calibration was deemed optimal. If the result was higher than this the 
camera position and resolution was checked and calibration repeated. As kinetic data was 
obtained the position of the two force plates required determination. Four markers were 
placed at the corners of each force plate to define their position and orientation with the 
global coordinate system. 
4.9.3. Oxford Foot Model – rationale for use 
The systematic review detailed in Chapter 3 explored the foot models that have been 
previously reported and the development of new models, for example the Salford foot 
model (248). Based on the findings from Chapter 3, the Oxford Foot Model was used to 
model the lower limbs (113). The Oxford Foot Model has been used by numerous research 
groups to quantify gait kinematics in paediatric, cerebral palsy, RA, healthy and flatfooted 
populations (110, 188, 249-253).  
 
The decision to use the Oxford Foot Model to derive kinematic gait data was based on two 
principles. Firstly, as identified by Chapter 3, the Oxford Foot Model had been the applied 
in the most gait studies in participants with inflammatory arthritis to quantify kinematic 
joint motion (110, 188, 190). Secondly, reliability work had been conducted on the Oxford 
Foot Model in RA (110). Woodburn (110) investigated the within and between-day 
repeatability and compared foot motion between healthy adults and participants with RA. 
Inter-segment coefficient of multiple correlation values related to the within and between-
day repeatability ranged between 0.83 and 0.98 for all foot segments assessed. Previous 
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research has demonstrated that coefficient of multiple correlation values > 0.8 indicate 
acceptable repeatability for motion assessed in the foot (110, 187). Through piloting work 
it was determined that skin-mounted markers based on the Oxford Foot Model were able 
to be tracked consistently.  
4.9.4. The Oxford Foot Model – skin mounted marker placement 
Nineteen Qualisys lightweight passive reflective markers (12 mm diameter) were attached 
to both limbs of each participant on specific anatomical bony landmarks. These defined 
relative segments of the foot and leg in accordance with the Modified Oxford Foot Model, 
described by Stebbins (249) (Figures 4.5 a & b). Marker locations were identified by 
palpation of the participant’s feet and legs by an experienced musculoskeletal podiatrist 
and were marked with a non-toxic, washable marker pen. The reflective markers were 
adhered to the participant’s skin using 3M® double sided tape. The segment marker name 
and anatomical location are displayed in Table 4.6.  
 
 
 
Figure 4.5a. Anterior view of marker positioning for Modified Oxford Foot Model 
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Figure 4.5b. Lateral view of marker positioning for Modified Oxford Foot Model 
 
Table 4.6: Name and position of markers used for the Oxford Foot Model (249) 
Marker name Marker position Segment 
KNE Femoral condyle Femur 
TTUB Tibial tuberosity Tibia 
HFIB Head of fibular Tibia 
LMAL Lateral malleolus Tibia 
MMAL Medial malleolus Tibia 
SHN1 Anterior aspect of shin Tibia 
CAL1 Posterior distal aspect of heel Hindfoot 
CAL2 Posterior medial aspect of heel Hindfoot 
LCAL Lateral calcaneus Hindfoot 
STAL Sustentaculum tali Hindfoot 
P1MT Base of first metatarsal Forefoot 
P5MT Base of fifth metatarsal Forefoot 
D1MT Head of first metatarsal Forefoot 
D5MT Head of fifth metatarsal Forefoot 
TOE Between second and third metatarsal heads Forefoot 
HLX Base of hallux Hallux 
CAL1 
CAL2 
LCAL TOE 
B 
118 
 
4.9.5. Oxford Foot Model - marker placement 
CAL1 and CAL2 were placed on posterior aspect of calcaneus such that they were on the 
distal and proximal ends of the midline in the sagittal plane, respectively. STAL was placed 
on the Sustentaculum tali. LCAL was placed on the lateral aspect of the calcaneus, at the 
same distance from the most posterior point as STAL. D1MT and D5MT were placed 
medially and laterally on the foot such that their centres lay along the line through the distal 
heads of the first and fifth metatarsal heads. P5MT was placed laterally over the proximal 
head of the fifth metatarsal in the plane containing the markers D1MT and D5MT. TOE 
was placed on the mid-point of the distal heads of the second and third metatarsals. P1MT 
was placed on proximal head of first metatarsal, just medial to the extensor halluces longus 
tendon (this structure was palpated by asking the subject to dorsiflex the hallux). HLX was 
placed on the medial side of the proximal phalanx of the hallux, mid-way between the 
superior and inferior surface (249).  
4.9.6. Oxford Foot Model – segment definition  
A four-segment, 3D rigid-link dynamic biomechanical model of the right and left lower 
legs representative of the Oxford Foot Model was constructed following the procedure 
outlined by C-Motion online tutorial (254). Segments were represented as geometric 
objects (cylinders) and scaled according to each individual (255). Segments and their 
relative axis were created defining the shank, the hindfoot, the forefoot and the hallux 
(Table 4.7).  
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Table 4.7: Anatomical reference frames for the Oxford Foot Model 
Segment Orthogonal 
Axis 
Description 
Shank X Lateral and to the right in the 
frontal plane 
 
Y Anterior in the sagittal plane 
Z Vertical and perpendicular to X 
and Y axis 
Orthogonal axes were aligned according to the medial and 
lateral markers at the ends of each segment, with the 
longitudinal axis passing through the segment endpoints. 
The original land mark was at the proximal end of the tibia.  
Rearfoot X Lateral to the right in the frontal 
plane 
 
Y Anterior in the sagittal plane 
Z Vertical and perpendicular to X 
and Y axis 
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Forefoot X Lateral to the right in the 
frontal plane 
 
Y Anterior in the sagittal plane 
Z Vertical and perpendicular to 
X and Y axis 
 
Hallux X Lateral to the right in the frontal plane 
Y Anterior in the sagittal plane 
Z Vertical and perpendicular to X and Y axis 
Note: while the hallux is represented as a segment, only one marker was 
placed on the hallux. The hallux segment therefore "shares" the medio-
lateral axis of the forefoot segment so that a coordinate system can be 
created for the hallux (254). 
 
4.9.7. Oxford Foot Model – joint rotation definitions 
Angles of rotation for each segment were calculated according to the defined joint co-
ordinate system. The sequence of rotation for the cardian angles was X (sagittal)–Y 
(frontal)–Z (transverse). Intersegment rotations were defined using the following terms: 
Ankle motion (rearfoot relative to the tibia), dorsiflexion (+) / plantarflexion (-) occurred 
about the x-axis, inversion (+) / eversion (-) occurred about the y-axis. Hallux motion 
(hallux relative to the forefoot), dorsiflexion (+) / plantarflexion (-) occurred about the x-
axis.  
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4.9.8. Creation of the kinetic foot segment 
Before Visual 3D was able to create force assignments (assigning segments to force 
platforms based on the estimated contact of a segment with the force platform) to permit 
calculation of ankle joint moments and power, it was necessary to create a kinetic foot 
segment. The one segment foot model was defined according to markers on the ankle and 
foot as described by C-Motion (254). 
4.9.9. Kinematic and kinetic data collection procedure 
Following application of the markers, a static trial was captured with the participant 
standing in upright double leg support in their natural base of gait. The static trial permitted 
calculation of off-set values for all joint rotations. These joint offset values were later 
subtracted from the appropriate joint rotations for the gait cycles of each participant (256). 
This process was conducted to account for variability in foot kinematics. Following 
completion of the static trial the two anatomical markers MMAL and CAL2 were removed. 
The dynamic trials were conducted with the remaining 34 markers (17 per limb). These 
markers acted as tracking markers during the dynamic trials.  
 
Participants completed a familiarisation trial where they walked barefoot along a 10m 
walkway at their normal self-selected walking speed. Participants completed a minimum 
of 5 and a maximum of 10 dynamic walking trials barefoot on the walkway at their natural 
walking speed. At the conclusion of each trial all markers were checked in case of 
movement. During data collection participants were monitored visually and verbally and 
encouraged to rest if required.  
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4.10. EMG procedures  
4.10.1. Rationale for selection of muscles for EMG analysis 
As reported in Chapter 3, the quantification of muscle activity in inflammatory arthritis is 
limited and has not been reported in participants with tophaceous gout. Muscle activity in 
the medial and lateral gastrocnemius and the tibialis anterior was normalised to the MVIC.  
The medial and lateral gastrocnemius were selected on the basis that: the muscles are a 
confluence of the AT (the primary structure under investigation of this thesis); they are the 
primary plantarflexors of the foot during the stance phase of gait; and they control 
movement of the ankle joint. The tibialis anterior was selected as it is the primary 
dorsiflexor of the foot (antagonist to the gastrocnemius).  
4.10.2. Measurement of muscle activity 
EMG data were recorded using a Noraxon Desktop Direct Transmission System (DTS) 
enabling wireless surface EMG signal to be captured. The Noraxon system was 
synchronised within the Qualisys 3D motion analysis system to enable kinematic, kinetic 
and EMG data to be captured simultaneously. The Noraxon system comprises four 
components: (a) EMG electrodes; (b) EMG preamplifier leads; (c) EMG probes; and (d) 
the desktop receiver. 
 
a) Noraxon dual surface electrodes (Noraxon USA Inc, Scottsdale, Az). The 
electrodes featured a self-adhesive Ag/AgCl contact material and an inter-
electrode distance of 20 mm.  
 
b) The preamplifier leads had no notch (50/60Hz) filters, 1st order high-pass filters 
set to 10Hz +/- 10% cut-off, a baseline noise: <1uV RMS, input impedance of > 
100 Mohm, an input range of +/- 6.3mV, a base gain 200 and final gain of 500.  
 
c) The EMG probes used were 3.4 x 2.4 x 1.4 cm and weighed approximately 14 
grams. 
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d) The Desktop Direct Transmission System (DDTS) is a desktop receiver. This 
enables direct transmission of data from the EMG sensor site to the desktop 
receiver. The DDTS was connected to the computer via a USB cable and was able 
to detect signal from up to 20m from the EMG probe. The sensor acquisition system 
has 16 bit resolution, selectable low-pass cut-off at 500, 1000 or 1500Hz and a 
selectable sample rate of 1500 or 3000Hz. EMG signals were low-pass filter at 
1000Hz and sampled at 1500Hz. 
4.10.3. EMG experimental procedures 
The location, preparation and application of the surface electrodes followed the Surface 
Electromyography for the Non-Invasive Assessment of Muscles (SENIAM) guidelines 
(257).  
4.10.3.1. Tibialis anterior electrode location and placement procedure 
Seated with hips and knee joint flexed at 90º, participants were asked to dorsiflex against 
resistance to determine the centre of the tibialis anterior muscle belly, an area 
approximately ⅓ of the distance between the head of the fibula and medial malleoli and 
orientated in the direction of the line between the tip of the fibula head and the tip of the 
medial malleolus (Figure 4.6a). A mark was made over the centre-most portion of the 
muscle belly where the electrode would be placed. The skin was prepared for electrode 
placement by shaving the site using a disposable safety razor, abrading the site with 
NuPREP® gel and gauze and cleaning the site with an isopropyl alcohol wipe. The 
electrode was placed in position and skin resistance assessed with a multimeter, if the skin 
resistance was greater than 5kΩ the electrode was removed and the preparation procedure 
repeated. If resistance levels were acceptable electrode position was verified and signal 
quality by visually inspecting the EMG signals while participants contracted each the 
muscle.  This involved supporting the leg superior to the ankle joint with the ankle joint in 
dorsiflexion and the foot in inversion without extension of the hallux. Pressure was applied 
against the medial side, dorsal surface of the foot in the direction of plantarflexion of the 
ankle joint and eversion of the foot (258).  
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4.10.3.2. Lateral gastrocnemius electrode placement procedure 
To determine electrode placement, subjects were asked to stand on both feet and perform 
a heel raise (rise up on to their toes) in order to locate the muscle belly. A mark was made 
to the central-most portion of the lateral gastrocnemius muscle belly to indicate electrode 
placement. The participant was moved to a plinth and placed in a prone position. The skin 
was prepared for electrode placement as for the tibialis anterior. The electrode was placed 
as displayed in Figure 4.6b. Skin resistance was assessed and electrode placement verified 
by manual muscle testing which involved the patient performing a standing heel raise 
(259).  
4.10.3.3. Medial gastrocnemius electrode placement procedure 
The procedure was replicated as for electrode placement on the lateral gastrocnemius 
(Figure 4.6b). Electrode placement was verified as for the lateral gastrocnemius (259).  
  
  
Figure 4.6. Electrode positioning for the tibialis anterior (A) and medial and lateral 
gastrocnemius muscles (B)  
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4.10.4. Maximum voluntary isometric contractions 
4.10.4.1. Positioning 
4.10.4.1.1. Medial and lateral gastrocnemius  
MVICs were measured with the participants standing in their natural base and angle of gait. 
Participants were instructed to perform a bilateral heel raise to a position of maximum 
ankle plantarflexion standing with 0º knee flexion (259). The participants were encouraged 
to squeeze their gastrocnemius in this maximum position for a duration of 3 seconds. 
Following this, participants were instructed to relax into to a full weight-bearing position. 
This position was selected based on the previous research to acquire MVIC from the triceps 
surae muscle group (259).  
4.10.4.1.2. Tibialis anterior 
MVICs were measured in both tibialis anterior muscles independently. MVICs were 
generated with the participants seated with hips and knees flexed at 90º and foot resting on 
the ground. From this position the participants were asked to dorsiflex their foot, without 
extending their hallux or lifting their heel of the ground. Pressure was applied by the tester 
against the medial side, with the dorsal surface of the foot in the direction of plantarflexion 
of the ankle joint (258). 
4.10.4.2. Protocol 
Prior to recording MVIC trials, participants were familiarized with the testing procedure. 
A 10 second resting baseline was acquired, taken simultaneously from the medial and 
lateral gastrocnemius and tibialis anterior muscles, while the participants were seated, with 
hips and knees flexed at 90º and feet resting on the ground. Each participant completed 
three MVIC trials. During each maximum contraction the participant was given verbal 
encouragement to produce a maximum contraction. Each MVIC lasted approximately 6-8 
seconds, which included a 2 second build-up followed by a maximum isometric 3 second 
effort contraction and a gradual 2 second decreased effort period. Maximum effort 
contractions were separated by a 2-minute recovery period.  
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4.11. Data processing  
4.11.1. Kinematic data processing 
Qualisys Track Manager (Version 2.8, build 1065, Qualysis AB, Gothenburg, Sweden) and 
Visual 3D Professional (Version 5.01.18, C-Motion Inc., Germantown, MD, USA) 
software programs were used for data processing. Marker coordinate data during the static 
and dynamic trials were captured using a Qualisys motion capture system (Qualisys 
Medical AB, Sweden) sampling at 240 Hz. 3D coordinate data were filtered at 6 Hz using 
a fourth order Butterworth filter. Following capture all dynamic trials were individually 
quality assessed by the researcher with the 3 best trials (which were determined by the 
placement of the feet in relation to the force plates) using Qualysis Track Manager. For 
each participant one dynamic trial was conducted, from this file an Automatic 
Identification File of Markers (AIM) model was generated and used to track two further 
trials.  Marker and ground reaction force (GRF) data were stored within the Qualisys C3D 
file format with each trial individually processed using visual 3D software in order to 
generate the .cmo file.  The .cmo file consisted of one static trial (used to build the model) 
and three dynamic trials from each participant (260).  
4.11.2. Kinetic data processing 
For dynamic data collection the raw GRF signals were filtered using a Butterworth low-
pass filter with a cut off frequency of 10 Hz. Data was sampled at 1200 Hz to capture 
horizontal and vertical ground reaction forces in real-time.  Kinetic data was analysed using 
Visual 3D (C-Motion Inc, USA) software. The vertical GRF was used to determine initial 
heel contact and terminal stance using rising and falling signals with a threshold of 20 
Newtons (N). Horizontal and vertical ground reaction forces were calculated relative to 
each participant’s bodyweight. The GRF data was stored within the C3D file and processed 
using Visual 3D software. Inverse dynamics were used to derive ankle joint moments and 
power.  Inverse dynamics is the method used to derive joint forces and moments. Inertial 
properties of segments (mass, centre of mass, moments of inertia) are used in conjunction 
with the kinematics and external forces (GRF) to derive the joint forces and moments (261). 
End-points of segments were determined from either skin-marker positions or landmarks. 
Centre of mass is assumed to be located along the segments’ longitudinal axis with a 
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distance expressed in percentage of the total length of the segment (255, 262).  These 
distances were estimated based on Dempster’s data and segments were modelled according 
to geometric shapes based on the work of Hanavan (255, 262). 
4.11.3. EMG data processing 
All EMG data reduction procedures were conducted using Visual 3D Professional (Version 
5.01.18, C-Motion Inc., Germantown, MD, USA). All EMG raw signals were full-wave 
rectified and subsequently processed through a linear envelope. The processed EMG data 
obtained during the walking trials were then normalised to the MVIC.    
 
EMG data were corrected for DC bias and high-pass filtered (4th order zero-phase lag 
Butterworth) with a cut-off frequency of 50 Hz. This was followed by low pass filtering at 
a cut-off frequency of 500Hz. A second order Butterworth Bidirectional filter was used 
(263). Background noise was removed. The purpose was to offset trial data to 
accommodate for any DC shift. A linear envelope was created. The signal was first high-
pass filtered at cut-off frequency of 50Hz, full wave rectified and finally low-pass filtered 
(cut off frequency 10Hz). Normalised EMG values were expressed as a percentage of the 
MVIC (%MVIC). To calculate, the linear envelope was normalised to the greatest ½ 
second of activity of the MVIC trial. A window of twenty five 0.2s intervals of integrated 
EMG were moved one interval at a time across the MVIC data to find the greatest EMG 
activity. The average integrated EMG during the ½ second was used to compute the 
normalization factor (254). 
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4.12. Gait variables selected for analysis 
The gait variables selected for investigation are displayed in Table 4.8.  
 
Table 4.8: Spatiotemporal, kinematic, kinetic and muscle activity parameters selected 
for analysis 
 
Gait parameter Gait variable 
Spatiotemporal  Walking velocity (m/s) 
Cadence (steps/min) 
Stride length (m) 
Double support time (s) 
Gait cycle time (s) 
Kinematic  Ankle range of motion sagittal plane 
(º) 
Ankle range of motion frontal plane (º) 
Hallux range of motion (º) 
Kinetic Peak ankle joint force (N) 
Peak ankle joint moment (Nm/kg) 
Peak ankle joint power (W/kg) 
Work (Integration under peak power 
curve) (J/kg) 
Peak angular velocity (º/sec) 
Peak force (percent of gait cycle) 
Peak moment (percent of gait cycle) 
Peak force (percent of gait cycle) 
Muscle activity Muscle activity expressed as %MVIC 
for the tibialis anterior, medial and 
lateral gastrocnemius muscles and 
normalised to stance cycle time 
m/s, meters per second; º, degrees; s, seconds; N, Newtons; Nm/Kg, Newton meters per kilogram; 
W/Kg, Watts per kilogram; J/kg (Joules per kilogram; º/sec, degrees per second; %MVIC, percentage of 
maximum voluntary isometric contraction 
4.12.1. Rationale for selection of spatiotemporal variables 
The spatiotemporal parameters of velocity, cadence, stride length, double support time and 
gait cycle time were selected on the basis for measurement as they have been extensively 
used to quantify gait strategy in inflammatory arthritis (detailed in Chapter 3).  
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4.12.2. Rationale for selection of kinematic variables 
4.12.2.1. Ankle range of motion (sagittal and frontal plane) 
Quantification of ankle ROM was a primary aim of the thesis. The results of Chapter 3 
indicated ankle ROM has been described in the sagittal and frontal plane in RA but not in 
tophaceous gout. On the basis of previous research in RA, ankle ROM was measured in 
the frontal and sagittal planes (110, 183, 186, 187, 220).  
 
4.12.2.2. Hallux range of motion 
Although not extensively investigated previously in any inflammatory arthritic condition, 
hallux range of motion was selected due to the relevance of the 1MTP joint in gout, with 
this joint being the most common site of an attack of gout in the foot (77-80). Previous 
research in tophaceous gout has also postulated that a reduced hallux range of motion may 
be a significant adaptation to gait strategy (18).  
4.12.3. Rationale for selection of kinetic variables 
4.12.3.1. Ankle power 
Quantification of ankle power was central to investigating hypotheses 3 and 6. Peak ankle 
power was measured during the stance phase of gait, in line with previous studies in RA as 
detailed in Chapter 3. Additionally, timing alterations or peak ankle power in relation to 
the stance phase of gait were investigated.  It was postulated that the timing of peak power 
may be altered in participants with tophaceous gout. Subsequently, the percentage in the 
stance phase at which peak power generation occurred was calculated. This parameter has 
not been previously reported in inflammatory arthritic gait research. The amount of positive 
work (concentric muscle activity) of the ankle plantar flexors that occurred during stance 
phase of gait was also calculated. It was postulated that the amount of concentric activity 
may be altered in participants with tophaceous gout. This was represented by the A2 area 
of ankle power curve as displayed in Figure 4.7 (261). This parameter has been previously 
reported in a RA study (191). 
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Figure 4.7. Power generation of the ankle during stance phase of gait. A1 represents 
eccentric muscle activity. A2 represents concentric muscle activity. 
4.12.3.2. Peak ankle force and moment 
The parameters of peak ankle force and peak ankle moment were also quantified in line 
with previous research in inflammatory arthritis, as detailed in Chapter 3. Additionally, the 
timing of the peak values of these parameters during the stance phase was of interest. 
Subsequently, the percentage of stance phase of gait when peak force and peak moment 
occurred were calculated. 
 
4.12.3.3. Angular velocity 
Reductions in ankle power have been reported in RA and PsA and in RA associated with 
reductions in angular velocity of the ankle joint (174, 189, 190, 203). Reporting of angular 
velocity is limited. Subsequently, the magnitude of the angular velocity component at the 
instant of peak ankle generation power was extracted. 
 
 
131 
 
 4.13. Statistical analysis 
All statistical analyses were performed using SPSS (version 22, SPSS Inc., Chicago, IL). 
4.13.1. Assessment of all data for normality 
Normality of all data was assessed using a Shapiro-Wilks test and visual inspection of their 
histograms, normal Q-Q plots and box plots (264, 265). All tests were two-tailed, and p 
values < 0.05 were considered significant. Data were analysed using SPSS software v20™. 
Where data was normally distributed it was presented as mean (SD). Where data was not 
normally distributed, the median (IQR) was reported. 
4.13.2. Analysis of patient, clinical characteristics and patient-reported outcome 
measures 
Descriptive statistics, including mean (SD) and percentages, were used to describe the 
patient and clinical characteristics. Median (IQR) were used to describe PROMs.  
4.13.3. Ultrasound imaging 
4.13.3.1. Inter-observer agreements 
To assess inter-observer agreement, the same 24 participants (12 cases and 12 controls) 
were scored by a second scorer (an experienced radiologist). Rescoring of images occurred 
6 months following the initial scanning session. Inter-observer agreements were estimated 
using the kappa statistic (ƙ) and 95% confidence intervals (95% CI). Inference of the ƙ-
statistic is based upon accepted benchmarks (266). A ƙ-value less than 0.20 was considered 
poor, between 0.21 and 0.40 fair, between 0.41 and 0.60 moderate, between 0.61 and 0.80 
good, and between 0.81 and 1 excellent (266).  
4.13.3.2. Analysis of ultrasound lesions 
As lesions were nested within participants, a general estimating equation (GEE) approach 
was used to analyse data (267). This approach accounted for key issues such as sparseness 
of data, ordinal scales with few observations and allowance for multiple observations on 
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the same individuals (left and right sides) and 3 zones of measurement in the AT 
(insertional, preinsertion and proximal). 
 
US lesions were graded 0-2 on a semi-quantitative scoring system (0 = absent, 1 = mild to 
moderate, 2 = severe). Due to very few lesions being scored ‘2’ the scoring system was 
restructured into a binary scoring system to enable useful statistical analysis. The grading 
of ‘mild to moderate’ was combined with the ‘severe’ grade to create 2 binary scoring 
categories (presence/absence). Frequencies of US lesions (absence/presence) were 
analysed by side (left, right), zone (insertional, mid portion and proximal to mid portion) 
and group (gout vs control), with a design matrix constructed (2x3x2, x2 for the 
presence/absence measures). GEE models were used to analyse the binary data, analyses 
which incorporated the 6 observations per person and compared tophaceous gout and 
control participants.  
 
In the GEE models, side was set up as a structural variable but was not formally compared. 
The GEE models also tested the interaction between zone and group (control/gout). This 
tested for statistically significant differences between zones in the differences between gout 
vs control. If significant interactions were identified they were further explored by 
comparing gout vs control for each zone. If there was no significant interaction between 
AT zone and group then the interaction term was removed from the model. If the zone 
effect was significant in the model, pairwise comparisons amongst the zones were 
completed to further explore the zone effect. If there were no significant differences 
amongst the 3 zone in the AT, pairwise comparisons were not undertaken. A separate 
model was used to analyse continuous US lesion data. 
4.13.4. Analysis of gait parameters 
For all variables, data from the 3 dynamic walking trials for each participant were input to 
Microsoft Excel Version 2010. The ensemble mean (SD) values of the 3 trials were 
calculated. The predetermined gait variables were then exported into SPSS.  Muscle 
activity in the medial and lateral gastrocnemii and tibialis anterior were expressed as 
%MVIC and normalised to stance phase duration. 
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4.13.4.1. Inter-trial reliability of gait parameters 
Inter-trial reliability analysis used Intraclass Correlation Coefficients (ICC, 2,1) and 95% 
confidence intervals (CI) to quantify reproducibility of kinematic and kinetic gait variables 
and muscular activity. Reliability findings were interpreted by arbitrary benchmarks 
initially proposed by Fleiss (268). The strength of the agreement was poor if the correlation 
ranged from 0-0.40; fair to moderate if the correlation ranged from 0.40-0.75 and excellent 
if the correlation ranged from 0.75-1.00. Standard error of measurement (SEM) 
calculations assessed differences between the actual measured score across the images and 
the estimated “true” scores (269).  
 
4.13.4.2. Comparisons of means between tophaceous gout and control participants 
To compare means between gait variables, one-way ANOVA was conducted (270). 
ANOVA is considered robust against violations in normality assumptions (normal 
distribution, homogeneity of variances) (271). An adjustment to control for type I error 
such as the Bonferroni was viewed as too conservative and would have yielded very strict 
thresholds of significance. As this research is novel, the risk of introducing type II error 
with such an adjustment may have also prevented the discovery of important between-
group differences that require further exploration (272, 273).  
 
4.13.5. Bivariate linear associations 
To investigate associations between US lesions and gait parameters correlation coefficients 
were used. The Pearson’s product moment correlation coefficient was used for all variables 
that were normally distributed (274). Where data were not normally distributed the 
Spearman’s rank-order correlation coefficient was calculated (274). 
 
The Pearson’s correlation coefficient (ρ) ranges from -1 to +1. A positive association (two 
variables tend to increase or decrease simultaneously) results in ρ > 0, and negative 
association (one variable tends to increase when the other decreases) results in ρ < 0. A ρ 
value of 0 corresponds to the absence of association. The absolute value of ρ indicates the 
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strength of the relationship between the two variables, with a ρ of 1 indicating a perfect 
linear relationship (275). The Spearman’s correlation coefficient is a rank-based version of 
the Pearson’s correlation coefficient. As with the Pearson’s correlation coefficient, the 
coefficient varies from -1 to +1 with values to 0 indicative of a weaker relationship between 
the variables (275). The level of association between variables was quantified using 
guidelines in Table 4.9. 
 
Table 4.9: Guidelines for interpreting the size of a correlation coefficient (276) 
Size of correlation Interpretation 
.90 to 1.00 (-.90 to -1.00) Very high positive (negative) correlation 
.70 to .90 (-.70 to -.90) High positive (negative) correlation 
.50 to .70 (-.50 to -.70) Moderate positive (negative) correlation 
.30 to .50 (-.30 to -.50) Low positive (negative) correlation 
.00 to .30 (.00 to -.30) Negligible correlation 
 
4.13.6. Multiple regression analysis 
4.13.6.1. Forward selection stepwise regression 
In examining relationships between gait variables and US lesions, data were investigated 
using forward selection stepwise multiple regression. All model assumptions (normal 
distribution of errors, linearity and heteroscedasticity) were assessed. The assumption of 
independence of observations was fulfilled by the study design. Normality or errors was 
assessed by visual interpretation of the histogram, and distribution of the normal P-P plot, 
or the residuals. Homoscedasticity was assessed by visual examination of a plot of the 
standardized residuals (the errors) by the regression standardized predicted value. 
Homoscedasticity was assumed if the residuals were randomly scattered around the 
horizontal line of the plot (277). Additionally, collinearity was assessed through assessment 
of tolerance. Tolerance is a measure of collinearity among independent variables, where 
possible values range from 0 to 1. A value for tolerance close to zero is an indication of 
multicollinearity.  
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4.13.6.2. Model sample size 
In recognition of the potential for model over fitting the number of independent variables 
entered into the model, a general rule of thumb was used based on the recommendations of 
Hair (278). This general rule of thumb is that the ratio of independent variables should be 
approximately 5:1. The desired outcome is approximately 15-20 subjects per independent 
variable (278).  
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CHAPTER 5  
RESULTS 
5.1. Introduction 
This chapter presents the findings from the US imaging and gait analysis studies. Data from 
the 48 participants (24 tophaceous gout, 24 controls) were analysed with results presented 
in 7 subsections to represent the main areas of investigation: (1) population demographics, 
(2) clinical characteristics, (3) patient-reported outcome measures, (4) US lesion 
characteristics, (5) gait characteristics, (6) bivariate correlation analysis and (7) multiple 
regression analysis. 
5.2. Population demographics 
The demographic characteristics of the cohort are summarised in Table 5.1. The 
participants with gout and the control participants were age and sex-matched. The majority 
of the participants were middle aged males (92%) predominately of European ethnicity 
(77%). The control participants demonstrated a significantly higher number of Europeans 
(p ≤ 0.01). Participants with gout had a higher mean BMI compared to controls (p < 0.01). 
 
Table 5.1: Demographic characteristics of study population 
 
Gout  
participants 
Control 
participants 
p-value 
Age, years, mean (SD) 61.88 (12.03) 61.67 (12.29) 0.95 
Sex 
Male, n (%) 22 (92) 22 (92) 0.70 
Female, n (%) 2 (8) 2 (8)  
Ethnicity 
European, n (%) 14 (58) 23 (96) < 0.01 
Māori, n (%) 1 (4) 1 (4) 
 Pacifica, n (%) 6 (25) 0 (0) 
Asian, n (%) 3 (13) 0 (0) 
BMI, (kg/m2), mean (SD) 31.13 (4.05) 26.31 (5.10) < 0.01 
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5.3. Clinical characteristics 
The clinical characteristics are displayed in Table 5.2. Participants with gout had well-
established disease with a mean serum urate level of 0.37 mmol/L. Comorbidities that 
included hypertension, cardiovascular disease and type 2 diabetes were found in 
approximately one-third of participants with tophaceous gout. The participants with gout 
had a higher prevalence of hypertension (p < 0.01) and cardiovascular disease (p = 0.03) 
compared to the control participants. The majority of participants with gout were 
prescribed allopurinol (n = 20, 83%).   
 
Table 5.2: Clinical characteristics of study cohort 
 
Gout 
participants 
Control 
participants 
p-value 
Disease duration, years, mean (SD) 17.44 (11.88) n/a  
Age at first episode, years, mean (SD) 44.29 (18.79) n/a  
Self-reported flares in preceding 3 months, mean (SD) 1.23 (1.45) n/a  
Foot tophus count, mean (SD) 2.17 (3.33) n/a  
Total tophus count, mean (SD) 7.21 (7.35) n/a  
Serum urate, mmol/L, mean (SD) 0.37 (0.11) n/a  
Serum creatinine µmol/L, mean (SD) 105.20 (38.90) n/a  
Hypertension, n (%) 17 (71) 7 (29) < 0.01 
Cardiovascular disease, n (%) 8 (33) 2 (8) 0.03 
Type 2 diabetes, n (%) 7 (29) 2 (8) 0.07 
Diuretic, n (%) 9 (38) 9 (38) 1.00 
Colchicine, n (%) 14 (58) n/a  
Urate lowering therapy    
Allopurinol, n (%) 20 (83) n/a  
Probenecid, n (%) 6 (25) n/a  
Febuxostat, n (%) 2 (8) n/a  
Benzbromarone, n (%) 1 (4) n/a  
Other medications    
Prednisone, n (%) 6 (25) n/a  
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5.4. Patient-reported outcome measures 
HAQ-II scores indicated participants with gout had significantly greater activity limitation 
(p < 0.01). There were significant differences between participants with gout and control 
participants for the LFISIF (p < 0.01) and LFISAP (p < 0.01). High levels of impairment 
(scores ≥ 7 points on the LFISIF) and disability (scores ≥ 10 points on the LFISAP) were 
found in the participants with gout. The participants with gout had significantly reduced 
ability in performing activities of daily living (LLTQADL) and recreational activities 
(LLTQAP) associated with the lower limb compared to the control participants (p < 0.01). 
Global health, global pain and foot pain were significantly higher in the participants with 
gout, compared to the control participants (Table 5.3).  
 
Table 5.3: Results from the patient-reported outcome measures 
Patient-reported outcome measures 
Gout  
participant 
median, (IQR) 
Control 
participant 
median, (IQR) 
p-value 
HAQ-II 0.50 (0.75) 0.05 (0.20) < 0.01 
LFISIF (range 0–21) 16.00 (14.00) 1.00 (3.00) < 0.01 
LFISAP (range 0–30) 9.50 (9.00) 0.50 (1.00) < 0.01 
LLTQADL (range 0–40) 32.00 (11.00) 39.00 (2.00) < 0.01 
LLTQRA (range 0–40) 14.00 (12.00) 37.50 (12.00) < 0.01 
Global pain (per 0–100 mm VAS unit) 27.00 (53.00) 0.00 (15.00) < 0.01 
Foot pain (per 0–100 mm VAS unit) 10.00 (60.00) 0.00 (1.00) < 0.01 
Global health (per 0–100 mm VAS unit) 25.50 (38.00) 2.50 (14.00) < 0.01 
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5.5. Ultrasound lesions of the Achilles tendon  
5.5.1. Inter-observer reliability of US lesion scoring 
The inter-observer agreement analysis of the present study revealed absolute or excellent 
agreement for all US lesions, with the exception of calcaneal enthesophytes and calcaneal 
bone cortex irregularities (moderate agreement) (Table 5.4).  
Table 5.4: Inter-observer reliability in the assessment of ultrasound lesions 
US lesion ĸ values (95% CI) 
Tophus present 0.91 (0.76, 1.00) 
Focal hypoechoic areas with loss of 
fibrillar echotexture 
1.00 
Intratendinous hyperechoic spots 0.93 (0.85, 1.00) 
Intratendinous power Doppler signal 0.87 (0.82, 1.00) 
Tendon tear 1.00 
Entheseal echogenicity: focal hypoechoic 
areas 
1.00 
Entheseal echogenicity: calcifications 0.92 (0.81, 1.00) 
Entheseal vascularity 0.84 (0.55, 1.00) 
Bursal snowstorm appearance 1.00 
Bursal power Doppler signal 1.00 
Calcaneal bone cortex irregularities 0.77 (0.60, 0.94) 
Calcaneal enthesophytes 0.68 (0.48, 0.88) 
Calcaneal bone erosions 1.00 
5.5.2. Frequency of US lesions in the Achilles tendon 
5.5.2.1. Tophus burden in AT 
Tophi were present through all zones of the AT in the participants with gout, with the 
frequency similar in zone 1 and 2 of the AT (Figure 5.1). No tophi were present in the AT 
of the control participants. The frequency of tophus present (combined left and right AT) 
for the case and control participants are displayed in Table 5.5.  
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 Figure 5.1. Number of tophi present in the Achilles tendon of the gout and control 
participants in relation to zones of the Achilles tendon. 
 
In the participants with gout, tophi were present in 73% of AT examined. The overall 
burden of tophus by zone of the AT is displayed in Figure 5.2.  
 
Figure 5.2. Tophus burden in relation to total Achilles tendons examined. 
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5.5.2.2. Fibrillar echotexture 
The frequency of alteration in fibrillar echotexture are displayed in Table 5.5. Ten percent 
(5/48) of participants with gout and 4% (2/48) of control participants (Table 5.5) 
demonstrated change in fibrillar echotexture. 
5.5.2.3. Intratendinous hyperechoic spots 
The frequency of intratendinous hyperechoic spots in the left and right leg are displayed in 
Table 5.5. Intratendinous hypoechoic spots were most prevalent in participants with gout 
but also present in control participants (p < 0.01). Intratendinous hyperechoic spots were 
also most prevalent in the insertional zone of the AT both in participants with gout and 
control participants (Figure 5.3). 
 
Figure 5.3. Prevalence of intratendinous hyperechoic spots in participants with gout and 
control participants in relation to zones of the Achilles tendon. 
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5.5.2.4. Intratendinous Doppler signal 
Intratendinous Doppler signal was present in all zones of the AT in participants with gout. 
Intratendinous Doppler signal was most prevalent in participants with gout but also present 
in control participants (p < 0.01). The frequency of intratendinous Doppler signal in the 
left and right leg is displayed in Table 5.5. The presence of intratendinous Doppler signal 
in relation to the zones of the AT is displayed in Figure 5.4.  
 
Figure 5.4. Number of Achilles tendons with intratendinous Doppler signal in gout and 
control participants’ relation to zones of the Achilles tendon. 
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5.5.2.5. Entheseal lesions 
Only one AT displayed hypoechoic change in the participants with gout. There were no 
significant differences in entheseal calcifications of the AT between the participants with 
gout (n = 28, 59%) and control participants (n = 19, 40%) (p = 0.43). There was no 
significant differences in entheseal vascularity of the AT between the participants with gout 
(n = 10, 21%) and control participants (n = 7, 15%) (p = 0.65). Frequencies for entheseal 
hypoechogenicity (focal hypoechoic areas, calcifications and vascularity) in the left and 
right leg are displayed in Table 5.5.  
5.5.2.6. Bursal lesions 
A bursal snowstorm appearance was only detected in one AT in a participant with gout. 
Bursal Doppler signal of the AT was detected in (n = 7, 15%) of participants with 
tophaceous gout. Bursal snowstorm appearance and bursal Doppler signal was not found 
in any control participants. Frequencies of bursal snowstorm appearance and bursal 
Doppler signal in the left and right leg are displayed in Table 5.5.  
5.5.2.7. Bone profile 
Calcaneal bone cortex of the AT irregularities were detected in both the participants with 
gout (n = 13, 27%) and control participants (n = 9, 19%), between group differences were 
not significant (p = 0.43). No significant differences in calcaneal enthesophytes were 
detected between participants with gout (n = 33, 69%) and control participants (n = 29, 
60%), (p = 0.64). Frequencies of calcaneal bone cortex irregularities and calcaneal 
enthesophyte formation are displayed in Table 5.5.  
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Table 5.5: Frequency of ultrasound lesions present at the insertion, pre-insertion and 
proximal zone of the Achilles tendon. 
US lesion 
Zone 
of AT 
Gout 
US lesion present 
 n, (%) 
Control US 
lesion present  
n, (%) 
Left AT 
n=24 
Right AT 
n=24 
Left AT 
n=24 
Right AT 
n=24 
Tophus present 
1 14, (58) 12, (50) 0, (0) 0, (0) 
2 15, (63) 10, (42) 0, (0) 0, (0) 
3 6, (25) 8, (33) 0, (0) 0, (0) 
Focal hypoechoic areas with loss of fibrillar 
echotexture 
1 1, (4) 0, (0) 1, (4) 0, (0) 
2 0, (0) 0, (0) 0, (0) 1, (4) 
3 1, (4) 3, (13) 0, (0) 0, (0) 
Intratendinous hyperechoic spots 
1 12, (50) 10, (42) 3, (13) 4, (17) 
2 9, (38) 8, (33) 2, (8) 0, (0) 
3 4, (17) 6, (25) 0, (0) 0, (0) 
Intratendinous power Doppler signal 
1 3, (13) 9, (38) 3, (13) 1, (4) 
2 7, (29) 8, (33) 2, (8) 1, (4) 
3 4, (17) 8, (33) 2, (8) 0, (0) 
Tendon tear 
1 1, (4) 0, (0) 0, (0) 0, (0) 
2 0, (0) 0, (0) 0, (0) 0, (0) 
3 0, (0) 1, (4) 0, (0) 0, (0) 
Entheseal echogenicity: focal hypoechoic areas 1 1, (4) 0, (0) 0, (0) 0, (0) 
Entheseal echogenicity: calcifications 1 16, (67) 12, (50) 7, (29) 12, (50) 
Entheseal vascularity 1 5, (21) 5, (21) 5, (21) 2, (8) 
Bursal snowstorm appearance 1 0, (0) 1, (4) 0, (0) 0, (0) 
Bursal power Doppler signal 1 3, (13) 4, (17) 0, (0) 0, (0) 
Calcaneal bone cortex irregularities 1 7, (29) 6, (25) 4, (17) 5, (21) 
Calcaneal enthesophytes 1 15, (63) 18, (75) 13, (54) 16, (70) 
Zones; 1, insertion; 2, pre-insertion; 3, proximal to pre-insertion 
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The majority of AT were less than 5.3mm in thickness, had bursal sizes of less than 2mm 
and had no bone erosions present at the calcaneus in both participants with gout and control 
participants. Scoring frequencies for AT thickness, bursal size score and calcaneal erosions 
are presented in Table 5.6.  
 
Table 5.6: Scoring frequencies for tendon thickness, bursal size and calcaneal bone 
erosions. 
US lesion 
Score 
Gout 
US lesion present 
 n, (%) 
Control US lesion 
present  
n, (%) 
Left AT 
n=24 
Right AT 
n=24 
Left AT 
n=24 
Right AT 
n=24 
Tendon thickness score  
(0: <5.3 mm; 1: between 5.3 and 6.3; 2: > 
6.3 mm)  
0 20, (83) 19, (79) 23, (96) 24, (100) 
1 4, (17) 4 (17) 1, (4) 0, (0) 
2 0, (0) 1, (4) 0, (0) 0, (0) 
Bursal size score 
(0: <2 mm; 1: between 2–4 mm; 2: > 4 
mm) 
0 24, (100) 22, (92) 24, (100) 24, (100) 
1 0, (0) 2, (8) 0, (0) 0, (0) 
2 0, (0) 0, (0) 0, (0) 0, (0) 
Calcaneal bone erosions  
(0: no bone erosion; 1: between 0.1 and 2 
mm; 2: > 2 mm) 
0 0, (0) 1, (4) 0, (0) 1, (4) 
1 0, (0) 0, (0) 0, (0) 0, (0) 
2 0, (0) 0, (0) 0, (0) 0, (0) 
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5.5.3. Differences between US lesions 
The GEE modelling demonstrated significant differences between participants with gout 
and control participants. The presence of tophi (p < 0.01), intratendinous hyperechoic spots 
(p < 0.01) and intratendinous PD signal (p < 0.01) were more common in participants with 
gout compared to control participants (Table 5.7). No significant differences were found 
for tophus presence (p = 0.07) and intratendinous PD signal (p = 0.60) between the three 
zones of the AT.  
 
Significant differences found in intratendinous hyperechoic spots were further analysed 
using pairwise comparisons (Table 5.8). There were significantly more hyperechoic spots 
present in zone 3 of the AT compared to zone 1.  
 
The US lesions of focal hypoechoic areas with loss of fibrillar echotexture, tendon tear, 
tendon thickness score, entheseal echogenicity focal hypoechoic areas, bursal size score, 
bursal snowstorm appearance, bursal Doppler signal and calcaneal bone erosions were 
unable to be analysed by the model as insufficient data were available.  
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Table 5.7: Ultrasound lesion scores between case and control participants and mean 
ultrasound lesion scores by zone of tendon. 
US lesion 
Gout 
participants 
Mean 
Control 
participants 
Mean 
p-
value 
Mean of AT 
zone in gout 
participants 
p-value for 
between 
zone 
difference in 
gout 
Tophus 0.78 0.00 <0.01 
Zone 1 0.77 
0.07 Zone 2 0.72 
Zone 3 0.84 
Intratendinous 
hyperechoic spots 
0.95 0.67 <0.01 
Zone 1 0.75 
<0.01 Zone 2 0.85 
   Zone 3 0.93 
Intratendinous power 
Doppler signal 
0.94 0.73 <0.01 
Zone 1 0.87 
0.60 Zone 2 0.85 
Zone 3 0.88 
Entheseal echogenicity: 
calcifications 
0.27 0.19 0.43 
  
Entheseal vascularity 0.21 0.17 0.65 
Calcaneal bone cortex 
irregularities 
0.27 0.19 0.43 
Calcaneal enthesophytes  0.69 0.60 0.64 
 
Table 5.8: Pairwise comparisons for intratendinous hyperechoic spots in tophaceous 
participants with gout. 
 
Zone of 
AT 
Comparison 
zone of AT 
p-value 
1 
2 0.06 
3 <0.01 
2 
1 0.06 
3 0.16 
3 
1 <0.01 
2 0.16 
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AT length and thickness as assessed by digital measurement did not significantly differ 
between the participants with gout and control participants (Table 5.9). 
Table 5.9: Mean ultrasound lesions measurements for entheseal tendon thickness and 
tendon length. 
US lesion 
Gout 
participants 
Mean, (SD) 
Control 
participants 
Mean, (SD) 
p-value 
Tendon thickness at the insertion of the 
deeper margin into the calcaneal bone 
(mm)  
4.65 (0.81) 4.32 (0.74) 0.85 
Tendon Length (mm) 57.90 (19.83) 57.31 (15.62) 0.90 
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5.6. Gait analysis 
5.6.1. Intra-trial reliability  
5.6.1.1. Three-dimensional gait analysis 
Reliability between trial 1 and 2 for all gait variables assessed by 3D motion analysis 
are displayed in Table 5.10. 
 
Table 5.10: Intra-trial reliability indices for gait variables 
Gait variable 
Gout 
Trial 1 
Mean 
Gout 
Trial 2 
Mean 
ICC 95% 
CI 
SEM Control 
Trial 1 
Mean 
Control 
Trial 2 
Mean 
ICC 95% 
CI 
SEM 
Walking velocity 
(m/s) 
1.04 1.02 0.99 0.96, 0.99 0.02 1.23 1.22 0.94 0.86, 0.97 0.03 
Cadence 
(steps/min) 
100.50 98.90 0.99 0.97, 0.99 1.43 111.97 115.13 0.77 0.44, 0.90 3.65 
Step length (m) 0.61 0.60 0.96 0.92, 0.98 0.02 0.64 0.64 0.94 0.98, 0.97 0.01 
Stance cycle time 
(s) 
1.16 1.16 0.98 0.94, 0.99 0.02 1.06 1.07 0.95 0.88, 0.98 0.01 
Double support 
time (s)  
0.26 0.27 0.92 0.80, 0.97 0.02 0.22 0.22 0.93 0.82, 0.97 0.01 
Sagittal plane 
ankle ROM (º) 
17.83 17.27 0.92 0.86, 0.96 1.13 17.75 17.38 0.94 0.88, 0.96 0.86 
Frontal plane ankle 
ROM (º) 
10.85 10.69 0.95 0.92, 0.98 0.86 9.19 8.90 0.97 0.94, 0.98 0.83 
Peak eversion (º) -3.95 -3.97 0.97 0.94, 0.98 0.46 -3.40 -3.67 0.66 0.40, 0.82 1.83 
1MTP joint ROM 
(º) 
14.53 13.99 0.83 0.62, 0.93 2.48 21.02 18.48 0.88 0.49, 0.96 2.02 
Peak ankle force 
(N)  
281.52 277.29 0.98 0.96, 0.99 10.19 262.56 268.47 0.95 0.92, 0.97 14.09 
Peak ankle 
moment (Nm/kg)  
1.20 1.20 0.97 0.94, 0.98 0.04 1.15 1.15 0.97 0.95, 0.99 0.03 
Peak ankle power 
(W/kg) 
1.89 1.85 0.96 0.93, 0.98 0.14 2.20 2.15 0.93 0.87, 0.96 0.14 
Peak angular 
velocity (deg/s)  
-208.33 -210.52 0.96 0.94, 0.98 -10.47 -252.34 -255.58 0.92 0.87, 0.96 -12.56 
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5.6.1.2. Muscle activity 
Reliability between trial 1 and 2 for muscle activity during the stance phase of gait are 
presented in Table 5.11.  
 
Table 5.11: Intra-trial reliability indices for muscle activity. 
Muscle 
Gout 
Trial 1 
Mean  
Gout 
Trial 2 
Mean 
ICC SEM 
Control 
Trial 1 
Mean  
Control 
Trial 2 
Mean 
ICC SEM 
Lateral gastrocnemius (%MVIC)  18.49 21.50 0.98 3.96 6.44 6.21 0.97 1.04 
Medial gastrocnemius (%MVIC)  20.63 21.71 0.95 2.46 16.73 16.66 0.96 1.60 
Tibialis anterior (%MVIC)  9.08 9.13 0.78 2.81 8.68 7.39 0.64 1.80 
ICC, intraclass correlation coefficient; SEM, standard error of measurement  
5.6.2. Spatiotemporal gait parameters 
Differences in spatiotemporal parameters between participants with tophaceous gout and 
controls are displayed in Table 5.12. Results showed that participant with gout had 
reduced walking velocity (F1,94 = 36.72, p < 0.01), reduced cadence (F1,88 = 25.16, p < 
0.01), reduced step length (F1,85 = 8.04, p < 0.01), increased double support time (F1,88 = 
17.99, p < 0.01) and increased stance cycle time (F1,94 = 28.79, p < 0.01) when compared 
to controls. 
Table 5.12: Descriptive statistics for spatiotemporal gait variables 
Gait variable Gout 
participants 
Mean, (SD) 
Control 
participants 
Mean, (SD) 
Mean difference  
(95% CI) 
p-value 
Walking velocity (m/s) 1.02 (0.19) 1.23 (0.13) -0.20 (-0.27, -0.14) < 0.01 
Cadence (steps/min) 104.99 (9.07) 113.55 (7.05) -8.57 (-11.96, -5.17) < 0.01 
Step length (m) 0.61 (0.07) 0.65 (0.16) -0.04 (-0.06, -0.01) < 0.01 
Double support time (s)  0.27 (0.62) 0.22 (0.38) 0.05 (0.02, 0.07) < 0.01 
Stance cycle time (s)  1.16 (0.10) 1.06 (0.70) 0.09 (0.06, 0.13) < 0.01 
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5.6.3. Kinematic gait parameters 
Descriptive statistics for between-group kinematic gait analyses are displayed in Table 
5.13. Sagittal plane ankle range of motion (F1,94 = 0.63, p = 0.43), frontal plane ankle 
range of motion, (F1,90 = 3.24, p = 0.08) and peak eversion (F1,90 = 2.51, p = 0.12) were 
not significantly different between participants with gout and control participants. 1MTP 
joint ROM (F1,90 = 14.98, p < 0.01) and peak angular velocity at the ankle joint (F1,94 = 
20.55, p < 0.01) were significantly reduced in participants with gout compared to control 
participants.  
 
Table 5.13: Descriptive statistics for kinematic gait variables. 
Gait variable Gout 
participants 
Mean (SD) 
Control 
participants 
Mean (SD) 
Mean difference  
(95% CI) 
p-value 
Sagittal plane ankle ROM (º) 18.02 (3.53) 17.48 (3.10) 0.54 (-0.81, 1.88) 0.43 
Frontal plane ankle ROM (º) 10.38 (3.18) 9.08 (3.72) 1.30 (-0.13, 2.73) 0.08 
Peak eversion (º) -3.85 (2.60) -2.99 (2.66) -0.86 (-1.93, 0.22) 0.12 
Sagittal plane 1MTP joint ROM (º) 14.88 (5.26) 19.55 (6.26) -4.66 (-7.05, -2.26) < 0.01 
Peak angular velocity (º/s)  -210.09 (53.01) -254.49 (42.37) 44.40 (24.95, 63.85) < 0.01 
By convention eversion and angular velocity are expressed as negative values 
5.6.4. Kinetic gait parameters 
Descriptive statistics for kinetic gait parameters are displayed in Table 5.14. The analysis 
revealed participants with gout had reduced ankle power (F1,94 = 6.49, p = 0.01) when 
compared to control participants. There were no significant differences between 
participants with gout and control participants in peak ankle force (F1,94 = 1.37, p = 0.25), 
peak ankle moment (F1,94 = 1.97, p = 0.16), the timing of peak ankle force (F1,91 = 0.06, p 
= 0.81), peak ankle moment (F1,94 = 1.97, p = 0.16), the timing of peak power generation 
in the stance phase (F1,94 = 0.55, p = 0.46), or ankle plantarflexor concentric work (F1,94 
= 2.91, p = 0.09).  
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Table 5.14: Descriptive statistics for kinetic gait variables 
Gait variable Gout 
participants 
Mean, (SD) 
Control 
participants 
Mean, (SD) 
Mean difference  
(95% CI) 
p-value 
Peak ankle joint force (N)  279.33 (70.08) 263.74 (59.93) 15.59 (-10.84, 42.01) 0.25 
Peak ankle joint force  
(% of stance phase)  
80.00 (5.13) 79.29 (7.12) 0.31 (2.26, 2.88) 0.81 
Peak ankle plantarflexor moment 
(Nm/kg)  
1.21 (0.21) 1.15 (0.19) 0.06 (-0.02, 0.14) 0.16 
Peak ankle plantarflexor moment  
(% of stance phase)  
78.54 (1.87) 78.04 (1.61) 0.50 (0.21, 1.21) 0.16 
Peak ankle joint power (W/kg) 1.86 (0.68) 2.17 (0.49) -0.31 (-0.55, -0.07) 0.01 
Peak ankle joint power 
 (% of stance phase) 
88.69 (13.17) 90.10 (1.18) -1.4 (-5.21, 2.37) 0.46 
Ankle plantarflexor concentric 
work (J/kg)  
0.16 (0.06) 0.17 (0.04) -0.02 (-0.04, 0.00) 0.09 
 
5.6.5. Muscle activity 
The results indicated that the cases had significantly more muscle activity in the medial 
(F1,110 = 5.27, p = 0.02) and lateral (F1,107 = 27.06,  p < 0.01) gastrocnemius during the 
stance phase of gait.  No significant difference was found with regard to tibialis anterior 
muscle activity (F1,104 = 3.51, p = 0.06) (Table 5.15).  When normalised to stance phase 
duration, mean muscle activity was lower in all 3 muscle groups.  Cases had significantly 
increased muscle activity in the medial (F1,110 = 1.14, p = 0.04) and lateral (F1,107 = 7.61, 
p < 0.01) gastrocnemius.  No significant difference was found with regard to tibialis 
anterior muscle activity (F1,104 = 0.01, p = 0.20) (Table 5.16).  
 
Table 5.15: Descriptive statistics for muscle activity 
Muscle Gout 
participants 
Mean, (SD) 
Control 
participants 
Mean, (SD) 
Mean 
difference  
(95% CI) 
p-value 
Lateral gastrocnemius activity 
(%MVIC)  
19.48 (9.44) 11.36 (5.94) 8.01 (5.24, 11.21) < 0.01 
Medial gastrocnemius activity 
(%MVIC)  
20.80 (7.76) 17.48 (7.40) 3.30 (0.45, 6.17) 0.02 
Tibialis anterior activity 
(%MVIC)  
9.04 (4.59) 7.44 (4.05) 1.59 (0.08, 3.25) 0.64 
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Table 5.16: Descriptive statistics for muscle activity normalised to stance phase time  
Muscle Gout 
participants 
Mean, (SD) 
Control 
participants 
Mean, (SD) 
Mean 
difference  
(95% CI) 
p-value 
Lateral gastrocnemius activity 
(%MVIC/s)  
16.87 (8.26) 10.71 (5.63) 6.16 (3.39, 8.92) < 0.01 
Medial gastrocnemius activity 
(%MVIC/s)  
18.91 (7.38) 16.20 (6.28) 2.70 (0.01, 5.33) 0.04 
Tibialis anterior activity 
(%MVIC/s)  
7.97 (4.30) 6.95 (3.66) 1.02 (0.5, 2.5) 0.19 
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 5.7. Bivariate correlations in participants with tophaceous gout 
All significant correlations between gait variables and ultrasound lesions are presented in 
Tables 5.17, 5.18 and 5.19. All non-significant correlations are presented in Appendix 8. 
 
5.7.1. Walking velocity 
All significant bivariate correlations between walking velocity, gait variables and US 
lesions in people with tophaceous gout are presented in Table 5.17. 
Table 5.17: Significant bivariate correlations for walking velocity with gait variables 
and US lesions. 
 r p-value 
Double support time -0.81 < 0.01 
Step length 0.81 < 0.01 
Cadence 0.71 < 0.01 
Ankle power 0.66 < 0.01 
Concentric ankle plantarflexor work 0.61 < 0.01 
Stance cycle time -0.59 < 0.01 
Hallux ROM -0.43 < 0.01 
Peak rearfoot eversion -0.42 < 0.01 
Ankle angular velocity 0.40 < 0.01 
Tibialis anterior muscle activity -0.39 < 0.01 
Intratendinous Doppler signal (pre-insertion) 0.34 0.02 
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5.7.2. Ankle power 
All significant bivariate correlations between ankle power, gait variables and US lesions 
are presented in Table 5.18.   
Table 5.18: Significant bivariate correlations for ankle power with gait variables and 
US lesions 
 r p-value 
Concentric ankle plantarflexor work 0.83 < 0.01 
Walking velocity 0.66 < 0.01 
Ankle angular velocity 0.67 < 0.01 
Peak ankle moment 0.65 < 0.01 
Peak ankle force 0.48 < 0.01 
Cadence 0.47 < 0.01 
Stance cycle time -0.47 < 0.01 
Double support time -0.40 < 0.01 
Step length 0.38    0.01 
Lateral gastrocnemius muscle activity  -0.38 < 0.01 
Medial gastrocnemius muscle activity -0.31    0.03 
AT thickness  -0.39 < 0.01 
5.7.3. Ankle range of motion (sagittal plane) 
All significant bivariate correlations between ankle range of motion in the sagittal and 
frontal plane, gait variables and US lesions are presented in Table 5.19. No significant 
correlations were found between ankle range of motion in the sagittal and frontal plane 
and US lesions. 
Table 5.19: Significant bivariate correlations for sagittal plane ankle range of motion 
and gait variables. 
 
 r p-value 
Peak ankle moment  0.37 0.01 
Peak ankle force  0.30 0.01 
Peak rearfoot eversion  0.41 0.01 
Peak ankle moment -0.40 0.01 
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5.8. Multiple linear regressions  
5.8.1. Walking velocity in participants with tophaceous gout 
Multiple linear regression analysis was used to develop a model for predicting walking 
velocity from the variables identified above as having a significant univariate association 
with walking velocity. The variables identified as independently associated with walking 
velocity from this analysis were entered into a multivariate regression model. These 
included: step length, cadence, ankle power and double support time (p < 0.01). The four 
predictor model was able to account for 97% of the variance in walking velocity, R2 = 
.97, F(4,37) = 265.21, p < 0.01. A summary of the forward selection stepwise regression 
model is presented in Table 5.20 and the regression coefficients are presented in Table 
5.21. 
Table 5.20: Walking velocity model summary 
Model R R2 R2adj ∆R2  Fchg p-value df1 df2 
1. Step length .81 .65 .64 .65 73.77 < 0.01 1 40 
2. Cadence .98 .95 .95 .30 240.97 < 0.01 1 39 
3. Peak ankle power .98 .96 .96 .01 8.91 < 0.01 1 38 
4. Double support time .98 .97 .96 .01 6.56 < 0.01 1 37 
 
Table 5.21: Coefficients for final walking velocity model 
Model B β t 
 Step length 1.43 .61 15.94* 
 Cadence .01 .39 6.60* 
 Peak ankle power .03 .13 3.54* 
 Double support time -.42 -.16 -2.56** 
*p < 0.01; **p < 0.05 
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5.8.2. Ankle power in participants with tophaceous gout 
Multiple linear regression analysis was used to develop a model for predicting ankle 
power from the variables identified above as having a significant univariate associations 
with ankle power. The variables identified as independently associated with ankle power 
from this analysis were entered into a multivariate regression model. These included: peak 
angular velocity, peak ankle moment and walking velocity (p < 0.01). The three predictor 
model was able to account for 83% of the variance in ankle power, R2 = .83, F(3,44) = 
69.52, p < 0.01. A summary of the forward selection stepwise regression model is 
presented in Table 5.22 and the regression coefficients are presented in Table 5.23. 
 
Table 5.22: Ankle power model summary 
Model R R2 R2adj ∆R2 Fchg p-value df1 df2 
1. Peak angular velocity .67 .45 .41 .48 37.23 < 0.01 1 46 
2. Peak ankle moment .83 .69 .68 .23 35.39 < 0.01 1 45 
3. Walking velocity .91 .83 .81 .14 34.13 < 0.01 1 44 
 
Table 5.23: Coefficients for final ankle power model 
Model B β t 
 Peak angular velocity -.01 -.39 -5.49* 
 Peak ankle moment 1.53 .46 6.99* 
 Walking velocity 1.42 .41 5.84* 
*p < 0.01 
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5.8.3. Ankle range of motion sagittal plane in participants with tophaceous gout 
Multiple linear regression analysis was used to develop a model for predicting sagittal 
plane ankle ROM from the variables identified above as having a significant univariate 
association with sagittal plane ankle ROM. The variables identified as independently 
associated with ankle ROM from this analysis were entered into a multivariate regression 
mode. These included: peak angular velocity, double support time and walking velocity 
(p < 0.01). The three predictor model was able to account for 30% of the variance in ankle 
ROM, R2 = .30, F(3,82) = 8.18, p < 0.01. A summary of the forward selection stepwise 
regression model is presented in Table 5.24 and the regression coefficients are presented 
in Table 5.25. 
Table 5.24: Sagittal plane ankle range of motion model summary 
Model R R2 R2adj ∆R2 Fchg p-value df1 df2 
1. Peak angular velocity .40 .16 .15 .16 16.24 < 0.01 1 84 
2. Double support time .50 .25 .23 .08 9.29 < 0.01 1 83 
3. Walking velocity .55 .30 .28 .06 6.74 = 0.01 1 82 
 
 
Table 5.25: Coefficients for final ankle range of motion model 
Model B β t 
 Peak angular velocity -.03 -.36 -3.44* 
 Double support time 34.15 .64 3.94* 
 Walking velocity 8.21 .45 2.60* 
*p < 0.01 
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CHAPTER 6 
Discussion 
6.1. Introduction 
The chapter will commence with a discussion of the demographic and clinical 
characteristics and the patient-reported outcome measures. The chapter will then explore 
the structure of the AT through analysis of the US lesions. Gait function will then be 
discussed with regard to walking velocity, ankle power and ankle range of motion. 
Finally, strengths and limitations will be addressed. 
 
6.2. Demographics and clinical characteristics 
Ninety two percent of participants with tophaceous gout were male (11:1 ratio). This is 
higher than the reported prevalence rates of (4:1) for males under the age of 65 years old 
(279). Of the 24 participants with gout 25% were Pasifika and 4% of Māori decent. With 
regard to the most recent gout prevalence estimates in Pasifika and Māori (Table 1.2) the 
case population was slightly over-representative of the Pasifika and under-representative 
of the Māori population (36). However, this is explained by the gout prevalence rates 
provided by Winnard (36) not being specific to tophaceous gout and representative of 
gout as a single entity not subdivided by disease stage.  
 
The burden of gout is elevated among overweight and obese adults (280). In the current 
study participants with gout were considered obese as defined by World Health 
Organisation (WHO) guidelines (BMI ≥ 30 kg/m2) with a mean (SD) BMI of 31.1 (4.1) 
kg/m2 (281). This was significantly higher than the control participants, yet with a mean 
(SD) BMI of 26.3 (5.1) kg/m2, the control participants were classified as overweight (BMI 
≥ 25 kg/m2 ) (281). The results are in concordance with Rome (18), where the participants 
with gout and control participants were also defined as obese with a mean (SD) BMI of 
32.1 (5.6) kg/m2 and 30.3 (6.4) kg/m2 respectively. The findings of high BMI in the 
participants with gout is congruent with previous research reporting a dose-response  
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relationship between BMI and prevalent gout, with prevalence rates of gout twice that of 
non-obese persons (280, 282). 
 
The prevalence of comorbid obesity related metabolic conditions is high in people with 
gout (283, 284). Results of the current study showed a significant number (29%) of 
participants with gout were diagnosed with Type 2 diabetes. This finding is in agreement 
with previous research indicating the incidence for diabetes mellitus of 25% in those with 
gout (285). The study findings of cardiovascular disease (8%) and hypertension (71%) 
are similar to previous studies (283, 286).  
 
Hypertension and diabetes are associated with gout and likely contribute to 
hyperuricaemia (287). Control of hyperuricaemia is crucial in people with gout as 
persistently elevated levels lead to the development of long-term disability and reduced 
health-related quality of life (31, 288). We found in the participants with gout the serum 
urate levels were well controlled.  Serum creatinine levels (marker of renal function) was 
within normative bands (68). With regard to control of hyperuricaemia, 83% of people 
were prescribed Allopurinol (xanthine oxidase inhibitor) and 58% prescribed colchicine. 
Although 38% of people with tophaceous gout were prescribed a diuretic, research has 
demonstrated an increase of serum urate level due to diuretics, this being most often 
attributed to thiazide diuretics (44, 289). However, the current study did not capture the 
class of diuretic the participants with gout were prescribed. 
 
6.3. Patient-reported outcome measures 
The burden of illness in gout has a substantial negative health and economic impact (290). 
Health-related quality of life is greatly reduced in people with gout, due to pain, activity 
limitation, disability and life quality (2, 291). Participants with gout had reduced overall 
functional ability and reduced functional ability pertaining to the lower extremity with 
reference to the performance of activities of daily living and recreational activities. Foot-
related impairment and disability were also significantly higher in participants with gout. 
The degree of foot-related impairment and disability is similar to that observed in 
previous tophaceous gout research (18, 292). Participants with gout also experienced 
greater levels of foot pain, greater general pain and perceived their overall level of well-
being as poorer when compared to control participants. 
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In the current study functional ability as assessed by the HAQ-II was significantly reduced 
in participants with gout compared to the control participants. The results are in 
agreement with Singh (293), who reported poorer functional ability in people with gout. 
The findings also parallel those of Rome (18) in a cohort of participants with gout. In 
addition to the generic measure of functional ability provided by the HAQ-II, the current 
study used the LLTQ to specifically assess functional ability in the lower extremity. 
People with tophaceous gout had reduced ability to perform recreational activities related 
to the lower limb compared to healthy controls. The ability to perform activities of daily 
living related to the lower limb were also significantly reduced in participants with gout 
compared to healthy controls. Although ability to perform activities of daily living were 
significantly reduced, participants with gout were able to perform activities of daily living 
with less difficulty than their reported ability to perform recreational activities. As shown 
by the LFISIF tophaceous gout has an impact on the foot in terms of footwear, impairments 
and activity limitation/participation. The LFISIF subscale was significantly higher in 
participants with gout and indicative high levels of foot pain, impairment and footwear 
problems.  
 
In agreement with Rome (18), results of the current study showed foot pain and global 
pain were significantly higher in participants with gout. Although participants with gout 
had decreased functional ability, decreased function in the lower limb and increased 
impairment and disability related to the foot in participants with gout, it is unclear how 
these factors contribute to the process of gait adaptation and, conversely, how adapted 
gait may influence pain, impairment and disability. Singh (293) demonstrated that a 
greater proportion of people with gout reported limitations in walking and noted that 
limitations in activities of daily living were attributable to differences in age, socio-
demographics and comorbidities, implying that variables other than gout conferred 
difficulty in walking.  
 
6.4. Ultrasound lesions of the Achilles tendon 
The current study showed that participants with gout had a higher prevalence of US 
lesions in the AT. Subsequently, hypothesis 1 was accepted that participants with gout 
have a higher prevalence of US lesions in the AT compared to control participants. 
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Intratendinous power Doppler signal, and bursal power Doppler signal and intratendinous 
hyperechoic spots, occurred more frequently in participants with gout.  
 
No previous US imaging research has quantified tophus deposition specific to anatomical 
zones in the AT. The current study showed that tophi were present in 73% of participants 
with gout. The prevalence of tophi were higher than reported in previous imaging studies 
and support previous findings that the AT is a site commonly affected by tophus 
deposition (17, 244, 294). Using US imaging, Naredo (244) reported 34% of AT 
examined had tophus deposition. Using DECT imaging Dalbeth (17) reported 39% of 
participants displayed MSU crystal deposition within the AT. Choi (294) also using 
DECT reported tophus deposition to the AT, however, the number of tophi in the AT 
were not described. Despite the results showing tophus prevalence was significantly 
different between the case and control participants, 27% of AT imaged in the case 
participants displayed no tophus deposition.  
 
Consistent with previous research, the current results demonstrated the enthesis and body 
of the AT (zone 1 and zone 2) were prevalent sites of tophus deposition (17). In addition, 
it was found tophi were present in the proximal section of the AT (zone 3). Previous 
research has only reported tophus deposition at the insertional zone and areas 5cm 
proximal to the calcaneal insertion of the AT (17). Dalbeth (17) reported 38% of AT’s 
examined had only non-entheseal involvement, 40% had both entheseal and non-
entheseal involvement and 22% had only entheseal involvement. Uri (295) reported in 
tophaceous gout, a large proportion of the total body MSU crystal burden is found intra-
articularly, but tophi can be found in any extra-articular location, preferentially in areas 
of repetitive mechanical stress or pressure.  
 
Three US lesions were statistically more prevalent in people with tophaceous gout 
compared to controls; tophus deposition, intratendinous hyperechoic spots and 
intratendinous power Doppler signal. Whilst the current findings support hypothesis 2, 
that participants with gout will have a higher prevalence of US lesions in the AT 
compared to control participants, no other US lesions were significantly different between 
the case and control participants. 
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Avascularity of connective tissues has been proposed as a predisposing factor for urate 
deposition (296). It is established that a zone of avascularity and maximum fibre rotation 
exists in the AT 2-6 cm proximal to the calcaneal insertion (297, 298). The results of the 
current study demonstrated that tophus prevalence was similar in Zone 2 (avascular zone) 
to Zone 1. This suggests that tophus deposition is not preferential to the avascular zone 
of the AT. 
 
The current study found no significant difference in the presence of focal hypoechoic 
areas with loss of fibrillar echotexture between case and control participants. Only five 
hypoechoic lesions recorded in participants with gout and two in control participants. The 
findings indicate that there was minimal disruption of collagen fibrillar echotexture in the 
AT, reflective of minimal intratendinous structural damage. The results are in contrast to 
previous research that has suggested tophus presence in tendons produces focal alteration 
to fibrillar structure (299). The results also differ from the findings of Grassi (35) who, in 
60 participants with crystal related arthropathies using US imaging, reported the normal 
fibrillar echotexture of tendons can be completely deranged by the presence of intra-
tendinous tophus deposits.  
 
Intratendinous hyperechoic spots were present in all zones of the AT in the participants 
with gout. The hyperechoic spots in the participants with gout may be representative of 
either intratendinous aggregate formation (83) forming in a linear fashion parallel to the 
collagen fibril or have represented calcified tophi. de Ávila Fernandes (129) reported 
calcified tophi in tophaceous gout but found no significant differences between groups of 
participants in relation to illness duration and the number of calcifications, concluding 
that calcified tophi were not necessarily older than non-calcified tophi.  
 
With MSU deposition not present in the control participants the intratendinous 
hyperechoic spots may have reflected a general calcific tendinopathy or may suggest that 
some of our control participants actually had MSU crystal deposits or asymptomatic gout. 
In non-rheumatological populations intratendinous calcifications, termed ‘calcific 
tendinopathy’ by Oliva (300) have been viewed as a sonographic sign of tendinopathy.  
 
Consideration must also be given that the hyperechoic spots observed in the participants 
with gout may be representative of a general calcific tendinopathy. With the single 
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mineral component of calcific deposits identified as calcium carbonate and the structural 
and cellular components of tophi identified, histological analysis of intratendinous 
calcification would be required to clarify the specific components of intratendinous 
calcifications and allow differentiation between calcified tophi and calcific tendinopathy 
in people with tophaceous gout (301). Previous research has postulated calcifications may 
be increased in tophaceous gout due to increased aberrations in calcium metabolism, 
related in part to chronic renal disease (129). However, Fernandes (129) found no 
statistical relationship between the presence of calcification in tophi and chronic renal 
failure in people with chronic tophaceous gout.  
 
Vascularisation of the fibrovascular matrix surrounding tophi as evidenced by positive 
Doppler signal is a common finding in tophaceous gout and is regarded as an indicator of 
inflammatory activity (130, 302). Previous research has shown that persistent low-level 
inflammation is present in asymptomatic chronic tophaceous gout, with Doppler signal 
present in and around tophaceous deposits in more than half of participants with 
asymptomatic chronic gouty arthritis (303). In support of these findings the results of the 
current study showed that participants with gout displayed significantly increased levels 
of power Doppler signal in the AT compared to controls (Figure 5.5).  
 
Although the prevalence of tophus and vascularisation were similar in all zones of the 
AT, due to limitations of the scoring system used vascularisation cannot be solely 
attributed to the presence of tophus. Particularly as data indicated 52% of AT imaged had 
no evidence of intratendinous vascularisation by zone of AT. This may reflect that not all 
AT in those with tophaceous gout demonstrate inflammatory activity.  Previous research 
based on analysis of synovial fluid has also reported that participants with chronic gout 
are frequently found without any signs of inflammation (304). This finding also supports 
the notion proposed by Chhana (305) that tendon involvement in gout may be an indolent 
process, suggesting that a containment of inflammation may occur. Recent research has 
reported that neutrophils recruited to sites of inflammation undergo oxidative burst and 
form neutrophil extracellular traps (NETs) (306). This finding indicates a possible 
shutdown mechanism of aggregated NET-mediated inflammation in gout. NET formation 
itself can also trigger a process of regulated cell death referred to as NETosis (307). 
NETosis provides another mechanism of efficient shutdown and removal of neutrophils 
thereby supporting inflammatory resolution. Tophi share characteristics with aggregated 
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NETs, and MSU crystals can induce NETosis and aggregation of NETs (308). The 
research also identified that, in people with impaired NETosis, MSU crystals induce 
uncontrolled production of inflammatory mediators from neutrophils and persistent 
inflammation (306). 
 
No previous studies have measured entheseal AT thickness in people with gout. The 
results indicate that entheseal thickening was not a significant US lesion, with no 
significant differences being found in AT entheseal thickness in participants with gout 
compared to control participants. The mean values of AT thickness in both the case and 
control participants were also not considered indicative of pathological thickening when 
referenced to the cut-off values proposed by Balint stemming from a study in SpA (150). 
The thesis is the first to quantify AT entheseal thickness in tophaceous gout, however AT 
thickness was not measured proximally to the enthesis. As discussed in Chapter 2 
quantifying thickness proximal to the enthesis is now considered an important comparator 
as the recent OMERACT definition of entheseal tendon thickness references the body of 
the tendon as a point of comparison (153). There are currently no defined normative bands 
to enable categorisation of tendon thickness in gout, both at the enthesis or in the mid-
portion of the AT. 
 
In the current study, evidence of tendon tear was only seen in 2 of the 48 ATs imaged in 
participants with gout. This result coupled with the finding of no significant alteration to 
fibrillar echotexture provides further evidence that the AT was not structurally altered in 
participants with gout. Previous single case reports have proposed a link between tophus 
deposition and AT rupture (85, 86). Whilst our results may be seen to contrast this link, 
based on minimal structural derangement, the results of the current study only 
demonstrated minimal structural alteration to the AT. The results provide no evidence or 
insight surrounding the mechanical properties (elasticity, stretch and strain) of the AT.  
 
Results showed no significant differences in entheseal vascularity or entheseal 
calcifications between the case and control participants. The results are suggestive that 
the enthesis is not preferentially targeted by the disease process in tophaceous gout as 
opposed to SpA (179). Doppler signal was observed in the enthesis and may be associated 
with MSU crystal deposition. Histological samples from participants with chronic gout 
have shown MSU crystals to be present in the enthesis (305). Entheseal inflammation has 
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also been linked to obesity and associated with systemic inflammation and high levels of 
proinflammatory cytokines (309). Research has also postulated that inflammation is a 
mediator mechanism for the increased entheseal abnormalities in obese individuals (310). 
However, research specific to gout has demonstrated that, whilst obesity elevates the 
inflammatory background in naive, non-adipose macrophages, obesity does not 
exacerbate inflammatory responses to MSU crystals (311). Entheseal vascularisation was 
also reported in the control participants. Although the healthy enthesis is generally 
considered an avascular point of attachment the results of the current study are consistent 
with previous research that has reported evidence of vascularisation through power 
Doppler assessment in healthy elderly populations (312-314).  
 
Data indicated that bursal morphology was not significantly affected by the tophus 
deposition. Bursal Doppler signal was positive in only 7 AT of the participants with gout. 
Although this is suggestive of a degree of inflammation the lesion is frequently found in 
other types of inflammatory arthritis (126, 141). Previous research has described floating 
hyperechoic foci, likely to be representative of micro-tophi, resulting in “snow storm 
appearance” (35, 141). The snow storm appearance was only observed in the 
retrocalcaneal bursae of one AT participant with gout. Delle Sedie (315) has suggested 
this lesion is not specific to gout.  
 
Only one AT in both the case and control participants displayed erosive change to the 
calcaneal enthesis. The finding of minimal erosive damage is suggestive that the calcaneal 
enthesis is not a common site of bone erosion in tophaceous gout. This finding is 
supported further by research that has demonstrated that bone erosions in tophaceous gout 
are predominately an intrarticular lesion (316). Tophus location in relation to bone also 
appears to be an important factor in formation of bone erosions, with tophi adjacent to 
bone likely to be in direct contact with bone cells (317). While tophus burden was 
recorded the in the distal 2 cm of the AT (calcaneal enthesis), the location and number of 
tophi that were in close vicinity to, or direct contact with the enthesis, were not recorded.  
 
As highlighted in Chapter 2 there was variation in the definitions associated with US 
lesions. It is possible that the presence of erosions at the calcaneal enthesis may have also 
been under-reported. The current definition applied to define erosion was based on the 
OMERACT recommendation stemming from work in RA (152). The definition of RA 
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erosions is less applicable to gout, because in RA it is specified that an erosion is an intra-
articular lesion, whereas gouty erosions may occur in extra-articular sites (318).  
 
The study found no difference between the cases and controls for calcaneal enthesophyte 
formation. The presence of calcaneal enthesophytes in control populations has also been 
demonstrated by previous research in inflammatory arthritis (166, 168). Enthesophytes 
are commonly found in healthy individuals and are, therefore, not necessarily an 
indication of disease. Previous studies have been attributed to secondary 
degenerative/mechanical factors rather than inflammatory mediated factors (319, 320).  
 
Formation of enthesophytes has been attributed to either a mechanical, degenerative, 
traumatic or metabolic origin (321). Benjamin (321) postulated that enthesophytes form 
resultant from an adaptive mechanism to ensure the integrity of the interface between the 
AT and calcaneus in response to increased mechanical loads. The results of similar 
prevalence rates compared to healthy controls, combined with the current findings 
indicating tendon degeneration, was not prevalent at the enthesis (no alteration to 
echogenicity, no entheseal tendon thickening) are suggestive that calcaneal enthesophyte 
formation in people with tophaceous gout may also be an adaptive response to increased 
mechanical load.  
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6.5. Gait analysis 
6.5.1. Spatiotemporal parameters 
The current study showed that walking velocity was significantly reduced in people with 
tophaceous gout compared with healthy controls. The results agree with hypothesis 3 that 
walking velocity is significantly reduced in participants with tophaceous gout compared 
to control participants. Based on evidence that decreased walking velocity is reflective of 
reduced functional ability (322), and as evidenced by Chapter 3 which noted walking 
velocity to be decreased across various forms of inflammatory arthritis, and the most 
frequently assessed gait parameter, the current thesis considers walking velocity to be the 
most significant gait parameter to quantify in the description of altered gait strategy.  
 
The results of decreased walking velocity and significant differences in the velocity- 
dependent parameters of cadence, step length and double limb support time compared to 
the control participants are in agreement with the previous research of Rome (18) in 
tophaceous gout. Table 6.1 shows the walking velocity values from the current study, 
compared to previous research into tophaceous gout. Interestingly, the mean walking 
velocity values in people with tophaceous gout in the current study were higher than both 
the studies by Rome (18) and Stewart (292). Across the three studies the age, sex, BMI, 
ethnicity, disease duration, comorbidities and patient-reported outcome measures were 
comparable. 
 
Table 6.1: Comparative baseline walking velocity values between the current study and 
previous studies in tophaceous gout. 
Study 
Case 
walking velocity (m/s) 
Mean (SD) 
Control  
walking velocity (m/s) 
Mean (SD) 
Current study* 1.02 (0.19) 1.23 (0.13) 
Rome (18)* 0.90 (0.30) 1.10 (0.30) 
Stewart (292)** 0.85 (NR) N/A 
*, walking velocity acquired barefooted; **, walking velocity acquired shod; NR, not reported; N/A, not 
applicable 
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The walking velocity of the control participants in the current study is closely aligned to 
the ranges reported for the control populations by previous research and also within 
proposed normative ranges of 1.2-1.4 m/s-1 (323). Variation in walking velocity between 
the current study and other forms of inflammatory arthritis may be attributable to the 
population characteristics. These include disease type, disease status (early vs 
established), population size, age and sex. The differing methods of acquiring walking 
velocity must also be considered. As demonstrated in Chapter 3, there is no one 
universally agreed method of quantifying walking velocity. In participants with 
tophaceous gout, both Rome (18) and Stewart (292) acquired gait velocity using an 
instrumented walkway as opposed to 3D gait analysis used in the current study.  
Acquisition of walking velocity also varied across differing forms of inflammatory 
arthritis. However, no previous research has accessed how comparable or reliable 
spatiotemporal gait parameters are that are collected by instrumented walkways compared 
to 3D gait analysis. Other acquisition factors including the distance walked and 
instructions surrounding walking pace must also be considered for their impact upon 
variation of walking velocity. 
 
Foot pain is considered the most influential factor leading to a reduced walking velocity 
in inflammatory arthritis (182, 186). In tophaceous gout a pain-avoidance strategy has 
been attributed as the driver of gait adaptation (18). Pain is driven by articular and 
periarticular effects of tophus deposition creating structural and functional alterations in 
the foot, necessitating the development of a pain avoidance strategy. This strategy 
ultimately has been demonstrated to culminate in a decreased walking velocity, and 
subsequent alterations to associated velocity-related spatiotemporal parameters, i.e. 
reduced cadence, increased double limb support time and decreased step length (18).  
 
The understanding of foot pain in relation to gait adaptation is not as advanced in 
tophaceous gout when compared other inflammatory arthritic conditions, particularly RA. 
This is attributable to the minimal study of gait analysis and foot and ankle function in 
tophaceous gout. There is also less understanding of the role foot deformity plays in the 
process of gait adaptation. No previous research has explicitly defined the characteristics 
of the foot in people with tophaceous gout. In the current study measures of self-reported 
pain were not specific to anatomical regions of the foot. Therefore, the thesis cannot 
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equivocally state whether pain in the foot is derived from the 1MTP joint, the forefoot as 
a whole, the rearfoot, or a combination of all regions.  
 
Although gait adaptation in RA is well described and related to alterations in foot function 
and pain avoidance, it is arguable that, in inflammatory arthritic conditions, particularly 
RA, the explanations to describe gait adaptation have been very focused on associations 
to foot function. Numerous foot models have been used to quantify kinematic and kinetic 
function inflammatory arthritis (as described in Chapter 3). Subsequent to this, the 
understanding of the role foot function plays in gait adaptation has increased. However, 
these explanations for adaptive change have become very narrow and solely focused on 
the foot, with little consideration for the role of the upper limbs, pelvis and trunk.  
 
The pain-avoidance strategy proposed by Rome (18) in gout provides no consideration 
for how the upper limb and trunk may contribute to an adaptive gait strategy. The pain 
avoidance strategy fails to take account of comorbidities (obesity, diabetes and 
cardiovascular disease) associated with tophaceous gout, and how these comorbidities 
may interplay to contribute to gait adaptation. However, the current thesis acknowledges 
that a pain avoidance strategy may partially explain gait adaptations.  
 
The results of the current study indicate that, although foot pain was present in people 
with tophaceous gout, there were also significant alterations to muscle activity. The 
alteration in gastrocnemius muscle activity provides a novel insight into alternative 
strategies that must be considered for their role in gait adaptation. Consequently, foot pain 
should not be considered the only significant driver of gait adaptation in tophaceous gout.  
6.5.2. Muscle activity 
Medial and lateral gastrocnemius muscle activity in the participants with tophaceous gout 
were signiﬁcantly higher compared with healthy controls. This indicates that greater 
levels of muscular effort are being invested by the gastrocnemii to maintain progression 
during the stance phase of gait. In the only previous case/control gait study in tophaceous 
gout, Rome (18) postulated that reduced walking velocity due to a pain avoidance strategy 
would lead to reduced ankle plantar flexor muscle activity and subsequent disuse and 
weakness of the ankle plantarflexor muscles. The current findings contradict the 
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conclusions of Rome (18), with ankle plantarflexor muscle activity being increased in 
people with tophaceous gout. 
 
Whilst our findings have demonstrated differences exist in muscle activity, there have 
been no studies undertaken in gout to enable comparison. Studies have been undertaken 
in RA by Keenan (324) and Barn (203), indicating no significant alterations to 
gastrocnemius, soleus or tibialis anterior activity (intensity or timing) during gait when 
compared to control subjects (203), or between RA participants with valgus rearfoot 
deformity (324). The conclusions of both studies are interesting, in that the only 
consideration for increased muscle activity was related to foot function. No consideration 
was presented for other factors above the foot that may influence muscle activity, such as 
knee, hip or pelvic function. 
 
Despite the differences in muscle activity, no significant correlational relationships were 
observed between muscle activity and gait parameters examined in people with gout. 
Muscle activity was also not a significant explanatory predictor in the regression models 
constructed to explain walking velocity, ankle power or ankle joint range of motion.  
Numerous compensatory factors adjunct to foot function may explain the increased 
gastrocnemius muscle activation reported in the current study. These include: (1) 
increased neural drive to the muscle, (2) a reduction in muscular strength, (3) structural 
characteristics of the muscle fibres, (4) AT compliance and (5) muscle fatigue.  
 
Firstly, increased muscle activity is indicative of increased motor unit recruitment and 
may reflect the increased central drive to the gastrocnemius muscle to maintain torque 
output, which is the major contributory factor for the increased force per unit area (325). 
The kinetic results of the current study showed that while peak power was decreased in 
people with tophaceous gout, the total amount of concentric work and total joint force 
generated did not significantly differ. This suggests people with tophaceous gout require 
more muscular output to maintain a similar degree of mechanical work. Even though 
similar degrees of concentric work were maintained, walking velocity was still reduced. 
Conversely, walking at a slower velocity may be mechanically less efficient (e.g. 
deviating more from natural frequency of the pendular movement). This would 
necessitate additional muscular effort as indicated by the increase in muscle activity.  The 
significant differences seen medial and lateral gastrocnemius activity when normalised to 
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stance phase duration also indicate that the higher degree of muscle activity observed in 
the participants with gout was not simply a function of increased muscle activation time, 
stemming from increased stance phase duration. 
 
Secondly, the increased muscular activity may be reflective of reduced muscle strength 
and the increased need to generate muscle force. However, it must be noted that, although 
SEMG is widely used to quantify muscle activity, the relationship between force and 
surface EMG during voluntary contractions is not fully understood (326). Factors that 
prevent the direct quantification of muscle force from EMG signal include cross-talk, 
variations in the location of the recording electrodes and the involvement of synergistic 
muscles in force generation (326). Although concentric or eccentric muscular strength 
were not measured in the current study, strength reductions may be present in people with 
tophaceous gout. Previous research has demonstrated that muscular mass and strength 
decline from the sixth decade of life in both men and women (327). Age-associated loss 
of muscle mass is postulated as a major factor in strength decline, with aging associated 
with functional impairments and a decline in the quantity and intensity of daily physical 
activities (328-331). There are additional interpretations of the association between age-
related loss of muscle mass and strength. Muscle weakness leads to decreased function, 
diminished physical activity, leading to secondary muscular disuse atrophy. The weak 
positive correlation observed in the current study between the foot impairment and muscle 
activity in the medial gastrocnemius and tibialis anterior support the notion that 
alterations to muscle function in tophaceous gout are in part related to alterations in 
activity participation.  
 
Two important factors seen in the people with tophaceous gout that may relate to a decline 
in muscle strength are inflammation and obesity. In chapter 5 demonstrated inflammation 
was a feature in the AT and indicative of a persistent state of low grade inflammation. 
Inflammation must be considered for its potential associations with strength reductions 
and increased physical decline in people with tophaceous gout. Recent studies implicate 
proinflammatory cytokines in the development of age-related decline in muscle mass, 
strength, power and physical performance (332, 333). TNF-α has been associated with 
muscle wasting and lower quadriceps strength reported in older men and women with 
high IL-6 and TNF-α levels (334, 335).    
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The level of obesity seen in the participants with tophaceous gout may also be associated 
to alterations in muscle strength. With weight gain there is a trend to replace muscle mass 
with fat (336). Individuals with high levels of body fat and low lean muscle mass are at 
risk of functional declines in the lower extremity (330, 336, 337). Excess body weight in 
older adults is also associated with a decline in physical function (338-340). Obesity itself 
is associated with an elevation of inflammatory markers (341, 342), and adipose tissue is 
a source of both IL-6 and TNF-a, and is increasingly viewed as a critical tissue in the 
inflammatory process (343). Elevated cytokine levels have been associated with both 
increased fat mass and reductions in muscle mass in older men and women (342). 
 
 
The third explanation for a difference in muscle activity may be related to architecture of 
the gastrocnemius muscle. The force-velocity relationship in a muscle states that the 
maximum force generated by a muscle is a function of its velocity (344). This relationship 
can also be stated in the reverse; that is, muscle contraction velocity is dependent on the 
force resisting the muscle (344). Altered force velocity characteristics may influence 
neural activation patterns because of altered proprioceptive feedback and coordination 
(345, 346). The alteration to the force-velocity relationship may also be attributable to the 
reductions in walking velocity demonstrated in the current study. Walking velocity 
influences each muscle's contractile state (i.e. fibre length and velocity), which may alter 
the muscle's ability to generate force and power. A previous study using simulated 
walking modelling demonstrated the ability of the ankle plantar flexors to produce force 
as walking velocity increased was greatly impaired, despite an increase in muscle 
excitation, due to sub-optimal contractile conditions i.e. increased muscle fibre lengths 
(347).   
 
Fourthly, the increased level of muscle activation may be an indicator of suboptimal AT 
compliance (reduced elasticity or increased AT stiffness). Tendon compliance can 
influence the length and the shortening velocity of the contractile elements and so affect 
the muscles force generating potential due to alteration of the force–length–velocity 
relationship (348). Subsequently the timing and duration of muscle stimulation and the 
amplitude of the change in length of the muscle–tendon unit are also likely to affect the 
capacity of a tendon to increase the power output and efficiency (349).  
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Finally, muscular fatigue is reflected by an increase in EMG activity (350). Muscle 
fatigue can be defined as an exercise-induced reduction in the ability of muscle to produce 
force or power, whether or not the task can be sustained (351). A critical feature of this 
definition is the distinction between muscle fatigue and the ability to continue the task. 
Accordingly, muscle fatigue is not the point of task failure or the moment when the 
muscles become exhausted. Rather, muscle fatigue is a decrease in the maximal force or 
power that the involved muscles can produce, and it develops gradually soon after the 
onset of the sustained physical activity (352). The results of the current study regarding 
significantly decreased peak ankle joint power production is supportive of the concept of 
fatigue.  
6.5.3. Ankle power and ankle range of motion 
The current study showed that peak ankle joint power during the stance phase of gait in 
participants with gout was signiﬁcantly reduced compared to the controls. The results 
confirm hypothesis 4, that ankle power is different in participants with gout compared to 
control participants. 
 
The result of increased peak ankle power compared to the control participants is in 
agreement with the previous research in RA (174, 189, 190, 203). Table 6.2 indicates that 
case participants in the current study demonstrated similar magnitudes in peak ankle joint 
power to one study, Barn (203). Data indicated that the mean peak ankle joint power 
magnitudes of the case and control participants in the current study were lower in 
comparison to previous research in inflammatory arthritis. The control participant’s ankle 
joint power magnitudes were also lower than the majority of the case participants in 
previous research. However, there were a number of dissimilarities in the methodology 
between these studies, including the condition type, disease status (early vs established), 
the age and sex of study participants and the biomechanical model used to estimate 
kinematic and kinetic data.   
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Table 6.2: Comparative baseline ankle joint power between the current study and 
previous studies 
Study Condition 
Case 
ankle joint power 
(W/kg) 
Mean (SD) 
Control  
ankle joint power 
(W/kg) 
Mean (SD) 
Current study Tophaceous gout 1.86 (0.68) 2.17 (0.49)† 
Turner (190) RA 3.40 (1.00) 4.60 (1.60)† 
Turner (189) RA 2.42 (1.22) 4.23 (1.30)† 
Barn (203) RA 1.70 (0.80) 3.10 (0.60)† 
Woodburn (174) PsA 2.93 (0.98)* 3.68 (0.75)†* 
2.40 (0.83)** 3.63 (0.69)†** 
†, (p < 0.01); *, enthesitis absent; **, enthesitis present 
 
With regard to the biomechanical model, both studies by Turner (189, 190) used the same 
foot model as the current study (Oxford Foot Model) but it was not clear by which method 
the studies estimated kinetic parameters. The studies by Barn (203) in RA and Woodburn 
(174) in PsA used a seven-segment foot model to derive kinetic parameter estimations, a 
model originally developed in people with PsA (109). The variation in the magnitude of 
peak ankle joint power may be attributable to overestimation of power derived from a 
single segment model as used in the current study, versus kinetic data estimated from a 
3D multi-segment foot models (353). Dixon (353) demonstrated in an adolescent 
population through comparison of a one-segment foot model to a multi-segment foot 
model that a one-segment foot model overestimates ankle joint power magnitudes, and 
may also overestimate the contribution of the triceps surae in ankle joint power.   
 
Joint power (Pj) is the scalar product of the joint moment (Mj) and the joint angular 
velocity (ωj):Pj = Mj x ωj (354). Alteration in one or both of these parameters may explain 
variation in ankle joint power mean magnitudes. The current study showed that peak 
ankle joint plantarflexion moments during the stance phase of gait in participants with 
gout were not signiﬁcantly different compared the control group. The peak ankle joint 
plantarflexor moments in the current study are similar in magnitude to previous research 
in inflammatory arthritis (Table 6.3). In contrast to previous research, in the current study 
the mean peak plantarflexor moment in the participants with gout were higher than the 
control participants, however not statistically significant. The increased magnitude in 
peak plantarflexor moment may be explained by the increased level of ankle plantarflexor 
muscular activity.  
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Table 6.3: Comparative baseline ankle joint plantarflexion moments between the 
current study and previous studies 
Study Condition 
Case 
ankle joint power 
(W/kg) 
Mean (SD) 
Control  
ankle joint power 
(W/kg) 
Mean (SD) 
Current study Tophaceous gout 1.21 (0.21) 1.15 (0.19) 
O’Connell (186) RA 1.13 (0.29) 1.43 (0.19)† 
Turner (190) RA 1.5 (0.1) 1.6 (0.1) 
Weiss (191) RA 1.05 (0.37) 1.49 (0.15)† 
Turner (189) RA 1.39 (0.28) 1.63 (0.15)† 
Barn (203) RA 1.2 (0.3) 1.4 (0.1) 
Woodburn (174) PsA 1.54 (0.16)* 1.67 (0.19)†* 
1.55 (0.23)** 1.63 (0.17)†** 
†, (p < 0.01); *, enthesitis -; **, enthesitis + 
 
The current study showed that peak ankle joint angular velocities during the stance phase 
of gait in participants with tophaceous gout were signiﬁcantly reduced compared with the 
control participants. Previous research has established that ankle joint power increases 
with walking speed because of increased ankle rotational velocity (355). Although no 
angular velocity magnitudes were reported, Turner (190) attributed reduced ankle joint 
power to reductions in angular velocity on the basis that no significant difference in ankle 
joint plantarflexion moment were demonstrated in people with RA.  
 
Previous research in RA indicates numerous gait parameters including peak ankle joint 
moment, peak ankle joint angular velocity, ankle joint ROM, muscular activity and 
walking velocity interplay to affect peak ankle joint power magnitudes. Turner (189) and 
Barn (203) linked reductions in ankle joint power to walking velocity, postulating that 
with increases in walking velocity there will be accompanied increase in joint angles, 
ankle joint moments and subsequently increased ankle joint power. Turner (190) stated 
that factors contributing to reduced ankle joint angular velocity included reduced walking 
velocity and reduced ankle joint range of motion. The results of the current study parallel 
the findings in RA research relating ankle joint power with ankle joint moment, ankle 
joint angular velocity and walking velocity (190). Regression analysis showed 83% of 
variation in ankle joint power being accounted for by peak angular velocity, peak ankle 
joint moment and walking velocity. There was also moderate correlations between peak 
ankle joint angular velocity, peak ankle joint moment and walking velocity.  
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The results showed no significant differences in the amount of ankle joint plantarflexor 
concentric work produced between the participants with tophaceous gout and control 
participants. No previous research has quantified concentric muscular work in the ankle 
plantarflexors in gout. Only one previous study in a population with RA has calculated 
concentric muscular work of the ankle plantarflexors (191). Weiss (191) reported reduced 
concentric muscular work of the ankle joint plantarflexors, postulating this to be a 
consequence of the reduced internal plantarﬂexor moments during the pre-swing phase 
of gait. Weiss (191) further stated that reduced plantarﬂexor moments could be attributed 
to reduced walking velocity, pain and muscular weakness in the plantarﬂexor muscle 
group.  
 
The results of the current study contrast with the findings of Weiss (191). There were no 
significant differences in concentric ankle joint plantarflexor work or peak ankle joint 
plantarflexor moments between the case and control participants. The results relating to 
concentric plantarflexor work may be explained by the increase in gastrocnemius muscle 
activity. Due to the reductions in walking velocity, ankle joint angular velocity and peak 
ankle joint power production the body may increase muscular activity. This may be a 
central mechanism by which the body maintains muscular work output to maintain 
forward progression.  
 
The current study showed that ankle joint range of motion both in the sagittal plane 
(plantarflexion/dorsiflexion) and frontal plane (inversion/eversion) during the stance 
phase of gait in participants with gout were not signiﬁcantly different compared with the 
control participants. The results of the current study refute hypothesis 5 that there is a 
significant difference in ankle range of motion in participants with gout compared to 
control participants.  
 
Few studies have reported the frequency of ankle involvement in tophaceous gout. Choi 
(294) with the use of Dual Energy Computed Tomography in 20 participants found tophus 
deposition in 70% of ankles. General mid-foot and ankle involvement has been reported 
to occur in 18-60% of participants (10, 81, 356). 
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The results provide an insight into the effect tophaceous gout has on the rearfoot and 
provides a tentative explanation as to why people with tophaceous gout may be less 
impaired by their foot function. The results also support the notion that pain avoidance 
resulting from foot deformity should not be considered the only significant driver of gait 
adaptation in tophaceous gout. The results indicate a lesser degree of rearfoot deformity 
than that observed in RA (357).  
 
Inflammatory synovitis and dysfunction of the peritalar joints and the tibialis posterior 
muscle-tendon unit are postulated mechanisms leading to instability of the rearfoot and 
midfoot in RA (357). As a consequence, people with RA may progressively develop a 
pes planovalgus foot type, as evidenced by a reduced longitudinal arch height and an 
increase in the maximum rearfoot eversion reached during the stance phase of gait (110, 
183, 187). Pes planovalgus foot deformity has a reported prevalence of between 46–64% 
in RA (183, 187, 358, 359). In contrast, the results of the current study showed no 
significant differences in rearfoot eversion or total range of motion in the sagittal plane 
when compared to the control participants. In the current study a peak eversion value of 
3.85º was observed in people with tophaceous gout. In RA, peak eversion values have 
been reported at 8.2 º (110), 5.5º (190) and 9.0º (189). The results of similar ankle ranges 
of motions in the sagittal plane with lower ranges of peak eversion are suggestive of less 
alteration to rearfoot and ankle joint function in people with tophaceous gout compared 
to RA.  
 
The results of the current study show that 1MTP joint range of motion is reduced during 
dynamic movement in people with tophaceous gout. This result is reflective of the 
functional consequences of the gout disease process. Previous studies have indicated a 
tendency for gout to affect the 1MTP joint with the initial attack of gout reported to affect 
the 1MTP joint in 56-78% of participants (77-80). The 1MTP joint is also reported to be 
involved at some point in the course of disease in 59-89% (10, 77, 79, 81).  
 
Osteoarthritis has been associated with the 1MTP joint with significant associations 
observed between the 1MTP joint and osteoarthritis (81). The presence of osteoarthritis 
also predisposes the 1MTP joint to formation of urate crystals (81). With this in mind, the 
reduced range of motion may be explained by two factors. Firstly, the 1MTP joint of the 
case participants may have been affected by osteoarthritis. Secondly, the reduced range 
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of motion may have occurred as a result of joint damage secondary to tophaceous gout. 
As the current study did not clinically assess the 1MTP joint prior to testing or use 
radiography to assess and grade 1MTP joint structure, the current thesis is unable to 
discriminate whether one or both of these factors were predominant in the participants 
with tophaceous gout. Coupled with the findings of Rome (18), who demonstrated 
reduced peak plantar pressures under the 1MTP joint, current evidence indicates joint 
function at propulsion is adapted through alterations to plantar pressure and restriction of 
joint ROM. Functionally, this may manifest as a disruption of the sagittal rocker function 
(22).  
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6.6. Relationships between gait variables and US lesions 
The results of the current study reject hypothesis 6 that there is a relationship between 
ankle power, ankle range of motion, walking velocity and US lesions in the AT in 
participants with tophaceous gout.  
 
The lack of statistical relationships between US lesions and gait function also support the 
US imaging findings that MSU crystal deposition does not cause significant structural 
alteration to the AT and adversely affect gait function. Furthermore, research by Chhana 
(305) has postulated that tendon involvement in gout may be an indolent process. While 
the current study investigated AT structure, consideration must also be given that the 
mechanical tendon properties such as tendon compliance and the response to stress and 
strain may be altered. AT compliance, tendon force transmission, energy storage and 
release during locomotion may be affected by intratendinous MSU crystal deposition. 
This may limit the effective use of strain energy (elastic recoil) by the AT during walking. 
This mechanism is thought to provide a significant proportion of propulsive energy for 
walking (360, 361).  
 
Factors associated with changes in the elastic properties of tendons include alteration to 
collagen deposition, histological changes affecting tendon architecture such as disruption 
of collagen fibres, increased ground substance and vascularisation, and an increase in 
fibroblast activity leading to an increase in tenocytes within the tendon tissue (27). 
Channa (305) demonstrated there was a down regulation of catabolic tendon enzymes in 
tenocytes following culture with MSU crystals. The author suggested this may be part of 
a protective mechanism to limit MSU crystal-induced degradation of tendon matrix (305).  
 
Drawing from the results of both US imaging and gait analysis studies the current thesis 
proposes two theoretical strategies that may coexist to explain gait adaptation or indeed 
drive gait adaptation in people with tophaceous gout. The strategies outlined in Figure 
6.2 are not definitive models of gait adaptation but should be used as the basis to guide 
future research. The strategies are not an alternative to the proposed pain avoidance 
strategy of gait adaptation however, as acknowledged in the thesis, the pain avoidance 
strategy is narrow, in that it is focused on the foot as the driver of gait adaptation.  
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Strategy 1 (in blue boxes): Chapter 3 reported that walking velocity is the most measured 
gait parameter in the explanation of gait adaptation. Strategy 1 raises the possibility that 
walking velocity should not simply be viewed as a gait adaptation. Regulation of walking 
velocity may well be the central strategy by which the body modulates joint forces and 
moments and subsequently joint kinematics and kinetics during locomotion. A reduction 
in walking velocity may lead to alterations in spatiotemporal and kinematic and kinetic 
parameters of the ankle joint. The novel findings with regard to muscular activity also 
raise the critical question as to whether the changes in motor unit activation plays a causal 
role in the functional changes in muscle activity in participants with gout or represent 
mechanism of compensation and adaptation aimed at conserving musculoskeletal 
performance. Conversely, they may be as a compensation and adaptation resultant from 
the deposition of MSU crystals in muscle or tendon fibres altering the internal tendon 
mechanical properties. 
 
Strategy 2 (in red boxes): This strategy considers an opposite approach to strategy 1 
whereby intratendinous changes may be associated with gait adaptation. Intratendinous 
and intramuscular MSU deposition may alter the mechanical properties of the tendon and 
muscle fibres. Changes to tensile force transmission, storage and release of energy during 
locomotion may drive changes in spatiotemporal, kinematic and kinetic gait parameters. 
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Figure 6.2. Proposed theoretical strategies of gait adaptation 
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6.7. Methodological strengths and limitations 
The thesis has numerous strengths. A case-control research design was an efficient way 
to contrast both the characteristics US imaging and gait analysis in two areas where no 
such evidence exists. The sample size of n = 48 (24 case and 24 control) participants was 
similar to previous case control imaging studies in tophaceous gout and larger than many 
previous study populations using 3D gait analysis in inflammatory arthritic conditions. 
The current work assessed participants with long disease duration and compared to a 
gender and age matched-control participants. The age-matching was a particular strength 
as previous studies have described numerous musculoskeletal changes to occur in the 
sixth decade of life (327). The scoring system used to grade lesion presence in the AT 
was also a strength with excellent inter-observer reliability observed. The gait study used 
a biomechanical foot model that has previously been used in RA, paediatric and various 
adult populations. The model was chosen as inter-trial reliability was high for all 
kinematic and kinetic parameters assessed in previous research. The intra-rater reliability 
results also support the use of the biomechanical model, with excellent reliability of the 
gait parameters obtained from the model demonstrated.  
 
The study was limited by the lack of generalisability of the participants. The study was 
undertaken in New Zealand and may not represent findings in other countries around the 
world. The US study did not use a gold standard method for comparison of ultrasound 
findings. The lack of a gold standard is justified by the inclusion criteria relating to 
diagnosis of tophaceous gout and because the definitive proof of tophi would be through 
the surgical extraction or needle biopsy of the tophi; however these invasive methods are 
not justified as routine nor are they ethically appropriate for research. Differences in BMI 
in the participants with gout and control participants may have led to differences in AT 
structure and function and gait parameters.  
 
In the gait study the knee and hip were not included in the biomechanical model. 
Subsequently, the study was unable to assess the relationship and contributions to gait 
strategy between ankle, knee and hip joint moments and powers. Specifically, kinetic data 
from the hip would have enabled the contribution that the ankle plantarflexion moment 
adds to knee and hip energy during gait to be examined (362).  
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Several factors must be taken into account when comparing current gait analysis results 
with previous research. These include differences in sampling rate, filtering techniques, 
data analysis, biomechanical models and walking velocity tested. As demonstrated, there 
was variation in reported walking velocities, ankle power and ankle moments when 
compared to previous research in gout and to research in other forms of inflammatory 
arthritis. An inverse dynamics approach, which is widely accepted for biomechanical 
analyses, was used to estimate foot and ankle joint moments through creation of a single-
segment foot model. Subsequently, it was not possible to distribute the contribution of 
net joint moments onto individual anatomical structures. The use of skin markers for 
measuring lower limb kinematics implies the risk of errors due to inaccurate placement 
and soft tissue artefacts. To limit errors due to inaccurate marker placement, the same 
researcher was responsible for placing all markers during testing.  
 
The multiple regression analysis was exploratory and needs to be interpreted with caution. 
Finally, the EMG normalization technique used in the gait study may not have produced 
true MVICs in participants with tophaceous gout. It is possible that relative muscle 
activity may have been the same in both the cases and controls. In participants with gout 
the ability to produce maximum contractions may have been limited by the presence of 
joint, tendon or muscular pain. While the results are encouraging in terms of detecting a 
difference between the participants with tophaceous gout and control participants, it was 
not possible to separate the contribution of the normalization method to the differences 
recorded.  
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CHAPTER 7 
Conclusions, implications for practice and 
future research 
7.1. Introduction 
The chapter will present the main conclusions of the thesis, followed by the implications 
for practice, implications for future research and an overall conclusion of the work. 
7.2. Ultrasound 
The systematic review identified that the majority of studies reports US lesions in SpA, 
but limited evidence relating to tophaceous gout. US lesions were not consistently defined 
with regard to OMERACT definitions (153) and numerous scoring systems were used 
across the majority of studies. Consistent application of the OMERACT US definitions 
and the scoring of US lesions is required in future studies of AT disease in inflammatory 
arthritis.  
 
Although tophus deposition was common throughout the entire AT there was minimal 
disruption to fibrillar echotexture in all zones of the AT. This suggests there is minimal 
intratendinous structural derangement in the AT. There was also no increase in deposition 
in the reported avascular zone of the AT, indicating no link between tophus deposition 
and avascularity in the AT. Inflammation was present throughout all zones of the AT as 
evidenced by Doppler signal and indicative of low grade persistent inflammation. The 
AT did not display entheseal thickening, significant erosive or cortical irregularities. This 
suggests that there was minimal entheseal pathology in the AT in participants with 
tophaceous gout. The high frequency of calcaneal enthesophytes in both the case and 
control participants may be suggestive of mechanical strain to the insertion of the AT 
rather than an inflammatory-driven enthesophyte formation.  
 
7.3. Gait analysis 
The understanding of foot and ankle function and the progression of gait adaptation in 
tophaceous gout is limited. There is currently no one universal method of capturing 
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spatiotemporal, kinematic and kinetic gait parameters. 3D gait analysis is evolving 
rapidly with the complexity of foot models increasing in order to explain the multi-
segment behaviour of foot function. With the development of foot models the 
understanding of the functional relationships within the foot and ankle has increased. 
However, knee and hip function are rarely reported in inflammatory arthritic conditions. 
Subsequently, the current explanations for gait strategy are considered narrow in focus.  
 
Explanations of gait adaptations in various types of inflammatory arthritis, particularly 
RA, are heavily focused on foot pain and pain avoidance. There is minimal research 
investigating alternative factors that may explain gait adaptation in inflammatory arthritis. 
Currently a pain avoidance strategy due to increased foot pain is postulated to initiate gait 
adaptation in tophaceous gout. However, the results of the current work indicate 
alternative pathways of gait adaptation should be considered by future research. 
 
Participants with tophaceous gout walked with a slower velocity and a reduction in peak 
ankle joint plantarflexor power. Despite the reduction in ankle joint power and walking 
velocity, the total concentric work produced by the ankle plantarflexors and the ankle 
joint, force and moments did not differ when compared to controls. In light of this 
evidence the current thesis found that gastrocnemius muscle activity is increased. 
Although speculative, the thesis proposes that the increased muscle activity maybe be 
reflective of many processes related to both the presence of tophus, the presence of 
comorbidities associated with tophaceous gout, or reflective of adaptations aimed at 
conserving musculoskeletal performance.  
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7.4. Implications for practice 
Imaging modalities should be carefully considered when managing musculoskeletal 
complaints and assessing pathological change in people with gout. Imaging allows the 
clinician to assess current pathological status and can also benchmark the success of 
intervention. Grey-scale and power Doppler US imaging are non-invasive and relatively 
low cost. US imaging can provide insight into inflammatory activity and structural 
damage of the entire AT and assess the characteristics of intratendinous tophus, but is 
limited in its ability to examine the intra-articular effects of tophus deposition.  
 
Walking velocity should be viewed as a key outcome measure when assessing and 
managing musculoskeletal pathologies in the foot and ankle in people with tophaceous 
gout. Walking velocity should be measured at baseline and assessed following the 
implementation of treatment, specifically if the goal of the treatment is aimed at 
increasing walking mobility. As highlighted in the thesis there are numerous methods to 
quantify walking velocity. Expensive systems are not required. Walking velocity can be 
measured by simple, cost-effective techniques such as stopwatch timing while walking 
over a short distance.  
 
When assessing musculoskeletal function assessment should include: determination of 
ankle ROM and lower leg muscle strength (particularly ankle plantar flexor strength). 
Due to the potential compensatory effects of restricted joint ROM, the ankle joint should 
be quantified. If joint motion is limited, discrimination should be made if the joint 
restriction is functional (soft tissue restriction), structural (restricted due to bony 
limitation) or related to pain shielding. Muscle strength is also important to determine as 
identified. As highlighted by the thesis weakness and associated fatigue may be present 
and able to be improved with an appropriate rehabilitation programme.  
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7.5. Implications for future research 
The current findings have produced various important findings that require additional 
investigation. Highlighted below are the areas of necessary research that will help develop 
greater understanding of musculoskeletal structure and function in tophaceous gout. 
 
Through imaging of AT lesions at differing stages of gout a sequence or severity of 
alterations to development of US lesions may be discovered. This may enable the 
categorisation of US lesions into those reflective of active (inflammatory) and chronic 
(structural) damage. This would involve imaging of AT lesions in populations with 
varying stages of gout (acute, intercritical and tophaceous gout).  
 
As the current thesis only considered the structural characteristic of the AT and the effects 
of MSU, deposition on the mechanical properties of the AT are unknown further 
investigation is warranted. This would include determination of AT elasticity, energy 
storage, stiffness and the stress strain relationship.  
 
The results indicated there were a percentage of participants with tophaceous gout where 
there was little evidence of MSU deposition. There may be numerous clinical and 
biomechanical features associated with this subgroup, therefore further investigation is 
warranted to determine if such a subgroup exists and if there are clinical and 
biomechanical features unique to this group. 
 
As postulated by the thesis, walking velocity may be the central mechanism by which the 
body modulates kinematic and kinetic parameters. Subsequently, determining 
mechanisms of how walking velocity acts as a modulator of other gait parameters is 
required. This would involve quantification of kinematic, kinetic, plantar pressure and 
muscle activity parameters in relation to variations in walking velocity. 
 
As the current thesis only quantify joint moments, force and torque at the ankle, future 
research should detail kinematic and kinetic data relating to the hip and the knee as well 
as the ankle. This would begin to build the picture as to distribution of joint moments, 
torque and power patterns in the lower limb. Quantification of knee and hip function 
would also provide information surrounding the weight acceptance component of stance 
phase (braking phase) not just the propulsive phase as presented in the thesis. Future 
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research should also quantify the contact and midstance period of stance phase. Although 
the current thesis examined terminal stance phase, the flow-on effects of poor propulsion 
may lead to alterations in the acceptance of bodyweight distinguishable by alterations to 
ground reaction forces and delayed progression of bodyweight. 
 
Further exploration of muscle structure and function in gout is required. From a structural 
perspective, it would be pertinent to determine the burden and presentation of MSU 
deposition in muscle fibres, as the current thesis only investigated tophus burden in the 
AT. From a functional perspective quantification of flexor and extensor muscular strength 
in the ankle and knee is required to determine if strength is reduced in people with 
tophaceous gout. It would also be useful to determine if a strengthening targeting the 
lower limb muscles can alter gait parameters, for example, increase walking velocity. As 
the thesis identified increased muscle activity in the gastrocnemius muscle group, a 
finding that may precede muscular fatigue, further study surrounding the concept of 
muscular fatigue is warranted. Further progression of quantification of muscle activity is 
also required specifically to determine the levels of muscle activity in the upper limb 
during walking. 
 
Further investigation into muscle activity in participants with gout is required. 
Specifically, investigation of co-contraction of lower limb muscles and the phasing and 
time duration of muscle activity.  As pain may have limited the ability to produce true 
MVICs, further investigation is warranted surrounding EMG normalisation techniques in 
those with tophaceous gout.  This may involve normalisation of muscle activity to peak 
or mean muscle activation levels obtained during the gait cycle.   
 
With evidence that numerous gait parameters are altered in people with tophaceous gout 
it would be of benefit to explore if interventions such as footwear, foot orthoses and 
strengthening exercises can modify gait parameters. 
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7.6. Thesis summary 
The aim of the thesis was to characterise the structure of the AT and gait adaptations in 
people with tophaceous gout. Two systematic literature reviews with meta-analysis and 
two experimental studies were conducted: the data describing US lesions of the AT in 
different forms of inflammatory arthritis, gait adaptation across different forms of 
inflammatory arthritis, the prevalence of US lesions of the AT and gait adaptations 
occurring at the foot and ankle in people with tophaceous gout. 
 
The systematic review presented in Chapter 2 was the first to pool data of US lesions in 
the AT. The review demonstrated poor data describing US lesions of the AT in gout. 
Additionally, the review demonstrated that no universally agreed and accepted definitions 
have been devised that can characterise between US lesions reflective of inflammatory 
and structural change in differing forms of inflammatory arthritis.  
 
The systematic review with meta-analysis detailed in Chapter 3 was the first review to 
pool gait data and demonstrate differences in key gait parameters compared to healthy 
controls across inflammatory arthritic conditions that included other forms of 
inflammatory arthritis with previous reviews only considering RA. The pooled results 
showed that gait pattern in RA was characterised by decreased walking speed, decreased 
cadence, decreased stride length, decreased ankle power, increased double limb support 
time and peak plantar pressures at the forefoot. Walking velocity was reduced in psoriatic 
arthritis and gout with no differences in ankylosing spondylitis. The review demonstrated 
the differences that exist in the instrumentation and acquisition methodologies used to 
assess spatiotemporal, kinematic and kinetic gait parameters. This finding highlights a 
significant issue in gait analysis: that there is no universal agreement or standardisation 
surrounding the capture and processing of data used to describe gait analysis. The review 
also highlighted that, while the understanding of foot and ankle function has increased 
with the rapid development of multi-segmented foot models, there has been less 
description of the relationships between foot, knee and hip. Subsequently, explanations 
of why and how gait adaptations occur in people with inflammatory arthritis are explained 
by alterations in foot function with minimal consideration for compensations that occur 
at the knee and hip. The review also showed that poor data exists describing gait 
adaptation in gout and how muscle activity is affected by gait adaptations across all forms 
of inflammatory arthritis.  
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The first study examined the prevalence of US lesions in three zones of the AT. This was 
the first study to examine US lesions of the AT in the insertional, pre-insertional and 
proximal zones of the AT. Results showed participants with tophaceous gout had 
significantly more intratendinous tophi, intratendinous hyperechoic spots and 
intratendinous inflammation throughout all zones of the AT compared to control 
participants. Despite this, there was no significant data indicating internal fibrillar 
derangement. These results raise two possibilities, firstly the presence of tophus 
deposition and associated inflammation in the AT may be a clinically silent process, with 
containment of inflammation. Secondly, whilst the current thesis examined the structure 
of the AT alterations to the mechanical properties in the AT due to MSU deposition and 
inflammation are unknown and may be significant in the development of pathology.  
 
The second study investigated key spatiotemporal, kinematic and kinetic gait parameters 
during walking. Significantly walking velocity and ankle power were reduced in people 
with tophaceous gout. The reduction in walking velocity could be viewed as the most 
significant gait adaptation due to the relationship between reduced walking velocity and 
reductions in other gait parameters reported. Reductions in walking velocity were 
associated with alterations in cadence, step length, double support time and gait cycle 
time. Reductions in walking velocity were also associated with decreased ankle joint 
angular velocity. With the ankle joint moments preserved and not significantly different, 
the reductions in ankle joint angular velocity explain the reduced ankle joint power 
output. These finding highlight the importance of walking velocity and imply that 
walking velocity may be the central mechanism by which the body modulates gait 
adaptation.   
 
The thesis challenges the presumption that avoidance of foot pain is the sole driver of gait 
adaptation in people with tophaceous gout. Based on the significance of MSU deposition 
in the AT, the unknown effect of deposition on the mechanical properties of the AT, the 
decrease in walking velocity and the potential reasons explaining alterations in muscle 
activity, the thesis proposes that future explanations of gait strategy in gout must not only 
consider foot and ankle function in isolation. Knee and hip function must be considered. 
Further consideration must also be given to the role deposition of MSU crystals in both 
tendon and muscle, comorbidities such as obesity, diabetes and cardiovascular disease 
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and poor physical conditioning contribute to the process of gait adaptation in tophaceous 
gout.  
 
The current work is clinically important, suggesting that when managing AT pathologies 
in people with tophaceous gout both structure and function must be considered. Firstly, 
the structural integrity of the AT must be determined. Secondly, the degree of gait 
adaptation must also be quantified. Quantifying walking velocity provides the clinician 
with a good overall perspective of functional ability. Other markers of function that 
should be considered in the assessment of foot and ankle function include ankle 
plantarflexor muscle strength, and ankle joint and 1MTP joint motion.  
 
The thesis has also identified important areas for the focus of future research. Gait 
compensations at the knee and hip must be quantified. The relationship between MSU 
deposition and mechanical properties of the AT must be investigated to further the 
understanding of tendon integrity. The interplay between adaptive mechanisms and the 
order at which gait adaptations occur also requires further research to establish if gait 
adaptation occurs in a sequential fashion and is related to increasing chronicity of gout. 
The impact of non-surgical interventions such as footwear, foot orthoses and strength 
training must also be considered for their ability to alter the process of gait adaptation. 
The impact of urate-lowering pharmacological intervention on lower limb function and 
soft tissue characteristics is warranted. 
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APPENDIX 1 
Patient information sheet 
The effect of tophaceous gout on structure and function of the Achilles tendon. 
An Invitation 
We would like to invite you to take part in a research study. Information from this research will be 
published as a PhD thesis and will also be presented within academic publications and verbal 
presentations. This research project is a related to my PhD studies, and I will be conducting the research 
with Professor Keith Rome, Associate Professor Nicola Dalbeth and Associate Professor Mark Boocock 
from AUT University and Auckland University. My name is Matthew Carroll and I am a PhD student. 
Participation is completely voluntary, and you may withdraw from the study at any time without giving a 
reason or being disadvantaged. 
 
What is the purpose of this research? 
The objective of the research is to investigate how changes of the Achilles tendon (muscle at the back of 
the heel) affects walking in people with tophaceous gout. We believe that leg and foot joint movement, 
the walking velocity and the strength of the calf muscle will be less in people with tophaceous gout. We 
are looking to invite 25 patients with tophaceous gout and 25 people without gout. We will be using 
ultrasound to image the muscle and equipment to measure your leg and foot motion whilst you are 
walking.  
 
How was I chosen for this invitation? 
Consent was provided by the Auckland District Health Board that we were able to contact you and your 
details were available through the Auckland District Health Board patient database. 
Subjects with chronic gout 
If you are over 18 years old and have been diagnosed with chronic gout, have at least one tophus and can 
walk 10m without the need of crutches or a walking stick you may want to take part in the study. We are 
unable to have you involved if you are under 18 years old, have previously ruptured your Achilles tendon, 
have a current injury to the foot or leg or have any loss of sensation in your feet. 
Subjects without chronic gout 
If you are over 18 years old and do not have gout or any other form of inflammatory arthritis, and can 
walk 10m without crutches or a walking stick you may wish to take part in the study. We are unable to 
have you involved if you have had a previous rupture of the Achilles tendon, a current injury to the leg or 
are experiencing a current gout flare. 
 
Where will the research take place? 
Data collection will take place in the Horizon Radiology and the Gait Analysis room located in AA 
Building, AUT University, Akoranga Campus, Northcote, Auckland. 
 
 
219 
 
When will the research take place? 
Data collection is planned from July 1st to October 30th 2013. You will be contacted 2 weeks prior to 
confirm the date and time. Data collection will take approximately 2 hours 30 minutes. 
 
What will happen in this research? 
When you first arrive you will have your height and weight measured, you will then be asked to fill out 3 
forms that measure how you are affected by your gout. You will then have two tests on your legs. First 
you will have an ultrasound test on your calf muscle and tendon; second you will have your walking 
measured. For the ultrasound test you will be asked to lie on your stomach on an examination table. You 
will then have gel put on your calf muscle and the person taking the ultrasound will then put the 
ultrasound tool on your leg and record pictures which will take about 30 minutes.  
To see how well you walk small marker balls will be stuck onto both of your legs with tape. To measure 
how much your muscle works during the walking we will also apply another set of markers to each leg, 
before we can attach the markers we will need to remove any hairs with a disposable razor. You will then 
be asked to walk along a flat walkway ten times. Before you walk on the walkway we will show you 
where to walk. This will take about 1 hour and 30 minutes.  
 
Support during the research 
You are more than welcome to bring a family member or friend along if you agree to participate in the 
study. 
 
What to wear for the research appointment? 
During the research you will need to wear either shorts or pants that are able to be rolled up to just over 
the knee.  
What are the discomforts and risks? 
If this discomfort becomes too uncomfortable we will stop the procedure. You may want to leave the 
study and if you wish to leave the study, we will respect your decision. 
 
What are the benefits? 
The findings of this study will allow us to look at rehabilitation programmes that may benefit people with 
walking difficulties related to chronic gout. 
 
What compensation is available for injury or negligence? 
In the unlikely event of a physical injury as a result of you being in this study, rehabilitation and 
compensation for injury by accident may be available from the Accident Compensation Corporation, 
providing the incident details satisfy the requirements of the law and the Corporation's regulations. 
 
How will my privacy be protected? 
Your privacy will be protected by your identification being a number, and access to the data is restricted 
only to the researchers.  
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We would like permission for your rheumatologist to access hospital records to obtain and release 
information about your current blood tests and any X-rays undertaken in the foot. The reasons we ask this 
information is that it allows us to understand more about the impact chronic gout has on the foot. 
 
What are the costs of participating in this research? 
The cost of your travel will be reimbursed through taxi or fuel vouchers. To collect all of the information 
it will take approximately 2 hours 30 minutes of your time. Because of the long time we would like to 
offer you a fuel voucher. We would also like to offer you a pair of walking socks. 
 
What opportunity do I have to consider this invitation? 
Before volunteering, please consider carefully whether you are prepared to be part of the study. We have 
a number of bookings available throughout July to October and we will organise a convenient time for 
you to come. 
 
How do I agree to participate in this research? 
If you wish to participate in the study please contact the Researcher Matthew Carroll (see contact details 
below). You will need to read and sign the Consent Form dated 19th March 2013 to participate in this 
study. A consent form can be obtained from the Researcher. 
 
Will I receive feedback on the results of this research? 
Results will be made available to you at the completion of the study, and will be in the form of a written 
summary. If you wish to receive this, please indicate on the relevant section of the consent form. Any 
papers that may be published arising from the research can be accessed on request. 
 
What do I do if I have concerns about this research? 
Any concerns regarding the nature of this project should be notified in the first instance to the Principal 
Investigator, Professor Keith Rome, krome@aut.ac.nz, 921-9999 ext 7688. 
Concerns regarding the conduct of the research should be notified to the Executive Secretary, AUTEC, 
Madeline Banda, mbanda@aut.ac.nz, 921 9999 x8044 
 
Whom do I contact for further information about this research? 
Please contact the research assistant Matthew Carroll  
Research assistant details: 
Matthew Carroll (Research student responsible for administration and data collection) 
Phone: 021 245 8796  
email: matthew.carroll@aut.ac.nz 
 
Project Supervisor contact details: 
Professor Keith Rome 
phone: 921-9999 ext 7688; email: krome@aut.ac.nz 
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APPENDIX 2 
Consent form 
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APPENDIX 3 
A) Pain visual analogue scale 
 
 
 
 
B) Foot pain visual analogue scale 
 
 
 
C) Patient global health visual analogue scale 
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APPENDIX 4 
Health Assessment Questionnaire II (HAQ II) 
 
We are interested in learning how your illness affects your ability to function in daily life.  
 
Place an x in the box which best describes your usual abilities over the past week. 
 
Are you able to: 
Without 
any 
difficulty 
[0] 
With 
some 
difficulty 
[1] 
With 
much 
difficulty 
[2] 
Unable 
to 
[3] 
 
Get on and off the toilet? 
 
    
Open car doors? 
 
    
Stand up from a straight chair? 
 
    
Walk outdoors on flat ground? 
 
    
Wait in a line for 15 minutes? 
 
    
Reach and get down a 5-pound object 
(such as a bag of sugar) from just above 
your head? 
    
Go up 2 or more flights of stairs? 
 
    
Do outside work (such as yard work)? 
 
    
Lift heavy objects? 
 
    
Move heavy objects? 
 
    
Subtotal     
Total  
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APPENDIX 5 
Lower Limb Tasks Questionnaire - Recreational Activities section  
 
Patient: _______________       Date:_____________ 
  
INSTRUCTIONS 
Please rate your ability to do the following activities in the past 24 hours by circling the number below the appropriate response. 
 
If you did not have the opportunity to perform an activity in the past 24 hours, please make your best estimate on which response would be the most accurate.  
 
Please also rate how important each task is to you in your daily life according to the following scale:  
1. = Not important 
2. = Mildly important 
3. = Moderately important 
4. = Very important 
 
Please answer all questions. 
 
        SEVERE            MODERATE       MILD             NO   IMPORTANCE 
                   UNABLE                   DIFFICULT        DIFFICULTY      DIFFICULTY DIFFICULTY  OF TASK 
 
1. Jog of 10 minutes 0 1 2 3 4 1  2  3  4 
2. Pivot or twist quickly while walking 0 1 2 3 4 1  2  3  4 
3. Jump for distance 0 1 2 3 4 1  2  3  4 
4. Run fast/sprint 0 1 2 3 4 1  2  3  4 
5. Stop and start moving quickly 0 1 2 3 4 1  2  3  4 
6. Jump upwards and land 0 1 2 3 4 1  2  3  4 
7. Kick a ball hard 0 1 2 3 4 1  2  3  4 
8. Pivot or twist quickly while running 0 1 2 3 4 1  2  3  4 
9. Kneel on both knees for 5 minutes 0 1 2 3 4 1  2  3  4 
10. Squat to the ground/floor 0 1 2 3 4 1  2  3  4 
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Lower Limb Tasks Questionnaire - Activities of daily living section  
 
Patient: _______________       Date:_____________ 
  
INSTRUCTIONS 
Please rate your ability to do the following activities in the past 24 hours by circling the number below the appropriate response. 
 
If you did not have the opportunity to perform an activity in the past 24 hours, please make your best estimate on which response would be the most accurate.  
 
Please also rate how important each task is to you in your daily life according to the following scale:  
 1 = Not important 
  2 = Mildly important 
  3 = Moderately important 
  4 = Very important 
 
Please answer all questions. 
 
 
        SEVERE                   MODERATE  MILD             NO     IMPORTANCE 
                               UNABLE   DIFFICULTY DIFFICULTY  DIFFICULTY  DIFFICULTY  OF TASK 
 
1. Walk for 10 minutes 0 1 2 3 4 1  2  3  4 
2. Walk up or down 10 steps (1 flight) 0 1 2 3 4 1  2  3  4 
3. Stand for 10 minutes 0 1 2 3 4 1  2  3  4 
4. Stand for a typical work day 0 1 2 3 4 1  2  3  4 
5. Get on and off a bus 0 1 2 3 4 1  2  3  4 
6. Get up from a lounge chair 0 1 2 3 4 1  2  3  4 
7. Push or pull a heavy shopping trolley 0 1 2 3 4 1  2  3  4 
8. Get in and out of a car 0 1 2 3 4 1  2  3  4 
9. Get out of bed in the morning 0 1 2 3 4 1  2  3  4 
10. Walk across a slope/uneven ground 0 1 2 3 4 1  2  3  4 
 
   TOTAL (/40):_____
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APPENDIX 6 
Leeds Foot Impact Scale 
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APPENDIX 7 
Ultrasound scoring system 
 Insertion Pre-insertion to 
midsection  
(2cm from 
insertion) 
Proximal to 
midsection 
Left Right Left Right Left Right 
Tophus Characteristics 
Tophus present Y  /  N Y  /  N Y  /  N Y  /  N Y  /  N Y  /  N 
If tophus present, longest diameter mm mm mm mm mm mm 
Tendon echogenicity 
Focal hypoechoic areas with loss of fibrillar echotexture 0  1  2 0  1  2 0  1  2 0  1  2 0  1  2 0  1  2 
Intratendinous hyperechoic spots 0  1  2 0  1  2 0  1  2 0  1  2 0  1  2 0  1  2 
Tendon vascularity Intratendinous power Doppler signal 0  1  2 0  1  2 0  1  2 0  1  2 0  1  2 0  1  2 
Tendon morphology 
Tendon tear: 0: absent, 1: partial tear, 2: complete rupture 0  1  2 0  1  2 0  1  2 0  1  2 0  1  2 0  1  2 
Tendon thickness at the insertion of the deeper margin into the calcaneal bone  mm mm   
Tendon thickness score (0: <5.3 mm; 1: between 5.3 and 6.3; 2: > 6.3 mm) 0  1  2 0  1  2    
Tendon Length mm mm  Scoring unless specified  
Enthesis 
Entheseal echogenicity: focal hypoechoic areas 0  1  2 0  1  2  0 = None / absent  
Entheseal echogenicity: calcifications 0  1  2 0  1  2  1 = mild to moderate  
Entheseal vascularity 0  1  2 0  1  2  2 = Severe  
Bursal morphology 
Bursal size mm mm   
Bursal size score (0: <2 mm; 1: between 2–4 mm; 2: > 4 mm) 0  1  2 0  1  2   
Bursal snowstorm appearance 0  1  2 0  1  2   
Bursal power Doppler signal 0  1  2 0  1  2   
Bone profile 
Calcaneal bone cortex irregularities 0  1  2 0  1  2   
Calcaneal Enthesophytes (new bone formation at enthesis-bone junction) 0  1  2 0  1  2   
Calcaneal bone erosions (0: no bone erosion; 1: between 0.1 and 2 mm; 2: > 2 mm) 0  1  2 0  1  2   
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APPENDIX 8 
Non-significant correlations between gait parameters and US 
lesions in participants with gout 
Table 8.1: Non-significant bivariate correlations for walking velocity US lesions 
 r p-value 
Intratendinous power Doppler signal (zone 1) -0.13 0.38 
Intratendinous power Doppler signal (zone 2) 0.25 0.82 
Intratendinous power Doppler signal (zone 3) 0.06 0.67 
AT thickness -0.24 0.10 
Calcaneal enthesophyte formation (zone 1) -0.20 0.18 
Tophus present (zone 1) 0.12 0.14 
Tophus present (zone 2) 0.35 0.82 
Tophus present (zone 3) 0.02 0.88 
Intratendinous hyperechoic spots (zone 1) -0.31 0.83 
Intratendinous hyperechoic spots (zone 2) -0.17 0.29 
Intratendinous hyperechoic spots (zone 3) -0.09 0.56 
Entheseal echogenicity (zone 1)  -0.78 0.59 
 
 
Table 8.2: Non-significant bivariate correlations for ankle power with and US lesions 
 r p-value 
Intratendinous power Doppler signal (zone 1) -0.15 0.31 
Intratendinous power Doppler signal (zone 2) 0.04 0.80 
Intratendinous power Doppler signal (zone 3) -0.30 0.87 
Calcaneal enthesophyte formation (zone 1) -0.12 0.41 
Tophus present (zone 1) 0.16 0.27 
Tophus present (zone 2) 0.17 0.25 
Tophus present (zone 3) 0.22 0.13 
Intratendinous hyperechoic spots (zone 1) -0.005 0.97 
Intratendinous hyperechoic spots (zone 2) -0.11 0.49 
Intratendinous hyperechoic spots (zone 3) -0.17 0.24 
Entheseal echogenicity (zone 1)  -0.14 0.32 
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Table 8.3: Non-significant bivariate correlations for ankle range of motion with and 
US lesions 
 r p-value 
Intratendinous power Doppler signal (zone 1) -0.13 0.38 
Intratendinous power Doppler signal (zone 2) -0.10 0.50 
Intratendinous power Doppler signal (zone 3) -0.18 0.90 
Calcaneal enthesophyte formation (zone 1) 0.17 0.26 
Tophus present (zone 1) -0.02 0.86 
Tophus present (zone 2) 0.002 0.99 
Tophus present (zone 3) 0.05 0.74 
Intratendinous hyperechoic spots (zone 1) -0.05 0.75 
Intratendinous hyperechoic spots (zone 2) -0.04 0.77 
Intratendinous hyperechoic spots (zone 3) -0.05 0.75 
Entheseal echogenicity (zone 1)  -0.23 0.12 
 
 
